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 Abstract 
 
Growth factor signalling controls multiple cellular functions, such as cell growth, 
proliferation, migration and cell survival, and misregulation of growth factor signalling has 
been shown to promote cancer development and progression. The study presented within this 
thesis focuses on the functions of a non-receptor tyrosine kinase Ack1 (Activated Cdc42-
associated kinase 1, TNK2) in epidermal growth factor (EGF) receptor (EGFR) trafficking. 
This study reveals that Ack1 subcellular localization greatly depends on EGF availability. 
Furthermore, this work also identifies a potential role for Ack1 in a non-canonical degradative 
pathway through its associations with several autophagosomal proteins. Analyses of a panel 
of the Ack1 deletion mutants further reveal key mechanistic aspects of these associations and 
identify the Ack1 domains which are required for these to occur. Finally, a mass 
spectrometric approach has been applied which identifies novel post-translational 
modification sites within Ack1, and in combination with stable isotope labelling of amino 
acids in cell culture (SILAC), has allowed for characterisation of novel Ack1 interactors. 
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Overview 
 
Growth factors control processes such as cellular proliferation and directed cell migration, and 
deregulated signalling through growth factor receptors is associated with oncogenesis and 
other pathologies. The field of growth factors and growth factor receptors has been 
extensively studied for decades, leading to the development of drugs administered, for 
example, as treatments of cancer. There is still a great deal of debate on the mechanisms 
underlying the regulation of growth factor signalling and trafficking pathways; however, new 
evidence has emerged which demonstrates the interdependence of these two apparently 
distinct areas.  
 
One of the proteins implicated in the regulation of growth factor signalling and trafficking is 
Ack1 (activated Cdc42-associated kinase 1). This non-receptor tyrosine kinase (NRTK) has 
been shown to regulate epidermal growth factor receptor (EGFR) degradation, leading to 
down regulation of EGF signalling; however, the precise roles for Ack1 in this context remain 
elusive. In addition to its functions in EGF signalling pathway, Ack1 contains a clathrin 
binding domain, which makes it a very interesting protein to study in the field of clathrin-
mediated endocytosis (CME). CME is the major internalization pathway for many cell-
surface receptors, including EGFR. 
 
The overall focus of the study presented in this thesis is to investigate the functions of Ack1 
in the context of growth factor receptor signalling and trafficking. 
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1 Introduction 
1.1 Growth factors and growth factor receptors 
Growth factors were first discovered in the 1950s by Stanley Cohen and Rita Levi-
Montalcini. Neuronal growth factor was the first identified in 1953 (Levimontalcini et al., 
1954), followed by the discovery of epidermal growth factor (EGF), which was isolated and 
described in 1962 (Cohen, 1962). These two discoveries had a large influence on the fields of 
cell biology and medicine, as evidenced by the awarding of the Nobel Prize in Physiology or 
Medicine in 1986 to Cohen and Levi-Montalcini (Garfield, 1987). These findings also led to 
identification of other growth factors and their receptors, and their function within the cell, 
thus allowing a greater understanding of the basis of many growth factor-related pathologies 
(Garfield, 1987). 
 
Since these initial discoveries, growth factors have been shown to regulate many cellular 
processes including cell growth, proliferation, differentiation, migration and survival (Turner 
and Grose, 2010; Avraham and Yarden, 2011). Growth factor signalling is crucial for correct 
cellular functions and misregulation of this signalling may lead to many disorders. One of the 
main fields in which aberrant growth factor signalling is being extensively studied is 
neoplastic transformation, an abnormal growth and proliferation of cells, which may lead to 
cancer development (Rajkumar, 2001; Turner and Grose, 2010). So far, 58 receptor tyrosine 
kinases (RTKs) have been identified in Homo sapiens alone, and are further divided into 20 
subfamilies, e.g. the epidermal growth factor receptor (EGFR), the vascular EGFR (vEGFR) 
and the fibroblast growth factor receptor (FGFR) families, examples of which are shown in 
Figure 1.1 (Lemmon and Schlessinger, 2010).  
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Figure 1.1. Receptor tyrosine kinases 
The examples of the RTK families are presented. RTKs, which reside at the plasma 
membrane, comprise an extracellular portion, single transmembrane domain and an 
intracellular portion. Adapted from (Lemmon and Schlessinger, 2010). 
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RTKs can be characterized as cell-surface receptors that bind extracellular ligands, such as 
growth factors or hormones (Gschwind et al., 2004). They all share a similar structure, which 
includes an extracellular ligand-binding domain, a single transmembrane helix and a 
cytoplasmic region, itself containing a juxtamembrane domain, a tyrosine kinase domain and 
a C-terminal tail (Figure 1.1) (Lemmon and Schlessinger, 2010). The majority of RTKs 
present at the plasma membrane are monomers (Schlessinger, 2000). Ligand binding 
stabilises dimeric or oligomeric states of RTKs, which in turn enhance intrinsic tyrosine 
kinase activity (Schlessinger, 1988; Gschwind et al., 2004). Once a stable complex is formed, 
activated receptor dimers trans-phosphorylate, i.e. phosphorylate the opposed bound 
monomer. This results in autophosphorylation of key tyrosine residues within the catalytic 
loop of the kinase domain, which further stimulates tyrosine kinase activity (Schlessinger, 
1988; Gschwind et al., 2004). Phosphorylated tyrosine residues also function as docking sites 
for other proteins and signalling molecules, described later in Chapter 1.2.4 (Lemmon and 
Schlessinger, 2010). Importantly, it has been shown that the autophosphorylation events occur 
in a precise order, and that the initial phosphorylation events enhance the catalytic function of 
the kinase domain, whereas subsequent phosphorylation events enable recruitment of 
signalling proteins. Typically, the recruited proteins contain the phosphotyrosine binding 
(PTB) domain and the Src homology-2 (SH2) domain, a conserved motif that recognizes 
phosphorylated tyrosine residues (Lemmon and Schlessinger, 2010).  
 
1.2 Epidermal growth factor receptor 
Epidermal growth factor receptor (EGFR), also known as ErbB1 or Her1 (human epidermal 
growth factor receptor 1), is perhaps the most studied among all RTKs. EGFR is a member of 
the EGFR/ErbB family of RTKs that also includes ErbB2/Neu/Her2, ErbB3/Her3 and 
ErbB4/Her4 (Hynes et al., 2001). Ligand binding to ErbB receptors has been shown to be 
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highly controlled, and different ligands recognise particular ErbB receptors. Upon ligand 
binding, members of the ErbB family can homodimerise or heterodimerise with one another, 
thus bringing additional diversity in signalling properties. Importantly, heterodimers acquire 
new signalling properties rather than a sum of properties of two homodimers. For example, 
stimulation of  NIH3T3 cells co-expressing ErbB2 and ErbB4 with neu differentiation factor, 
a growth factor that binds ErbB3 and ErbB4, led to activation of signal transducer and 
activator of transcription 5b (STAT5b); however, STAT5b was not activated in cells co-
expressing ErbB1 and ErbB4, or ErbB2 and ErbB3 (Olayioye et al., 1999; Schneider and 
Wolf, 2009). The signalling cascades activated by the members of the EGFR family play 
pivotal roles in embryogenesis. This came to light in 1995, when it was shown that mice 
lacking ErbB2 and ErbB4 die during embryonic development due to failure in development of 
myocardial trabeculae in the heart ventricle (Gassmann et al., 1995; Chan et al., 2002). 
Additionally, signalling through ErbB receptors also promotes angiogenesis, and aberrant 
ErbB signalling vastly contributes to development of various types of cancer (Casanova et al., 
2002; Klos et al., 2006; Burgess, 2008).  
 
Following ligand binding at the plasma membrane, EGFR has been shown to be internalized 
mainly through a certain type of endocytosis called clathrin-mediated endocytosis (CME) 
described later in Chapter 1.3 (Rappoport and Simon, 2009). Endocytosis followed by EGFR 
sorting for lysosomal degradation, as well as dephosphorylation of activated EGFRs by 
cellular phosphatases (described in Chapter 1.2.5) play fundamental roles in downregulation 
of EGF signalling (Avraham and Yarden, 2011).  
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1.2.1 Structure 
As a prototypical RTK, EGFR shares similar structural features with other RTKs, as it 
consists of an extracellular ligand-binding region, single transmembrane domain and an 
intracellular tyrosine kinase domain, shown in Figure 1.2. The high-resolution crystal 
structure of the ErbB receptors reveals that within the extracellular portion they all contain 
two large beta-helical domains (L1 (I) and L2 (III)) and two small cysteine-rich regions (S1 
(II) and S2 (IV)), which contain several disulfide bounded modules. Since the domains I and 
III are homologous, as are domain II and IV, it has been proposed that the extracellular 
portion evolved by gene duplication of the region containing domains I and II (Leahy, 2004). 
A single-spanning α-helical transmembrane (TM) domain is followed by a juxtamembrane 
(JM) region, a tyrosine kinase domain and an intracellular C-terminal tail. The TM domain 
has been shown to stabilise receptor dimerisation (Jorissen et al., 2003). Relatively little is 
known about the functions of the JM domain and the C-terminal region, although multiple 
tyrosine and lysine residues characterised within the C-terminus have been found to regulate 
EGFR activation (Ferguson, 2008; Goh et al., 2010).  
 
1.2.2 EGFR activation 
In an inactive state, the extracellular domain II interacts with domain IV via a hairpin loop, 
also known as a „dimerisation arm‟, thus preventing an interaction between domains I and III 
(Cho and Leahy, 2002; Ferguson et al., 2003). Ligand binding to domain I and III brings them 
into close proximity resulting in disruption of the interaction between domains II and IV. As a 
result, the hairpin loop from domain II is free and can interact with another receptor molecule 
(Garrett et al., 2002; Ogiso et al., 2002).  
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Figure 1.2. Structure of EGFR 
a) Schematic structure of EGFR comprises the extracellular portion with the ligand binding 
and cysteine rich domains, a single transmembrane domain and adjacent juxtamembrane 
domain, and the cytoplasmic portion that comprises the tyrosine kinase domain and the C-
terminal tail; on the right: schematic of EGFR dimer with two EGF molecules. Adapted from 
(Lemmon and Schlessinger, 2010); b) Crystal structure of the EGFR extracellular domains 
bound to EGF resolved by Ogiso et al. (Ogiso et al., 2002), from the Protein Data Bank 
database (www.rscb.org). 
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This is unusual among RTKs, as typically the ligand mediates an interaction between two 
receptor molecules, e.g. in the case of FGFR, the dimer is stabilised by direct interaction 
between the ligand and the adjacent receptor (Plotnikov et al., 1999). In the case of EGFR, 
however, receptor dimeriation is mediated by receptors themselves. The ligand binds 
simultaneously to the domain I and III of the same receptor, and the released dimerisation arm 
of domain II is able to interact with domain II in the partner receptor molecule. This has been 
proposed to be true for three members of the ErbB family: EGFR, ErbB3 and ErbB4. In the 
case of ErbB2, the extracellular domain of the receptor has been shown to be in an active 
conformation in the absence of ligand, and domains I and III have been found to be in a close 
proximity  (Cho et al., 2003; Garrett et al., 2003). This may explain why ErbB2 over-
expression leads to tumorigenesis, since the close proximity of domain I and III disrupts the 
interaction between domain II and IV, leading to ligand-independent dimerisation. Similarly, 
this may be the reason why no ErbB2 ligand has been described, as there may not be enough 
space for any ligand to bind between the interacting domains I and III (Cho et al., 2003; 
Garrett et al., 2003). Additionally, although the ErbB2 extracellular domain structure 
resembles that of an active EGFR dimer, the negatively charged dimerisation arm and the 
pocket into which it would dock prevents ErbB2 homodimerisation and promotes 
heterodimerisation with other ErbB receptors (Garrett et al., 2003).  
 
In the case of EGFR, the interaction between domain II and IV observed in an inactive 
„tethered‟ state of the receptor does not seem to be sufficient to inhibit receptor activation. 
This was shown with mutations disrupting this interaction and thus exposing the dimerisation 
arm, which did not lead to receptor dimerisation or activation (Mattoon et al., 2004; Walker et 
al., 2004). Therefore other factors have been proposed to additionally stabilise an inactive 
state of the receptor, or to promote receptor activation. For example, the conformational 
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changes within the domain II following ligand binding may promote receptor dimerisation 
and activation (Dawson et al., 2005). Also, a linkage between domains II and III has been 
proposed to be very rigid and stabilised by disulfide bond, thus promoting formation of an 
inactive conformation even when the interaction between domains II and IV is removed 
(Dawson et al., 2007). Finally, oligosaccharides which are not entirely visualised in the 
crystal structure, have been proposed to sterically restrict the position of the domains involved 
in dimerisation, and thus ligand binding could potentially disrupt these restrictions (Dawson 
et al., 2007). 
 
In addition to the unusual mechanism of EGFR dimerisation, EGFR tyrosine kinase activation 
is also unique among other RTKs. Typically, the autoinhibitory interactions within the kinase 
domain are disrupted by trans-autophosphorylation, e.g. in the case of FGFR or insulin 
receptor; however, EGFR autophosphorylation is not required for activation. This has been 
shown using mutant EGFR with a tyrosine residue within the activation loop replaced by 
phenylalanine, which was activated to a similar level as wild type EGFR (Gotoh et al., 1992; 
Zhang et al., 2006). Additionally, it has been shown that two leucine residues within the 
activation loop of EGFR (Leu834 and Leu837) provide an autoinhibitory mechanism through 
packing against a crucial catalytical region (helix αC) within the N-lobe of the kinase domain 
and thus reinforcing its displaced orientation. In accordance with this, replacement of Leu834 
with arginine has been found to promote EGFR activation (Zhang et al., 2006).  Therefore an 
allosteric model of EGFR activation has been proposed, which suggests that upon receptor 
dimerisation, an asymmetric interaction takes place between the C-lobe of one receptor 
tyrosine kinase („activator‟) and the N-lobe (helix αC) of the other receptor („receiver‟). This 
leads to the activation of the kinase domain of the „receiver‟, which then phosphorylates the 
C-terminal tail of the other receptor, and vice-versa, leading to receptor trans-
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autophosphorylation (Zhang et al., 2006). Additionally, the juxtamembrane (JM) domain of 
EGFR may also contribute to receptor dimerisation and activation, and it has been suggested 
that the flexibility of the JM domain may enable the kinase domains to switch positions and 
activate each other (Zhang et al., 2006; Thiel and Carpenter, 2007; Jura et al., 2009).  
 
1.2.3 EGFR ligands 
Currently there are seven EGFR ligands characterised, some of which may also activate 
ErbB3 and ErbB4. The EGFR ligands include EGF, transforming growth factor-α (TGF-α), 
heparin-binding EGF (HB-EGF), amphiregulin (AREG), betacellulin (BTC), epiregulin 
(EREG) amd epigen (Roepstorff et al., 2009; Schneider and Wolf, 2009). Additionally, 
another group of ligands collectively known as neuregulin typically activate ErbB3 and 
ErbB4. As explained above (Chapter 1.2.2), no ligand has yet been described for ErbB2 
(Leahy, 2004; Schneider and Wolf, 2009). The EGFR ligands all contain the EGF module, an 
approximately 40 amino acid-long motif with six conserved cysteine residues forming three 
disulfide bonds and three loops. Upon synthesis, the EGFR ligands traffic to the plasma 
membrane, where the extracellular EGF module undergoes enzymatic cleavage resulting in a 
soluble ligand being released to the intracellular matrix. The cytoplasmic tail regulates ligand 
targeting to the plasma membrane, and upon cleavage of the EGF module, it has been 
proposed to regulate gene transcription (Schneider and Wolf, 2009). 
 
The EGFR ligands share little sequence identity (approximately 25 %) and differ in 
biochemical properties, such as the presence and distribution of glycosylation sites. 
Additionally, they may exhibit different activities, e.g. autocrine, paracrine or juxtacrine 
activity (Harris et al., 2003; Schneider and Wolf, 2009). They also vary in their affinity to 
EGFR and in the effects they exert on EGF signalling and EGFR trafficking (Roepstorff et 
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al., 2009), which is described in more detail in Chapter 1.3.1. Binding of all known EGFR 
ligands results in EGFR endocytosis and trafficking towards early endosomes; however, each 
ligand differentially regulates trafficking through the lysosomal and recycling compartments. 
Additionally, binding of some of the ligands has been shown to be more persistent in acidic 
pH, e.g. EGFR binding of HB-EGF, BTC and AREG has been found to be more acid-resistant 
than that of EGF or TGF-α (Roepstorff et al., 2009). Furthermore, EGFR stimulation with 
HB-EGF and BTC have been shown to result in complete EGFR degradation, whereas both 
TGF-α and EREG led to EGFR recycling to the plasma membrane. EGF, which is the only 
EGFR ligand used throughout the study presented in this thesis, has been shown to promote 
EGFR degradation; however, some recycling can also be detected (Roepstorff et al., 2009). 
 
1.2.4 EGF signalling pathway 
Currently the EGF signalling and EGFR trafficking pathways are being extensively 
investigated and an intersection, or a mutual interplay, between EGFR trafficking (explained 
in Chapter 1.3.1) and signalling is emerging. There are several major signalling pathways 
activated by the EGF-EGFR complex; these include the Ras/MAPK, PI3K/Akt, PLCγ/PKC 
and JAK/STAT pathways (Jorissen et al., 2003). Activation of these cascades promotes cell 
proliferation, migration and cell survival. Interestingly, activation of particular signalling 
pathways may predominantly lead to different phenotypes; e.g. activation of PI3K/Akt 
pathway has been predominantly linked to cell proliferation and cell survival, whereas 
activation of PLCγ/PKC pathway has been found to promote cell migration (Chen et al., 
1994; Jorissen et al., 2003). The schematic representation of the EGF signalling cascades is 
shown in Figure 1.3. 
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Figure 1.3. EGF signalling pathway 
Upon ligand binding, EGFRs at the plasma membrane dimerise and trans-autophosphorylate, 
thus triggering series of phosphorylation and dephosphorylation events within various 
signalling molecules. All these changes modify gene expression, regulate cytoskeletal 
rearrangements, promote cell growth and survival, and inhibit apoptosis. Adapted from 
(Jorissen et al., 2003; Reuter et al., 2007). 
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As described in Chapter 1.2.2, upon ligand binding EGFRs dimerise, leading to activation of 
the kinase domains and trans-autophosphorylation of the intracellular tyrosine residues 
(Honegger et al., 1989; Ferguson, 2008). These phosphorylation events allow for interaction 
with proteins containing Src homology 2 (SH2) and phospho-tyrosine binding (PTB) 
domains, such as adaptor proteins (the proteins that lack an enzymatic function, but contain at 
least two protein binding motifs, thus allowing binding of at least two signalling molecules at 
the same time) (Flynn, 2001). For example an adaptor protein Shc interacts with 
phosphorylated EGFR through its SH2 and PTB domains (Rozakisadcock et al., 1992).  
 
Following interaction with activated receptor, phosphorylated Shc associates with a complex 
composed of an adaptor protein growth factor receptor-bound protein 2 (Grb2) and son of 
sevenless (Sos), a guanine nucleotide exchange factor (GEF) (described in more detail in 
Chapter 1.3.4). In the Shc-Grb2-Sos complex, the SH2 domain of Grb2 binds phosphorylated 
Shc, whereas the Src homology 3 (SH3) domain interacts with proline-rich region within Sos 
(Rozakisadcock et al., 1992; Simon and Schreiber, 1995). When recruited to the plasma 
membrane, Sos activates a membrane resident Ras, leading to recruitment of downstream 
effectors of Ras and initiation of multiple signalling cascades (Sakaguchi et al., 1998; 
Kyriakis, 2009). Grb2 has also been shown to interact with phosphorylated EGFR directly 
through its SH2 domain (Rozakisadcock et al., 1992). Furthermore, during early stages of 
receptor internalization, Grb2 has been identified as recruiting Cbl, a ubiquitin ligase, thus 
allowing for EGFR ubiquitylation (described in Chapter 1.3.3) (Jiang et al., 2003).  
 
The Ras/MAPK pathway is one of the major signalling cascades activated downstream of 
EGFR. When Ras is stimulated by the Shc-Grb2-Sos complex, it becomes active through 
conversion of guanosine diphosphate (GDP) to guanosine triphosphate (GTP) (explained in 
Chapter 1 - Introduction 
 
14 
 
Chapter 1.3.3) (McCubrey et al., 2007). Activated Ras recruits Raf to the plasma membrane, 
which is followed by multiple phosphorylation and dephosphorylation events within Raf 
domains (McCubrey et al., 2007). Activated Raf phosphorylates mitogen-activated protein 
kinase/extracellular signal-regulated kinases 1 and 2 (MAPK/Erk 1/2), which activate many 
downstream targets. MAPK/Erk 1/2 can also translocate to the nucleus and phosphorylate 
various transcription factors, thus modifying gene expression (McCubrey et al., 2007). 
Ras/MAPK activation promotes entry into cell cycle and cell proliferation (Avraham and 
Yarden, 2011), and stimulates cell migration possibly through focal adhesion (adhesion 
between the cell and the extracellular matrix)  disassembly (Jorissen et al., 2003). 
 
Apart from activation of Raf, there are other downstream targets of Ras. For example RalGEF 
interacts with activated Ras and promotes the GDP to GTP exchange within Ral, a small Ras-
like GTPase. This leads to the activation of RhoGTPases, for example Cdc42, leading to 
cytoskeletal rearrangements and cell migration (Cantor et al., 1995; Jullienflores et al., 1995). 
In addition to Raf and RalGEFs, phospholipase C gamma and epsilon (PLCγ/ε) are other Ras 
effectors (Kelley et al., 2001). PLCγ/ε perform hydrolysis of phosphatidylinosidol 4,5-
biphosphate (PIP2) to diacylglycerol (DAG), which activates protein kinase C (PKC), and to 
inositol 1,4,5-triphosphate (IP3), which mediates intracellular calcium release (Rhee, 2001).  
Signalling via PLCγ/ε has been proposed to regulate cell migration. In particular, activated 
PLCγ promotes release of actin-modifying proteins from the plasma membrane, which then 
bind actin filaments thus regulating actin cytoskeleton reorganization (Chen et al., 1996).  
 
Another major signalling cascade downstream of EGFR is the PI3K/Akt pathway. PI3K is 
composed of two subunits: a regulatory subunit p85 and a catalytic subunit p110. The SH2 
domain of p85 associates with phosphorylated EGFR, resulting in PI3K recruitment to the 
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plasma membrane. PI3K then binds and phosphorylates PIP2 leading to formation of 
phosphatidylinositol 3,4,5-triphosphate (PIP3), which is a second messenger that binds 
plextrin homology (PH) domains in target proteins (Kyriakis, 2009). Conversion of PIP2 to 
PIP3 is negatively regulated by phosphatase and tensin homologue deleted from chromosome 
10 (PTEN), which dephosphorylates PIP3 back to PIP2 (Chalhoub and Baker, 2009). PIP3 
recruits phosphoinositide-dependent kinase 1 (PDK1) and Akt, a serine-threonine kinase, both 
of which contain PH domains. This close proximity enables PDK1 to phosphorylate Akt, 
which integrates and coordinates multiple signalling pathways. Activation of the PI3K/Akt 
pathway is perhaps the most prominent regulator of cellular functions, promoting anti-
apoptotic responses, cell cycle entry and cell survival (Jorissen et al., 2003). 
 
When activated, Akt phosphorylates diverse downstream proteins, some of which are 
inhibited, e.g. BAD (a pro-apoptotic member of the Bcl-2 family) (Datta et al., 1997), whilst 
others are activated. Through phosphorylation of κB inhibitor (IκB), which is subsequently 
degraded, Akt facilitates activation of NFκB (nuclear factor κ-light-chain-enhancer of 
activated B cells), leading to transcription of anti-apoptotic genes (Bai et al., 2009). 
Additionally, Akt phosphorylates mouse double minute homolog 2 (Mdm2), a negative 
regulator of p53, thus downregulating p53-mediated apoptosis (Ogawara et al., 2002). By 
phosphorylation of tuberous sclerosis protein 2 (TSC2), Akt inhibits GTPase activity of TSC1 
and TSC2 dimer toward Rheb (RAS homologue enriched in brain), enabling Rheb to activate 
mammalian target of rapamycin (mTOR), leading to protein synthesis and cell survival 
(Courtney et al., 2010). Akt also phosphorylates cell cycle inhibitor p27, leading to its 
degradation (Fujita et al., 2002) and inhibits glycogen synthase kinase 3 (GSK-3), a protein 
which induces apoptosis (Pap and Cooper, 1998). Therefore, Akt promotes cell survival and 
activation of anti-apoptotic mechanisms. 
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There are other proteins which can be recruited to active EGFR, e.g. Janus kinase (JAK), 
which associates and phosphorylates signal transducers and activators of transcription 
(STATs) leading to STATs translocation to the nucleus (Andl et al., 2004). Nevertheless, 
JAK-independent and likely Src-dependent STAT activation has also been reported (Rawlings 
et al., 2004). Activated EGFR also binds and phosphorylates insulin receptor substrate 1 
(IRS1), which in turn may activate several signalling pathways, for example the PI3K/Akt 
pathway (Knowlden et al., 2008; Metz and Houghton, 2011).  
 
The Src family of non-receptor tyrosine kinases comprises other important regulators of EGF 
signalling. The SH2 domain of Src has been found to bind EGFR upon EGF stimulation; 
however, it is unclear whether Src acts downstream of the EGF signalling cascade, or whether 
it is required for receptor activation (Biscardi et al., 1999; Jorissen et al., 2003). For example, 
EGFR kinase inhibitor has been shown to inhibit EGF-dependent Src activation in colon 
cancer cells, suggesting that Src acts downstream of EGFR (Mao et al., 1997). Similarly, 
EGFR has also been shown to activate Src following EGF treatment in epidermoid cancer 
cells, and Src activation then stimulated clathrin redistribution and EGFR endocytosis (Wilde 
et al., 1999). On the other hand, Src overexpression in breast cancer cells has been shown to 
result in EGFR phosphorylation, thus suggesting that EGFR activation may occur 
downstream of Src (Biscardi et al., 1999).  
 
1.2.5 Negative regulation of EGF signalling  
Taking into consideration how many important cellular functions are regulated by EGF 
signalling, it is understandable that mechanisms exist which tightly control these signalling 
pathways and protect cells from aberrant activation. The negative feedback regulation may be 
roughly divided into two types of response: early, or primary, and secondary response 
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(Avraham and Yarden, 2011). The early loop involves the events that take place immediately 
upon ligand binding and therefore are mainly restricted to the cellular components already 
present within the cell. These include receptor endocytosis, protein modifications such as 
dephosphorylation and ubiquitylation (described in Chapter 1.3.2 and Chapter 1.3.3), as 
well as degradation of a group of microRNAs which would otherwise negatively regulate 
gene expression. In contrast, the late loop involves the regulation of the EGF-stimulated 
response by newly synthesized proteins and RNAs. Activation of the late loop leads to 
modulation of cellular functions such as metabolism and membrane biogenesis. The 
secondary response also leads to an establishment of a newly acquired cellular state, e.g. in a 
process of epithelial-mesenchymal transition, in which highly organized epithelial cells lose 
their polarity and become motile (Avraham and Yarden, 2011).  
 
Receptor endocytosis (described later in Chapter 1.3) is perhaps the most prominent signal 
attenuator. It is also the first step for the activated receptor towards lysosomal degradation, 
thus allowing for desensitization from continuous ligand stimulation (Beguinot et al., 1984; 
Roepstorff et al., 2009). Endocytosis removes growth factor receptors from the plasma 
membrane; however, signalling is not simply abrogated upon receptor internalization, but 
rather continues from within endosomes (Vieira et al., 1996) (described in more detail in 
Chapter 1.3.4). In general, acidic pH of the endosomes leads to the dissociation of the ligand-
receptor complexes. As described in Chapter 1.2.3, different ligands vary in their affinity for 
EGFR, and some dissociate from EGFR earlier than others, thus leading to signal attenuation 
and receptor recycling, e.g. TGF-α. Other ligands, e.g. HB-EGF, bind EGFR more efficiently 
and therefore do not dissociate from the receptor until the endosomes become highly acidic 
(Roepstorff et al., 2009).  
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Apart from internalization, EGFR dephosphorylation by phosphatases is another mechanism 
of signal attenuation. For example, receptor-type protein-tyrosine phosphatase-κ (RPTP-κ) 
has been shown to dephosphorylate EGFR in human keratinocytes, and RPTP-κ knockdown 
(KD) resulted in increased EGFR and Erk phosphorylation both at the basal levels, and 
following EGF stimulation (Xu et al., 2005). Therefore, EGFR dephosphorylation leads to 
inhibition of EGF signalling. In addition to dephosphorylation, ubiquitylation (described in 
more detail in Chapter 1.3.3) also contributes to signal downregulation. Ubiquitylation, a 
post-translational modification that involves the attachment of ubiquitin to lysine residues on 
a target protein, has been proposed to be critical for lysosomal targeting and degradation of 
EGFR, but not for EGFR endocytosis (Staub and Rotin, 2006; Huang et al., 2006a; 
Seshacharyulu et al., 2012). This has been shown with the EGFR mutants, in which several 
lysine residues within the kinase domain were mutated to arginines; these mutants were 
poorly ubiquitylated and failed to undergo degradation when compared to the wild-type 
EGFR (Huang et al., 2006a). 
  
There are several proteins described to act as negative regulators of EGF signalling. For 
example Mig6/RALT is an adaptor protein that has been shown to interact with the tyrosine 
kinase domain of EGFR following ligand binding and to inhibit EGF signalling (Zhang et al., 
2007). Mig6 knockout mice showed hyperactivation of EGFR and downstream signalling 
pathways, further supporting the suppressive effects of Mig6 on EGF signalling (Ferby et al., 
2006). Fibroblast growth factor receptor substrate 2β (FRS2β) has similarly been shown to act 
as an EGFR inhibitor. FRS2β has been found to bind EGFR independently of ligand 
stimulation and to inhibit EGFR autophosphorylation following EGF treatment, through 
interaction with Erk2 (Huang et al., 2006b). Another example includes suppressors of the 
cytokine signalling (SOCS) and leucine-rich repeats and immunoglobulin-like domains 1 
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(LRIG1). Expression of both groups of proteins is enhanced following EGF stimulation, and 
they have been proposed to recruit the E3 ubiquitin ligases RING-box protein 1 (RBX1) and 
Cbl, respectively, resulting in EGFR ubiquitylation and degradation (Gur et al., 2004; Kario 
et al., 2005; Gotoh, 2009). 
 
1.2.6 EGF signalling in development 
EGF was first isolated from the salivary gland of mice, and characterized as a factor 
promoting eyelid opening and teeth development (Cohen, 1962). Following from this 
discovery, numerous approaches were undertaken to investigate the functions of EGF and 
EGF signalling in development. Removal of salivary glands resulted in reduced EGF levels in 
mice, and this led to a decrease in the thickness of the epidermis (Tsutsumi et al., 1987), and 
in reduced size of the mammary glands (Okamoto and Oka, 1984). Further studies with 
dominant negative EGFR confirmed the functions of EGF signalling in development of the 
mammary duct (Xie et al., 1997), whereas a point mutation within the EGFR kinase domain 
which dramatically impaired EGFR kinase activity, led to abnormalities in skin development 
(Luetteke et al., 1994). Studies on mice with disrupted EGFR gene revealed that EGF 
signalling is critical for embryogenesis; depending on the genetic background, disruption of 
the EGFR gene led to early or late embryonic death, or post-natal death, due to multiple organ 
failure (Threadgill et al., 1995). Similar studies emphasized the functions of EGF signalling in 
epithelia development, and impaired epithelial maturation in mice lacking functional EGFR 
gene has been proposed as a cause for a multiple organ failure (Miettinen et al., 1995). On the 
other hand, mice injected with EGF showed delay in body weight gain and in 
neurobehavioural development (Calamandrei and Alleva, 1989). These studies established 
EGF signalling as a critical determinant in proper embryo development. Examples of EGF 
signalling functions in this context are presented in Table 1.1. 
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Skin 
Differentiation and survival of keratinocytes 
Development of hair follicles 
Hair cycle progression 
Lung 
Maturation of type II pneumocytes 
Branching morphogenesis 
Heart 
Differentiation of valve mesenchymal cells 
Formation of semilunar valves 
Brain 
Survival of cortical astrocytes 
Migration of postmitotic neurons 
Controling migration and/or differentiation of astrocytes 
Bone 
Inhibition of chondrocyte and osteoblast differentiation 
Proliferation of osteoblasts 
Liver 
Proliferation of hepatocytes 
Liver regeneration 
 
Table 1.1. Multiple functions of EGF signalling in development and physiology 
Examples of the functions for the EGF signalling in organogenesis. Adapted from (Sibilia et 
al., 2007). 
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1.2.7 EGF signalling in cancer 
Due to multiple signalling pathways activated downstream of EGFR which promote cell 
proliferation, migration and survival, as described in Chapter 1.2.4, it is understandable that 
misregulation of EGF signalling may lead to uncontrolled cell proliferation and ultimately 
cancer. EGFR gene amplifications, aberrant EGFR expression and mutations within the 
EGFR gene have all been found in different types of cancer (Avraham and Yarden, 2011). For 
example, mutations within the EGFR gene can contribute to ligand-independent receptor 
activation (Normanno et al., 2006; Lemmon and Schlessinger, 2010). In particular, mutant 
EGFRs frequently display a basal level of activation, which is sufficient to stimulate 
downstream signalling cascades, but insufficient to target EGFR for degradation (Avraham 
and Yarden, 2011). 
 
The majority of high-grade astrocytic gliomas exhibit EGFR overexpression and this has been 
correlated with EGFR gene amplification (Libermann et al., 1985; Kuan et al., 2001). EGFR 
overexpression has been further identified as a result of both gene amplifications and 
increased transcription, and has been linked to early stages of tumorigenesis in several cancer 
types, such as oral, lung and prostate cancers (Grandis and Sok, 2004). In the case of non-
small cell lung cancer (NSCLC), which represents the majority of all lung cancers (Sharma et 
al., 2007), EGFR has been found overexpressed in over 60 % of cancers (Hirsch et al., 2003), 
and increased EGFR levels have been associated with shorter survival (Veale et al., 1993). 
Additionally, in a subset of NSCLCs activating mutations within the EGFR gene have been 
shown to lead to activation of downstream signalling cascades, and drugs targeting EGFR 
kinase activity are currently in clinical use (Hirsch et al., 2003; Sharma et al., 2007). 
Similarly, EGFR overexpression has been identified in approximately 70 % of colorectal 
tumors and has been associated with increased cancer cell metastasis, and monoclonal 
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antibodies targetting EGFR are currently in use for a subgroup of patients with this type of 
cancer (Radinsky et al., 1995; Yarom and Jonker, 2011).  
 
As mentioned above, mutations within the EGFR gene may also promote cancer 
development. For example, an in-frame deletion mutant of EGFR, EGFRvIII, with deletion of 
exons two through to seven, has been reported to be constitutively active and oncogenic. This 
has been suggested to be the most common in-frame deletion mutant of EGFR and to be 
exclusively expressed in cancers, such as brain, breast, lung and prostate cancers (Grandis and 
Sok, 2004; Seshacharyulu et al., 2012). Additionally in gliomas, tandem duplications of the 
regions of the EGFR gene within the extracellular or intracellular portion of the receptor have 
been characterized (Kuan et al., 2001). Several mutations within the kinase domain of EGFR 
have also been detected in a subgroup of patients with NSCLC, e.g. in-frame deletions, with 
overlapping deletion of four amino acids (Leu747, Arg748, Glu749, Ala750), and point 
mutations of Leu858Arg, Leu861Gln and Cys719Gly (Lynch et al., 2004). All of these 
mutations have been proposed to drive tumorigenesis, and the patients carrying these 
mutations have been found to respond to the therapy with EGFR kinase inhibitor; however, an 
additional mutation within the EGFR kinase domain (Thr790Met) in these tumours has been 
linked with cancer relapse and acquired resistance to the EGFR inhibitor (Kobayashi et al., 
2005). 
 
In addition, infections with some oncogenic viruses have been found to promote EGFR 
overexpression and activation. For example, the Epstein-Barr virus encodes the latent 
membrane protein 1, which has been shown to induce expression and activation of EGFR 
(Miller et al., 1995), and infection with hepatitis B virus has been found to induce EGFR 
expression in liver cancer cells (Menzo et al., 1993). Finally, EGF signalling plays critical 
roles in angiogenesis, e.g. EGF signalling via PI3K has been found to increase mRNA    
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levels of pro-angiogenic factors, such as vesicular EGF (vEGF) (Petit et al., 1997; Maity et 
al., 2000). 
  
1.3 Endocytosis and endocytic trafficking 
The first reports on the discovery of clathrin-mediated endocytosis (CME) come from the 
1960s, when coated pits were seen by electron microscopy to pinch off from the plasma 
membrane of mosquito oocytes (Roth and Porter, 1964). The pits carrying yolk proteins were 
pinching off from the membrane and ultimately uncoating. Similar structures were observed 
following uptake of horseradish peroxidise in the epithelium of the rat vas deferens (Friend 
and Farquhar, 1967). These studies led to identification of a particular type of endocytosis, 
known as clathrin-mediated endocytosis (CME) (described below). Clathrin was first isolated 
and characterised by Barbara Pearse in 1976. She isolated coated vesicles from bovine and pig 
brains, adrenal medulla and lymphoma cell line and identified clathrin as the major 
component of these vesicles. She also described lattice structures of clathrin and proposed that 
the vesicles are coated by a hexagonal and pentagonal network of clathrin subunits (Pearse, 
1976). In addition to CME, further studies revealed the co-existence of clathrin-independent 
endocytosis (CIE), when uptake of cholera and tetanus toxins via non-coated invaginations 
was discovered in liver cells (Montesano et al., 1982).  
 
Endocytosis (internalisation), the process by which a cell absorbs extracellular molecules, e.g. 
hormones, cytokines and growth factors, is prevalent throughout evolution and can be 
distinguished in plants (Samaj et al., 2004) and recently in bacteria (Jermy, 2010). When a 
membrane invaginates, a vesicle (or a phagosome in phagocytosis; described below) pinches 
off from the membrane and traffics within the cell (Soldati and Schliwa, 2006). Internalised 
cargoes are delivered to various destinations, e.g. to lysosomes for degradation, or back to the 
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plasma membrane for recycling (Sorkin and von Zastrow, 2009). During these processes, 
internalised molecules provide nutrients and activate multiple signalling pathways, thus 
providing information for the cell, e.g. whether to grow, proliferate or undergo apoptosis.  
Therefore, endocytosis enables the cell to sense and react to external stimuli.  
 
There are two types of endocytosis described: phagocytosis and pinocytosis. The former 
involves the engulfment of particles into a phagosome, whereas the latter describes the uptake 
of fluid, extracellular ligands and integral membrane proteins into a vesicle. In phagocytosis, 
membrane protrusions surround an object and engulf it with assistance of motor proteins 
(Soldati and Schliwa, 2006). With respect to the work presented in this thesis, phagocytosis is 
not investigated and therefore the term endocytosis is strictly limited to pinocytosis. The types 
of endocytosis are summarised in Figure 1.4. 
 
There are many different types of endocytosis, some of which are understood better than the 
others. The most studied and the best characterised mechanism of internalisation is CME. 
Clathrin, a protein which regulates the formation of coated vesicles, plays a major role in 
transport between organelles, plasma membrane and endosomes (Ohno, 2006). Clathrin forms 
a triskelion composed of three heavy and three light chains, and assembles into lattice 
structures on the membrane in places enriched in PIP2 (Madshus and Stang, 2009). Clathrin 
itself cannot bind membranes, and thus requires adaptor proteins such as adaptor protein 
complex 2 (AP2), which bind both clathrin and membrane lipids and proteins (Ohno, 2006). 
Newly formed vesicles pinch off from the plasma membrane with engagement of the GTPase 
dynamin (Mayor and Pagano, 2007). Upon internalisation, vesicles uncoat and clathrin 
recycles back to the plasma membrane (Lemmon, 2001). 
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Figure 1.4. Types of endocytosis 
Phagocytosis is a type of endocytosis in which a particle is engulfed by membrane protrusions 
known as lamellopodia. Motor proteins myosins are also involved in this process. In the 
process of pinocytosis, fluid is engulfed by the plasma membrane. Macropinocytosis 
morphologically resembles phagocytosis and involves myosins. Clathrin-mediated 
endocytosis is a dynamin-dependent process, in which dynamin pinches off the vesicle from 
the membrane. Caveolar endocytosis similarly requires dynamin. Clathrin- and caveolar-
independent endocytosis does not require dynamin and is poorly characterised. Upon 
endocytosis, the vesicles or phagosomes traffic to subcellular destinations. Adapted from 
(Soldati and Schliwa, 2006; Mayor and Pagano, 2007). 
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Apart from CME, which is a dynamin-dependent type of internalisation, there also exist an 
undefined number of CIE pathways, which can be further divided into two major groups: 
dynamin-dependent and dynamin-independent (Mayor and Pagano, 2007). Caveolar 
endocytosis, which is the best characterised among CIE, is a dynamin-dependent pathway. In 
this internalisation route, the vesicles formed are smaller compared to clathrin-coated pits, and 
are marked by the presence of a protein called caveolin; they are also enriched in 
sphingolipids and cholesterol (Mayor and Pagano, 2007).  
 
Apart from caveolar endocytotis, another recognised dynamin-dependent pathway is RhoA-
dependent internalisation (Mayor and Pagano, 2007). It has been proposed that this pathway 
requires the action of a small GTPase RhoA to recruit the actin machinery. Other example of 
CIE dynamin-independent endocytosis is Cdc42-regulated internalization (Mayor and Pagano, 
2007). In this pathway, a small GTPase Cdc42 has been proposed to recruit actin-
polymerization machinery in a manner which is highly sensitive to cholesterol levels (Mayor 
and Pagano, 2007). Finally, macropinocytosis is the type of endyctosis considered as a bulk 
process, morphologically similar to phagocytosis, in which the fluid uptake takes place 
through large membrane invaginations with involvement of a motor protein myosin (Soldati 
and Schliwa, 2006). 
 
Following internalisation the vesicle traffics towards early (sorting) endosomes. Interestingly, 
a novel type of endosomes has been characterised in addition to early endosomes, marked by 
the presence of Rab5 and Rab5 effectors DCC (deleted in colorectal cancer)-interacting 
proteins 13 α and β (APPL1 and APPL2), but not early endosome antigen 1 (EEA1) 
(described in Chapter 1.3.4); however, only a minority of internalised EGF has been found 
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within APPL-positive endosomes and the majority localizes within EEA1-positive early 
endosomes (Miaczynska et al., 2004a; Miaczynska et al., 2004b). 
 
There are two proposed models of the progression between early and late endosomes. In the 
first model proposed by Griffiths and Gruenberg in 1991 (Griffiths and Gruenberg, 1991), the 
early and late endosomes are stable compartments and the carrier vesicles shuttle between 
them to provide internalised cargo. In support of this model, both early and late endosomes 
have been shown to have a complex structural organisation, as compared to the carrier 
vesicles, and to differ in polypeptide composition. Additionally, in vitro experiments show 
that early and late endosomes do not fuse with each other; however, the carrier vesicles have 
been found to fuse with late endosomes. Finally, the studies with polarised cells identify two 
sets of early endosomes (apical and basolateral). Both of these sets have been proposed to 
have a separate population of carrier vesicles, whose content is mixed within the late 
endosomal compartment, indicating that fusion takes place between carrier vesicles and late 
endosomes (Griffiths and Gruenberg, 1991). 
 
 In the other model proposed by Murphy in 1991 (Murphy, 1991), the endosomes are transient 
compartments undergoing maturation, during which their composition and properties change. 
This model argues that the separation of fractions of early endosomes, late endosomes and 
lysosomes is possible due to rate-limiting steps in the process of endosomal maturation. 
Furthermore, the early endosomal fraction may also contain recycling vesicles, leading to the 
observed differences in the composition between early and late endosomes. Further alterations 
in the content of the cytoplasmic proteins bound to early or late endosomal membranes may 
result from the pH changes during endosomal maturation, e.g. some proteins may dissociate 
from the membranes upon endosome acidification, since late endosomes are more acidic than 
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early endosomes (Clague, 1998). Additionally, a study by Rink et al. argues that the 
conversion between Rab GTPases, in particular Rab5 and Rab7 (described in Chapter 1.3.4), 
is a determinant for endosomal progression and that the endosomal cargo becomes 
progressively enriched in fewer and larger endosomes (Rink et al., 2005). These data 
therefore also support the maturation model. Nevertheless, Murphy does not exclude the 
possibility that, while some processes involve endosomal maturation, others may engage 
carrier vesicles shuttling between compartments. In the process of phagocytosis, in which 
large molecules are internalised, the maturation model is more preferable, as large particles 
may not fit into carrier vesicles. In contrast, the stable endosomal model is proposed to be 
more applicable to the other types of endocytosis (Soldati and Schliwa, 2006).  
 
From early endosomes, the internalised lipids, proteins and other molecules can be delivered 
back to the plasma membrane, either through fast or slow recycling; the latter involves transit 
through the perinuclear recycling compartment (PNRC) (Soldati and Schliwa, 2006). 
Alternatively, the cargo can be delivered to late endosomes and ultimately to lysosomes for 
degradation, or to the trans-Golgi network (TGN), which is the major sorting hub in 
thesecretory pathway. From TGN the cargo can be delivered to different cellular destinations 
(Gu et al., 2001; Soldati and Schliwa, 2006).   
 
The vesicles move along microtubules and this is directed by motor proteins, which associate 
with membrane lipids, membrane proteins or adaptor proteins within the vesicles. Following 
endocytosis, the vesicles traffic towards the negatively charged microtubule minus-ends. At 
later stages, microtubule plus-end transport also takes place, e.g. between early and recycling 
endosomes or between trans-Golgi network and late endosomes. This bidirectional transport 
has been proposed to promote scattered distribution of organelles, as well as organelle 
encounters and fissions (Soldati and Schliwa, 2006). The long-range transport of vesicles and 
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organelles, e.g. from the perinuclear compartments to the cell periphery, has been proposed to 
involve microtubules, whereas the vesicle trafficking steps during short-range transport are 
controlled by actin cytoskeleton (Soldati and Schliwa, 2006). 
 
1.3.1 Endocytic trafficking of growth factor receptors 
Ligand-bound RTKs activate multiple signalling pathways at the cell surface and undergo 
regulated endocytosis primarily through clathrin-dependent pathways (Aguilar and Wendland, 
2005; Goh et al., 2010; Lemmon and Schlessinger, 2010) (Figure 1.5). EGFR has been 
shown to be internalized at the pre-formed clathrin clusters (Rappoport and Simon, 2009). 
Nevertheless, a substantial role for clathrin-independent pathways in RTKs internalization has 
also been proposed, especially when cells are treated with higher ligand concentrations 
(Yamazaki et al., 2002; Haglund et al., 2003; Sigismund et al., 2005).  
 
In the case of EGFR, ligand binding results in receptor internalization and trafficking towards 
early endosomes, where it is sorted for recycling or degradation. Stimulation with a particular 
ligand determines EGFR fate, i.e. recycling or degradation, as described in Chapter 1.2.3. 
This has been shown to largely depend on the persistence of ligand binding in the acidic pH 
of the endosomes. In particular, the majority of ligands which remain bound to EGFR at a 
relatively low pH (pH 4.0-5.0), such as HB-EGF and BTC, promote increased EGFR 
ubiquitylation and degradation, whereas the ligands which dissociate from EGFR at higher 
pH (pH 6.0-7.0), such as TGF-α, promote EGFR recycling (Roepstorff et al., 2009). 
Endocytosis has been proposed to play a major role in the regulation of signal attenuation, via 
removal of RTKs from the plasma membrane (Lemmon and Schlessinger, 2010). 
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Figure 1.5. Classical endocytic route of EGFR  
Upon ligand binding, EGFRs dimerise, trans-autophosphorylate and become ubiquitylated. 
Activated EGFRs undergo clathrin-mediated internalisation, with assistance of adaptor 
protein 2 (AP2) complex and dynamin. Internalised EGFRs traffic through the endo-
lysosomal pathway for degradation. Alternatively, endocytosed EGFRs may be recycled back 
to the plasma membrane. Adapted from (Soldati and Schliwa, 2006). 
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Nevertheless, recent reports show that growth factor signalling is not abrogated by receptor 
internalization, rather it continues from within endosomes (Wang et al., 2002; Miaczynska et 
al., 2004b; Le Roy and Wrana, 2005; von Zastrow and Sorkin, 2007). Therefore, a strong 
interplay between RTK trafficking and signalling is emerging, with the suggestion that 
activated receptors sense signals which control intracellular trafficking, and vice versa, 
subcellular compartmentalisation regulates signalling outcomes. 
 
As described later in Chapter 1.3.3, EGFR ubiquitylation has been found to promote EGFR 
sorting within early endosomes for degradation (Duan et al., 2003) and several proteins and 
protein complexes have been found to regulate this step. These include Cbl, a RING-domain 
E3 ubiquitin ligase which mediates EGFR ubiquitylation (Levkowitz et al., 1998; Lipkowitz, 
2003), and endosomal sorting complex required for transport (ESCRT) complexes-0 (the 
hepatocyte growth factor (Hrs)-regulated tyrosine kinase substrate/signal-transducing adaptor 
molecule (STAM) complex), I, II and III, which regulate EGFR sorting for degradation (Urbe, 
2005; Clague et al., 2012). The ESCRT-0 complex recognizes and sequesters ubiquitylated 
cargo within early endosomes, and recruits the ESCRT-I complex. ESCRT-I and II further 
concentrate ubiquitylated cargo, whereas ESCRT-III is recruited by ESCRT-II and promotes 
membrane budding and formation of intraluminal vesicles. Importantly, ESCRT-III does not 
bind ubiquitin, but it engages deubiquitylating enzymes and other proteins to enable removal 
of ubiquitin and disassembly of the ESCRT machinery. Ultimately, the ESCRT components 
are released from the limiting membranes of late endosomes by the action of adenosine 
triphosphatase (ATPase) vacoular protein sorting 4 (Vps4) (Williams and Urbe, 2007; Roxrud 
et al., 2010). 
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Two major ubiquitin-binding domains present within the proteins that recognize ubiquitylated 
cargo include the ubiquitin-interacting motif (UIM) and the ubiquitin-associated (UBA) 
domain. Hrs and STAM, two components of the ESCRT-0 complex, both contain the UIMs 
as well as the N-terminal VHS (Vps27 (yeast homolog of Hrs)/Hrs/STAM) domains, which 
provide further ubiquitin-binding sites (Clague et al., 2012). These ubiquitin-binding proteins 
recognise ubiquitylated cargo, such as EGFR, which is designated for degradation. Many 
components of the ESCRT complexes are monoubiquitylated themselves, thus providing 
additional opportunities for interactions with ubiquitin-binding proteins (Clague et al., 2012). 
Furthermore, deubiquitylating enzymes which remove attached ubiquitin moieteies, such as 
ubiquitin-specific protease Y (UBPY) and associated molecule with the SH3 domain of 
STAM (AMSH), have also been proposed to regulate degradation of ubiquitylated cargo 
(described in more detail in Chapter 1.3.3). Thus, the fate of ubiquitylated cargo greatly 
depends on the balance between ubiquitylating and deubiquitiylating activities.  
 
1.3.2 Phosphorylation in endocytic sorting 
Post-translational modifications (PTMs) of the EGFR cytoplasmic domains, in particular 
phosphorylation and ubiquitylation, have been shown to greatly regulate receptor trafficking 
and signalling (Deribe et al., 2010). Phosphorylation, an attachment of a phosphate to a 
serine, threonine or tyrosine residue on a substrate, is the most commonly researched PTM 
that regulates cell signalling. It is catalysed by kinases, and mechanisms have evolved to 
control the specificity of substrate recognition. In particular, the features of the kinase active 
site and the docking sites on the substrate ensure substrate specificity. Additionally, the 
subcellular localization of kinases and/or their substrates may promote or prevent 
phosphorylation from occuring, as may the presence or absence of the scaffold proteins. 
Finally, the action of phosphatases results in removal of the attached phosphate groups from 
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the proteins (Ubersax and Ferrell, 2007). Thus, the processes of phosphorylation and 
dephosphorylation are tightly controlled by multiple mechanisms. 
 
Protein kinases are the third largest family of genes, representing approximately 2 % of the 
human genome, and can be divided into two major groups: the serine/threonine kinases and 
the tyrosine kinases; however, dual specificity kinases also exist which can phosphorylate 
serine, threonine and tyrosine residues  (Ubersax and Ferrell, 2007; Endicott et al., 2012). The 
majority of kinases show different conformations between inactive and active states and are 
often activated by phosphorylation, dimerization or by scaffold proteins (Endicott et al., 
2012). An active conformation of helix αC within the kinase domain may be stabilised 
through different mechanisms, e.g. through dephosphorylation of Tyr527 followed by 
phosphorylation of Tyr416 in Src kinase (Cartwright et al., 1987; Kmiecik and Shalloway, 
1987), through cyclin A binding to the cylin-dependent kinase 2 (CDK2) which leads to 
conformational changes and CDK2 activation (Jeffrey et al., 1995), or through dimerisation as 
in the case of EGFR (described in Chapter 1.2.2).  
 
In the process of phosphorylation, a γ-phosphate from adenosine triphosphate (ATP) is 
transferred onto the hydroxyl group of a tyrosine, serine or threonine residue. In the case of 
serine/threonine kinases, local negative charges that develop during catalysis have been 
shown to be stabilised by a lysine residue, which is localized two residues away from the 
conserved catalytic aspartate, whereas in the tyrosine kinases this role has been assigned to an 
arginine located four residues away (Endicott et al., 2012). The process of phosphorylation 
also requires magnesium ions, which regulate the correct orientation of the ATP substrate and 
additionally stabilise the negative charges during catalysis. Although both ATP and the 
substrate have an unlimited access to the catalytic site of the kinase, ATP is usually the first to 
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bind to the catalytic site due to its high concentrations within the cell. Kinetic studies also 
revealed that the catalytic step is fast and that the rate-limiting factor is release of adenosine 
diphosphate (ADP) (Adams and Taylor, 1992; Shaffer et al., 2001; Waas et al., 2003).  
 
Phosphorylation events following ligand stimulation have been found to regulate receptor 
endocytosis, trafficking and signalling. For example, phosphorylation of EGFR pathway 
substrate 15 (Eps15) by EGFR has been shown to be required for EGFR endocytosis 
(Confalonieri et al., 2000). Additionally, Src has been proposed to regulate endocytosis 
through phosphorylation of clathrin heavy chain which promotes clathrin redistribution 
(Wilde et al., 1999), whereas PKC phosphorylation of EGFR at Thr654 has been found to 
enhance EGFR recycling and decrease degradation (Bao et al., 2000). Furthermore, protein 
phosphorylation creates the binding sites for many proteins and lipids that recognise 
phosphorylated residues, leading to activation of signalling pathways which regulate cellular 
functions. As the binding between receptor and ligand is preserved within the endosomal 
membranes, the signalling from receptor dimers continues to activate other molecules (Sorkin 
et al., 1988; Grimes et al., 1996; Roepstorff et al., 2009).  
 
As mentioned above, the level of phosphorylation is opposed by the action of cellular 
phosphatases (Ostman and Bohmer, 2001) and the balance between the activity of kinases and 
phosphatases modifies signalling outcomes. Phosphatases, similarly to kinases, can be divided 
into two major groups: protein serine/threonine phosphatases (PSPs) and protein tyrosine 
phosphatases (PTPs), although dual activity phosphatases also exist. In the case of PTP, the 
catalysis involves the cysteinyl-phosphate intermediate, which then undergoes hydrolysis by 
the glutamine residue within PTP. In contrast, PSPs catalyse direct hydrolysis of the substrate, 
without an intermediate and in the presence of metal ions (Barford et al., 1998; Tonks, 2006).  
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1.3.3 Ubiquitylation in endocytic sorting 
Ubiquitylation is the process of a covalent attachment of ubiquitin, a 76 amino acid protein, to 
a lysine residue within a protein. Ubiquitin attachment has been recognized as a destructive 
tag and has been shown to promote protein degradation via lysosomal and proteasomal 
degradative pathways. The process of ubiquitylation involves the sequential action of an E1 
ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase. 
In particular, ubiquitin has been shown to be activated by the E1 activating enzyme, which 
transfers ubiquitin moiety to the E2 conjugating enzyme; the E3 ligase has been shown to 
bind both the E2-ubiquitin thioester and the substrate, and to transfer the ubiqutin moiety onto 
the substrate. The specificity of the ubiquitylation reaction is conferred by the recognition of 
particular E3 ligases for particular substrates (Deshaies and Joazeiro, 2009).  
 
Ubiquitin contains seven intrinsic lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, 
Lys63) which themselves may be ubiquitylated, thus providing additional divergence to the 
ubiquitin-dependent signalling and trafficking (Chen and Sun, 2009; Clague et al., 2012). For 
example, monoubiquitylation and Lys63-oligoubiquitylation (attachment of ubiquitin to a 
Lys63 residue within a ubiquitin moiety) have been proposed to regulate endocytosis and 
lysosomal degradation, whereas Lys48 polyubiquitylation promotes proteasomal degradation 
(Chau et al., 1989; Finley et al., 1994; Haglund et al., 2003; Mosesson et al., 2003; Urbe, 
2005; Huang et al., 2006a). Lys63 polyubiquitylation has been shown to regulate both 
proteasomal and lysosomal degradation, as well as to promote RTK endocytosis (Huang et 
al., 2006a; Lauwers et al., 2009; Saeki et al., 2009; Boname et al., 2010). Additionally, the 
linear ubiquitin chain assembly complex (LUBAC), an E3 ubiquitin ligase, has been 
identified to promote formation of linear ubiquitin chains, in which the C-terminal glycine 
residue of one ubiquitin moiety is linked to the N-terminal methionine residue of another 
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(Kulathu and Komander, 2012; Tokunaga and Iwai, 2012). Linear polyubiquitylation has been 
associated with activation of the canonical nuclear factor κB (NFκB) signalling pathway. 
NFκB activation, which may be triggered by pathogens or pro-inflammatory cytokines such 
as tumour necrosis factor α (TNFα), requires several ubiquitylation events and formation of 
the Lys63-linked and linear polyubiquitylated substrates. These then recruit kinase-ubiquitin-
adaptor complexes, which activate inhibitor of NFκB (IκB) complex (IKK). Active IKK 
phosphorylates IκB, leading to its Lys48-polyubiquitylation and degradation. Upon IκB 
degradation, NFκB translocates to the nucleus and regulates gene expression (Tokunaga and 
Iwai, 2012). Therefore, ubiquitylation also regulates non-degradative signalling pathways. 
 
In the case of EGFR, ubiquitylation of the lysine residues within the kinase domain has been 
described (Huang et al., 2006a; Huang et al., 2007; Goh et al., 2010) and EGFR mono- and 
polyubiquitylation has been found to regulate EGFR trafficking and degradation (Huang et 
al., 2006a; Eden et al., 2012). Although ubiquitylation has been shown to be dispensable for 
EGFR internalization (Duan et al., 2003; Huang et al., 2007), it has been found to promote 
EGFR endocytosis. In particular, mutant EGFR with multiple lysine residues substituted to 
arginines was poorly internalized (Goh et al., 2010). EGFR ubiquitylation has been found to 
be critical for EGF-stimulated formation of intraluminal vesicles of late endosomes, and thus 
for EGFR degradation. This was shown with the negligibly ubiquitylated EGFR mutant, 
whose degradation was impaired and recycling enhanced due to impaired binding of the 
ESCRT machinery (Eden et al., 2012).  
 
Furthermore, EGFR deubiquitylation has also been shown to influence EGFR trafficking. For 
example, knockdown of UBPY deubiquitylase has been found to retain EGFR in clustered 
endosomes and severly impaired EGFR deubiquitylation and degradation (Row et al., 2006). 
This is proposed to be due to polyubiquitylation and proteasomal degradation of critical 
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components of ESCRT machinery, such as Hrs and STAM, which occurs in the absence of 
UBPY. In contrast, knockdown of AMSH deubiquitylase has been found to enhance EGFR 
degradation, and AMSH has been suggested to promote EGFR deubiquitylation and recycling 
(McCullough et al., 2004). Interestingly, AMSH and UBPY both bind the same SH3 domain 
of STAM and have been suggested to compete for its binding (Kato et al., 2000; Row et al., 
2006).  
 
1.3.4 The Rab family of small GTPases in endocytic trafficking 
As discussed above, following endocytosis the internalized cargo traffics via the endocytic 
compartments. This movement between different membrane compartments and organelles is 
regulated by multiple mechanisms and interactions, and the Rab family of GTPases are the 
most pronounced regulators of the intracellular trafficking (Zerial and McBride, 2001; 
Stenmark, 2009).  
 
Rab GTPases exist in two conformational states: an active GTP-bound state and an inactive 
state in a GDP-bound form, as shown in Figure 1.6. The switch from inactive to active form 
is catalysed by guanine nucleotide exchange factors (GEFs) and release of GDP is 
immediately followed by binding of GTP due to its high concentrations within the cell. When 
active, Rab-GTPases activate multiple downstream effectors, e.g. kinases and phosphatases. 
The conversion to the inactive form is mediated by GTPase-activating proteins (GAPs) and 
by intrinsic GTPase activity of Rab proteins, which results in hydrolysis of GTP (Fukui et al., 
1997; Wada et al., 1997; Cuif et al., 1999; Chamberlain et al., 2004; Yoshimura et al., 2010).  
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Figure 1.6. Rab-GTPases circuity 
Conversion of an inactive GDP-bound form of Rab proteins to an active GTP-bound form is 
catalysed by guanine nucleotide exchange factors (GEFs), whereas conversion of GTP-to-
GDP form is mediated by GTPase activating proteins (GAPs). GDP-dissociation inhibitor 
(GDI) prevents GDP release and stabilises the GDP-bound form. It also regulates Rab 
GTPases cycles between the cytosol and the membrane. Adapted from (Stenmark, 2009). 
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Upon synthesis, inactive Rab proteins are posttranslationally modified by geranylgeranyl 
transferase, which catalyses an attachment of one or two hydrophobic geranylgeranyl groups 
onto the C-terminal cysteine residues (Kinsella and Maltese, 1992). This is proposed to enable 
the Rab proteins to be anchored to the lipid membranes of subcellular compartments. 
Modified Rab proteins associate with Rab GDP dissociation inhibitors (GDIs) and are 
transported to their destination by GDI displacement factors (Ullrich et al., 1993; Soldati et 
al., 1994; An et al., 2003). The specific subcellular localization of different Rab proteins is an 
important factor in organizing intracellular traffic (Zerial and McBride, 2001). 
 
As explained above, Rab GTPases play fundamental roles at the various stages of membrane 
trafficking. Examples include regulation of the early endosomal membrane fusion by Rab5 
(Stenmark et al., 1994) or regulation of transport from endosomes to Golgi apparatus by 
Rab9, which promotes formation and docking of transport vesicles (Carroll et al., 2001). 
Rab5 has also been found to facilitate vesicle uncoating following clathrin-mediated 
endocytosis (Semerdjieva et al., 2008). Examples of the functions of chosen Rab GTPases are 
shown in Figure 1.7. 
 
Rab proteins also coordinate vesicle motility along microtubules, e.g. Rab11 directly and 
indirectly interacts with the motor proteins myosins (Hales et al., 2002; Roland et al., 2007). 
Interestingly, plus- and minus-end transport along microtubules is regulated by different 
members of the Rab family. In particular, the minus-end trafficking of late endosomes has 
been shown to be regulated by Rab7 effector Rab-interacting lysosomal protein (RILP), which 
recruits a complex of motor proteins (Cantalupo et al., 2001; Jordens et al., 2001).  
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Figure 1.7. Examples of Rab-GTPases function in membrane trafficking 
Rab4 regulates fast recycling and trafficking from early endosomes; Rab5 mediates 
trafficking from the plasma membrane towards early endosomes; Rab7 promotes fusion with 
lysosomes; Rab9 mediates transport from endosomes to Golgi apparatus; Rab11 regulates 
slow recycling. Adapted from (Stenmark, 2009). 
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On the other hand, the plus-end movement of early endosomes towards the plasma membrane 
has been found to be regulated by the motor protein kinesin and to depend on the activity of 
Rab5 and its effector vacuolar protein sorting 34 (Vps34) (Hoepfner et al., 2005). 
 
In addition, Rab GTPases are critical for membrane fusion events. This has been widely 
studied in the case of Rab5, which was shown to promote fusion between early endosomal 
membranes. In particular, early endosome antigen 1 (EEA1) and rabenosyn 5, two Rab5 
effectors, have been proposed to regulate fusion between Rab5-positive vesicles, via their 
association with the components of fusion machinery, such as soluble NSF attachment protein 
receptor (SNARE) proteins (Stenmark et al., 1994; Christoforidis et al., 1999; Nielsen et al., 
2000).  
 
The majority of the effectors are recruited by Rab GTPases from the cytosol, although in 
some cases the effectors are permamently located within organelles or compartments. This 
was shown to be the case for Rab1 effector Golgi matrix protein GM130, which is localized 
within the Golgi apparatus and facilitates the fusion of the vesicles with the cis-Golgi network 
(Moyer et al., 2001).  
 
An interesting feature of the Rab proteins is their specific subcellular localization. For 
example, the membrane of the early endosomes has been shown to be rich in Rab5, which 
controls vesicle fusion, and Rab4, which regulates recycling (Chavrier et al., 1990; 
Vandersluijs et al., 1991; Bucci et al., 1992; Vandersluijs et al., 1992; Clague, 1998). Rab5 
has also been found to localize to early and late phagosomes and to regulate autophagosome 
maturation (Vieira et al., 2003; Ravikumar et al., 2008). Furthermore, recycling endosomes 
have been demonstrated to contain Rab4, wchich regulates trafficking from early endosomes, 
and Rab11, which enables delivery to the plasma membrane (Ullrich et al., 1996; Ren et al., 
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1998). Late endosomes contain Rab7, which controls trafficking to lysosomes, and Rab9 
which regulates trafficking to the trans-Golgi network (Chavrier et al., 1990; Lombardi et al., 
1993; Soldati et al., 1994; Clague, 1998). Rab7 has also been found within autophagosomes 
and has been shown to regulate the fusion between autophagosomes and lysosomes (Harrison 
et al., 2003; Vieira et al., 2003). Therefore, several different Rab GTPases can localize to the 
same compartment, e.g. early endosomes are enriched in Rab4 and Rab5, and recycling 
endosomes in Rab4 and Rab11. An interesting proposal by Zerial and McBride suggests that 
when Rab GTPases localize to a particular membrane, they are present within distinct 
microdomains, which have different composition and function (Zerial and McBride, 2001). 
These microdomains enriched in a particular Rab GTPase and its effectors would interact with 
one another, but display a relatively stable composition, and the internalised cargo would 
traffic sequentially through these microdomains (Zerial and McBride, 2001). 
 
From these characteristics of the Rab family emerges an extremely attractive image of the 
specific cellular markers which are widely used as a tool for marking distinct subcellular 
compartments in the fields of cell biology and membrane trafficking. 
 
1.3.5 An intersection between trafficking and signalling 
The finding that EGF bound in a highly specific manner to human fibroblasts (Carpenter et 
al., 1975; Carpenter and Cohen, 1976) was followed by identification of EGF receptor in A-
431 epidermoid cancer cells (Cohen et al., 1980; Cohen et al., 1982). Since then, the number 
of studies investigating the mechanisms and funtions of endocytosis and trafficking of growth 
factor receptors has blossomed. Primarily, it was thought that EGFR signalling takes place at 
the plasma membrane, and endocytosis along with receptor trafficking towards lysosomes 
were perceived solely as mechanisms for signal attenuation; this was proposed by Cohen and 
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Carpenter in 1979 (Carpenter and Cohen, 1979). Further studies on B-cell antigen receptor 
(BCR) supported this notion by showing that actin depolarisation along with inhibition of 
CME sufficiently blocks BCR internalisation, yet leads to prolonged phosphorylation of BCR 
and Erk signalling (Stoddart et al., 2005). Similarly, studies on the mutant EGFR with 
truncated C-terminus that did not internalise revealed that EGFR activation at the plasma 
membrane is sufficient to induce mitogenic responses and thus internalisation and degradation 
serve as mechanisms for signal attenuation (Wells et al., 1990). Nevertheless, since more and 
more research has been carried out, the view that the growth factor signalling is not abrogated 
following endocytosis has emerged, and currently the determination of the signalling 
outcomes of the receptors at the plasma membrane and within endosomes is a major topic of 
investigation. 
 
The roles for RTK endocytosis and endocytic trafficking in signal transduction first came into 
light in 1985 when Cohen and Fava isolated internalised vesicles from A-431 cells, and found 
phosphorylated and enzymatically active EGFR present within these vesicles, which was able 
to phosphorylate its substrate (Cohen and Fava, 1985). Following this discovery, they 
proposed that endocytosis may act as an underlying mechanism for providing active ligand-
receptor complexes into intracellular compartments, which activate substrates not available at 
the plasma membrane. In support of this, similar studies described EGF-bound and active 
EGFR present within endosomes (Lai et al., 1989). These discoveries suggest that EGFR 
phosphorylation and activation is not abrogated upon endocytosis, and it may potentially be 
an important regulator of intracellular trafficking. 
 
In order to to reveal the functions of protein kinases in endocytosis, a genome-wide screen of 
human kinases has been completed in HeLa cells (Pelkmans et al., 2005). In the study the 
mRNA levels of human kinases were downregulated using RNA interference (knockdown), 
Chapter 1 - Introduction 
 
44 
 
and the consequences were analysed for the internalisation of two viruses: vesicular stomatitis 
virus (VSV) which enters through CME, and simian virus 40 (SV40) which enters through 
caveolar endocytosis as well as clathrin and caveolin-independent endocytosis. This screen 
identified approximately 200 kinases as modulating endocytosis. For example, knockdown of 
the members of the mTOR signalling pathway inhibited CME of VSV as well as endocytic 
trafficking of transferrin (Tf), an iron-binding protein that binds Tf receptor (TfR) at the cell 
surface and undergoes CME. Endocytosis of SV40 was inhibited following depletion of Src 
and focal adhesion kinase (FAK), which control integrin-mediated focal adhesion assembly, 
thus indicating that focal adhesion and integrin signalling regulates endocytosis of SV40. 
Interestingly, knockdown of a subset of kinases promoted VSV and SV40 endocytosis. For 
example, Ack1 knockdown has been found to promote SV40 internalisation, and it has been 
proposed that SV40 endocytosis is inhibited by Cdc42- and Ack1-mediated actin 
polymerisation. In contrast, knockdown of p21-activated kinase PAK1, which is a Cdc42 
effector that promotes actin depolymerisation, increased VSV endocytosis and suppressed 
SV40 internalisation. Therefore, the data presented in this study reveal the complex 
modulation of CME and CIE via the potential signalling networks regulated by particular 
kinases (Pelkmans et al., 2005). 
 
In addition to EGFR phosphorylation, EGFR ubiquitylation and association with ubiquitin-
binding proteins have been proposed as an underlying mechanism for CIE of EGFR. This 
came into light when the ubiquitin-binding proteins: Eps15, Eps15-related protein (Eps15R) 
and epsin have been shown to be required for CIE of the EGFR chimera, which was fused to 
ubiquitin and thus endocytosed exclusively through CIE (Sigismund et al., 2005). This was 
shown by the triple knockdown experiments (Eps15, Eps15R and epsin knockdown), in which 
CIE of the EGFR chimera was blocked; however, CIE progressed normally in single 
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knockdowns thus indicating that these proteins play redundant roles in CIE of EGFR  
(Sigismund et al., 2005). Furthermore, rescue experiments with Eps15, but not mutant Eps15 
unable to bind ubiquitin, were able to restore EGFR endocytosis. Therefore, ubiquitylation 
has been proposed as a prerequisite for EGFR internalisation via CIE. Additionally, triple 
knockdown also resulted in a substantial reduction in CME, indicating that these proteins also 
contribute to CME of EGFR. Intrestingly, EGFR degradation, but not downstream signalling, 
has been shown to be enhanced in the case of CIE, thus suggesting that EGF signalling is 
more efficient when EGFR enters via CME, which is followed by EGFR recycling to the 
plasma membrane (Sigismund et al., 2005; Sigismund et al., 2008).  
 
Interestingly, the studies on EGFR internalisation show that upon stimulation with low doses 
of EGF (1-2 ng/ml), EGFR is internalised almost exclusively through CME, whereas upon 
treatment with high doses of EGF (20-100 ng/ml) approximately half the receptors enter 
through CIE (Sigismund et al., 2005; Sigismund et al., 2008). These studies also demonstrate 
that the majority of the receptors entering through CME are recycled back to the plasma 
membrane, whereas those entering through CIE are almost exclusively degraded (Sigismund 
et al., 2008). CME has been found to be required for sustained EGF signalling and gene 
expression following ligand stimulation, as knockdown of the components of CME 
machinery, such as clathrin or AP2, decreased EGFR recycling and dramatically shortened 
the longevitity of the Erk1/2 and Akt signalling. Importantly, inhibition of CME or CIE had 
no effect on phosphorylation of an adaptor protein Shc (Vieira et al., 1996; Sousa et al., 
2012). Thus, even though the first phosphorylation events took place under CME inhibition, 
possibly at the plasma membrane, the prolonged signalling was dramatically reduced 
indicating that CME is critical for sustained signalling and gene expression downstream of 
EGFR activation (Sigismund et al., 2008). 
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Another study supporting the notion that endocytosis is required for signal propagation 
employed HeLa cells conditionally expressing wild type (WT) or mutant (K44A) dynamin, 
which inhibits dynamin-dependent endocytosis. This study revealed that phosphorylation of 
EGFR, Erk1/2 and PI3K subunit p85 were reduced upon inhibition of endocytosis (Damke et 
al., 1994; Vieira et al., 1996). These results argue that the transit of EGFR through the 
endocytic system is required to induce complete activation of EGFR and downstream 
signalling cascades. Interestingly, PLCγ and Shc phosphorylation were increased in the 
presence of the K44A mutant, and this mutant promoted cell proliferation upon EGF 
treatment. Therefore, endocytosis-deficient, less phosphorylated EGFR has been found to 
stimulate cell proliferation, and increased PLCγ and Shc phosphorylation has been counted 
for enhanced proliferative potential of the endocytosis-deficient cells (Vieira et al., 1996).  
 
Additionally, subcellular distribution of late endosomes has been proposed to affect EGF 
signalling (Taub et al., 2007). In particular, when endosomes were mislocalized to the cell 
periphery due to disrupted transport of the organelles toward the cell centre, the activation of 
EGFR downstream targets Erk, p38 (MAPK) and transcription factors following EGF 
treatment was enhanced, whereas EGFR degradation was delayed. In contrast, clustering of 
the late endosomes in the perinuclear region due to expression of a dominant-active Rab7 had 
different effects on signalling outputs. In this case, activation of Erk was also enhanced and 
EGFR degradation was reduced; however, activation of p38 (MAPK) was not affected, 
whereas activation of transcription factors was decreased (Taub et al., 2007). Therefore, 
EGFR subcellular localization and trafficking via endocytic compartments have further been 
proposed to modulate signalling outputs. 
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In contrast to the presented reports on the regulation of cell signalling by endocytosis and 
endocytic trafficking, the global analysis of the function of endocytosis in RTK signalling 
reveals that EGFR endocytosis is dispensable for activation of several major signalling 
pathways. The study was performed on isotopically labelled HeLa cells in order to 
quantitatively characterise the changes in protein phosphorylation following administration of 
dynasore, which inhibits dynamin-dependent internalisation (Omerovic et al., 2012). Cells 
were additionally treated with EGF to determine proteins activated upon EGF treatment. The 
data show that several signalling cascades are initiated by receptors arrested at the plasma 
membrane, indicating that endocytosis is dispensable for their activation. In particular, several 
kinases regulating MAPK signalling pathway, such as MAPK1, MAPK7 and MAPK14, have 
been found to be phosphorylated upon EGF stimulation independently of dynasore treatment. 
Other EGF-sensitive proteins phosphorylated in the presence of dynasore include Cbl, PLCy, 
Eps15 and Erk1. In contrast, the members of the ESCRT machinery involved in endosomal 
sorting have been identified as sensitive to inhibition of endocytosis, and phosphorylation of 
Hrs, STAM and Rab7 has been found dramatically decreased in dynasore-treated cells 
(Omerovic et al., 2012). The requirement for EGFR endocytosis to phosphorylate Hrs has 
further been shown with mutant (K44A) dynamin, as well as with incubation in hyperosmotic 
medium, both of which have been shown to inhibit endocytosis (Heuser and Anderson, 1989; 
Urbe et al., 2000).  Therefore, endocytosis has been proposed to be dispensable for activation 
of several signalling pathways, but to be critical for phosphorylation and activation of the 
ESCRT components. 
 
Further support of the notion that endocytosis is not a prerequisite for activation of particular 
signalling cascades comes from the study of mouse fibroblasts with inducible knockout of 
dynamin (Sousa et al., 2012). In these cells ligand-induced EGFR endocytosis was inhibited, 
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yet EGFR phosphorylation and ubiquitylation were both increased. Interestingly, whereas 
activation of Erk was similar to the control, activation of Akt was enhanced in dynamin 
knockout cells. Together these results indicate that RTK signalling occurs predominantly at 
the plasma membrane and that ligand-induced endocytosis and trafficking act as the 
mechanisms for signal attenuation.  
 
In summary, an intersection between signalling and trafficking pathways is unclear and data 
exist supporting the regulation of signalling by endocytosis and endocytic trafficking, and the 
modulation of trafficking by cell signalling. 
 
1.4 Autophagy 
Apart from lysosomal degradation which is the classical way of RTK degradation (described 
in more detail in Chapter 1.3.1), there exist other non-canonical degradative pathways, e.g. 
autophagy (Kraft et al., 2010). In this process, ubiquitylated protein aggregates, organelles 
and bacteria are engulfed in double-membrane structures called autophagosomes, which fuse 
with lysosomes to undergo degradation (Kraft et al., 2010). The schematic process of 
autophagy is presented in Figure 1.8.  
 
Autophagy (Greek „self-eating’) is perceived as one of the mechanisms of programmed cell 
death, along with apoptosis and necrosis, which is accompanied by autophagosome formation, 
cell shrinkage and degradation of organelles (Ouyang et al., 2012).  
Chapter 1 - Introduction 
 
49 
 
 
 
Figure 1.8. The process of autophagy 
In the process of autophagy, isolation membranes, or phagophore, engulf ubiquitylated 
proteins, protein aggregates, organelles and bacteria. Membrane closure results in an 
autophagosome formation, and fusion with endosomes enables autophagosome maturation. In 
the final step of the process autophagosome fuses with lysosome, which acidifies the content 
of autophagosome, thus enabling degradation. Adapted from (Mizushima, 2007; Kraft et al., 
2010). 
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In contrast to apoptosis, the cytoskeletal degradation is delayed until the late stages, along 
with caspase activity and DNA fragmentation. In contrast to necrosis, autophagy does not 
induce tissue inflammation (Levine and Yuan, 2005). So far three types of autophagy have 
been distinguished in mammals. The first type, known as macroautophagy, is the most 
common and involves formation of double membrane autophagosomes. The second type, 
microautophagy, describes a direct engulfment of the ubiquitylated cargo by the lysosome. 
The final type, chaperone-mediated autophagy (CMA), does not require cargo ubiquitylation 
but rather depends on a sequence recognition by the chaperone complex (Ravikumar et al., 
2009). The work presented in this thesis is focused on the first type, macroautophagy, which 
for simplicity is referred to as autophagy.   
 
On the other hand, autophagy is also perceived as a cell-survival mechanism, providing amino 
acids and fatty acids during starvation and removing damaged organelles, toxic proteins and 
bacteria (Levine and Yuan, 2005). Autophagy has long been perceived as a bulk process, in 
which double membranes randomly engulf the cytoplasm. Nevertheless, recently it has 
emerged that certain proteins specifically recognise ubiquitylated cargo and target it for 
autophagosomal degradation. 
 
The source of a double membrane required for autophagosome formation is unclear, with 
plasma membrane (Ravikumar et al., 2010; Ravikumar et al., 2010), mitochondria (Hailey et 
al., 2010) and endoplastic reticulum (ER) (Hayashi-Nishino et al., 2009) all proposed to 
provide the autophagosomal membrane. Interestingly, the ER-mitochondrion interface has 
been proposed to be the original source of the membrane, whereas other structures to be 
important for membrane expansion (Lamb et al., 2013). Additionally, fusion of 
autophagosomes with endosomes has been shown to be required for autophagosome 
maturation (Razi et al., 2009; Tooze and Razi, 2009). Depending on the cargo engulfed by the 
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autophagosomal membrane, several types of autophagy can be distinguished. For example, 
mitophagy is the process of the autophagosomal degradation of mitochondria, aggrephagy – 
of protein aggregates, pexophagy – of peroxisomes, and xenophagy – of viruses and bacteria 
(Lamb et al., 2013). 
 
As mentioned above, the process of selective autophagy has been shown to be mediated by 
several groups of proteins. In particular, a family of autophagy related gene (Atg) proteins 
have been shown to be essential for autophagosome formation. The Atg proteins, of which 
there are 35, with 18 being essential during autophagosome formation and throughout the 
process, were first identified in yeast (Mizushima et al., 2011). Numerous Atg proteins have 
mammalian homologues, for example microtubule-associated protein light chain 3 (LC3) is 
an Atg8 homologue in mammals and it associates with autophagosomal membranes. Other 
proteins implicated in autophagic clearance are sequestosome 1 (p62/SQSTM1) and 
neighbour of BRCA1 (NBR1), both of which are proposed to act as receptors targeting 
ubiquitylated cargo for autophagic degradation (Lamark et al., 2009). Figure 1.9 presents a 
schematic composition of a phagophore (pre-autophagosomal structure) during 
autophagosome formation. 
 
One of the mechanisms of autophagy induction by nutrient deprivation is through the 
inhibition of the mTOR complex 1 (mTORC1) by the TSC1/2 complex. Upon nutrient 
starvation, the reduction in the ATP to AMP ratio is sensed by the 5‟-AMP-activated protein 
kinase (AMPK).  
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Figure 1.9. Phagophore membrane composition 
Atg5-Atg12-Atg16 complex is essential for phagophore formation and it dissociates shortly 
before or after membrane closure, when the autophagosome is formed. The UBA domain of 
p62/SQSTM1 recognises ubiquitylated proteins or organelles, whereas the LC3-Interacting 
Region (LIR) binds LC3, which is conjugated to phosphatidylethanolamine (PE) and isolating 
membrane.Adapted from (Lamark et al., 2009; Johansen and Lamark, 2011).  
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AMPK phosphorylates the TSC1/2 complex leading to the inhibition of a small GTPase Rheb, 
which would otherwise activate mTORC1 (Courtney et al., 2010; Jung et al., 2010) (as 
described in Chapter 1.2.4). 
 
1.4.1 Autophagy-related proteins 
Recently, an excellent review by Mizushima et al. described the complexity of the processes 
of autophagosome formation, maturation and degradation, which are tightly regulated by the 
sequential action of the autophagy-related (Atg) family of proteins (Mizushima et al., 2011). 
The Atg proteins have emerged as essential throughout the process, from the formation of the 
isolation membranes (phagophores), membrane closure, autophagosome maturation through 
to fusion with lysosomes for degradation.  
 
Although autophagy in mammals was first identified and named in 1960s by Christian de 
Duve following his discovery of lysosomes, which was awarded with the Nobel Prize in 
Physiology and Medicine in 1974 (Klionsky, 2008), it was not characterised in depth due to 
technical limitations. In particular, the visualisation of autophagy was restricted to electron 
microscopy, and the biochemical assays were technically complicated. Subsequent discovery 
of autophagy in yeast accelerated the investigations into the process, as studying budding 
yeast was technically less difficult, and the genetic studies were relatively simple. In 1992 
Takeshige et al. noticed that under starvation, yeast strains deficient in vacuolar proteases 
accumulated autophagic bodies within the vacuoles (Takeshige et al., 1992). The Atg proteins 
were then discovered in yeast and later mammalian homologues were also described. So far 
35 ATG genes have been identified in yeast, and 15 of these (Atg1-10, Atg12-14; Atg16, 
Atg18, Atg29 and Atg31) have been identified as essential for autophagosome formation 
(Mizushima, 2007; Nakatogawa et al., 2009; Mizushima et al., 2011).  
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They can be divided into five complexes: the Atg1/ULK kinase and its regulators complex; 
the class III PI3K complex; the Atg2-Atg18 complex, Atg9 and other proteins; the Atg12 
conjugation system; and the Atg8/LC3 conjugation system. This is summarised in Table 1.2. 
 
Initial reports on the functions of the Atg proteins come from 1990s. The protease-deficient 
strain of yeast was treated with mutagenic agent and placed in starvation medium: the cells 
which did not accumulate autophagic bodies within the vacuoles were selected, leading to 
identification of the Atg1 gene. Since the Atg1 mutants exhibited lower viability under 
starvation conditions, the loss of viability was further used as a screening test for isolation of 
other mutants, leading to identification of another 14 Atg genes (Atg2-10, Atg12-14, Atg16-
17) (Tsukada and Ohsumi, 1993). As different groups named newly characterised genes and 
proteins in different ways, in 2003 Klionsky et al. proposed a unified nomenclature system, 
and the Atg name is now widely utilised (Klionsky et al., 2003). 
 
The studies in yeast with fluorescently tagged Atg proteins revealed the existence of the pre-
autophagosomal structure (PAS), to which several Atg and Atg-related proteins localize 
(Suzuki et al., 2001). These studies suggest that during starvation, enhanced activity of the 
Atg1 kinase complex promotes formation of PAS. The Atg12-Atg5 conjugate is also found to 
be required for formation of PAS and for recruitment of phosphatidylethanolamine (PE)-
conjugated Atg8. Furthermore, Atg16 has been found in complex with Atg12-Atg5, and 
Atg16 along with class III PI3K complex have been proposed to recruit Atg5 and Atg8-PE to 
PAS. Atg9 has also been shown to regulate Atg8-PE localization to PAS. Additionally, Atg13 
and Atg17 (a counterpart of mammalian FIP200 (Hara and Mizushima, 2009)) have been 
proposed to be essential for Atg1 activation in the first steps of autophagy induction (Kamada 
et al., 2000).  
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Mammalian Yeast Function 
Atg1/ULK kinase and its regulators – promotes autophagosome formation 
ULK 1/2 yeast Atg1 
The complex stably associates and localizes 
to the forming autophagosome 
Atg13 yeast Atg13 
Atg101 - 
FIP200 - 
Class III PI3K complex – produces  phosphatidylinositol-3-phoosphate (PI3P) 
Vps34 yeast Vps34 
The complex produces PI3P thus stimulating 
autophagy 
Vps15 yeast Vps15 
Beclin 1 yeast Atg6 (Vps30) 
Atg14L yeast Atg14 
AMBRA1 - 
Other proteins: Atg2-Atg18/WIPI complex, Atg9 and others 
Atg2A/B yeast Atg2 
Atg9L1/2, WIPI1-4 and VMP1 localize to the 
autophagosome membranes; Atg2 and 
Atg18/WIPI form a complex and regulate 
Atg9 dynamics; WIPI/Atg18 binds PI3P 
Atg9L1/2 yeast Atg9 
WIPI1-4 yeast Atg18 
DECP1 - 
VMP1 - 
Atg12 conjugation system – determines and promotes Atg8/LC3 lipidation site 
Atg12 yeast Atg12 
The Atg5-12-16L complex localizes to the 
outer membrane of the autophagosome and is 
required for membrane elongation and 
Atg8/LC3 conjugation 
Atg7 yeast Atg7 
Atg10 yeast Atg10 
Atg5 yeast Atg5 
Atg16L1/2 yeast Atg16 
Atg8/LC3 conjugation system – regulates membrane tethering and fusion 
LC3A-C, 
GABARAP, 
GABARAPL1, L2 
(GATE-16), L3 
yeast Atg8 The Atg8/LC3 complex with 
phosphatidylethanolamine are essential for 
membrane elongation and closure, and for 
interaction with p62/SQSTM1, NBR1 and 
other receptors 
Atg4A-D yeast Atg4 
Atg7 yeast Atg7 
Atg3 yeast Atg3 
 
Table 1.2. The functions of Atg and Atg-related proteins in autophagosome biogenesis 
The Atg proteins required for autophagosome formation in yeast and mammals. Adapted from 
(Hara and Mizushima, 2009; Nakatogawa et al., 2009; Mizushima et al., 2011). 
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Furthermore, systematic analysis of the yeast strains expressing fluorescently tagged Atg 
proteins, in which the Atg genes were individually disrupted, led to identification of the 
hierarchy of PAS organisation, shown in Figure 1.10 (Suzuki et al., 2007). In this hierarchic 
model Atg17 acts upstream of PAS formation, and further characterisation of Atg29 and 
Atg31 revealed that Atg29 and Atg31 form a complex with Atg17 (Kawamata et al., 2005; 
Kabeya et al., 2007; Kabeya et al., 2009). In mammals structures similar to PAS have also 
been described as being rich in autophagic factors and closely associated with endoplasmic 
reticulum (ER) (Itakura and Mizushima, 2010).  
 
Although the function of Atg9 is not fully understood, it is the only integral membrane protein 
among the Atg proteins; it has been shown to be recruited by Atg17 to PAS, self-associate 
and promote membrane flow at the early stages of PAS formation (Noda et al., 2000; He et 
al., 2008; Sekito et al., 2009). Atg8 (mammalian LC3) and Atg12 have been described as 
ubiquitin-like proteins and their attachment to phosphatidylethanolamine (PE) and to Atg5, 
respectively, has been shown to be mediated via an E1 enzyme Atg7 and the E2 enzymes 
Atg3 and Atg10, respectively. In particular, the C-terminal glycine residue of Atg8 has been 
found covalently attached to an amino group of PE, and in the case of Atg12, the glycine 
residue has been found attached to the lysine residue within Atg5 (Mizushima et al., 1998; 
Shintani et al., 1999; Tanida et al., 1999; Ichimura et al., 2000). A yeast two-hybrid screen 
with Atg12 as a bait identified Atg16 interaction with the Atg12-Atg5 conjugate, and Atg16 
has further been shown to directly interact with Atg5 and preferentially with the Atg12-Atg5 
conjugate. Atg16 has further been found to homo-oligomerise, thus resulting in formation of 
the Atg12-Atg5-Atg16 complex (Mizushima et al., 1999).  
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Figure 1.10. Hierarchy of the Atg proteins in autophagosome formation 
The proposed hierarchy model of Atg proteins during autophagosome formation. Colours 
indicate members of the same complexes: Blue: Atg1/ULK complex; Orange: Atg9; Violet: 
PI3K complex; Grey: Atg2-Atg18/WIPI complex; Green: Atg12 conjugation system; Red: 
Atg8/LC3 conjugation system; Transparent: Atg29 and Atg31 which form a ternary complex 
with Atg17. Adapted from (Mizushima et al., 2011). 
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Interestingly, Atg5 has been shown to localize to pre-autophagosomal structures (phagophores 
or isolation membranes), but not to enclosed, fully formed autophagosomes or autolysosomes, 
and has been proposed to dissociate shortly before or after membrane closure. Additionally, 
conjugation of Atg12 to Atg5 has been found required for the elongation of the isolation 
membranes (Mizushima et al., 2001). The Atg12-Atg5 conjugate has been identified to recruit 
Atg8 to a forming autophagosome, and whereas the Atg12-Atg5-Atg16 complex 
predominantly localizes to the outer membrane of pre-autophagosomal structures, PE-
conjugated Atg8 is found on both inner and outer membranes of autophagosomes (Mizushima 
et al., 2001; Mizushima et al., 2003).  
 
LC3 was first isolated from bovine brain as binding to microtubules and identified as a 
subunit of the microtubule associated protein 1 (MAP1) (Kuznetsov and Gelfand, 1987). Two 
forms of LC3 have been since characterised: the cytosolic LC3-I and the autophagic 
membranes-associated LC3-II (Kabeya et al., 2000). LC3 was found to be present both on the 
membranes and within autophagosomes. LC3-I is suggested to originate from a newly-
synthesized full-length precursor protein upon the C-terminal cleavage by Atg4, which results 
in an exposure of the C-terminal glycine. Under starvation conditions, LC3-I is further 
processed into LC3-II, and the amount of LC3-II has been shown to increase along with 
enhanced autophagosomal activity (Kabeya et al., 2000; Kirisako et al., 2000). The LC3-II 
form has been shown to be PE-conjugated (Kabeya et al., 2004), and this is critical for 
isolation membrane elongation, as the Atg3 knockout mice, which are deficient in formation 
of the PE-conjugated LC3 (LC3-II), show malfunctions in isolation membrane elongation and 
closure and die within one day of birth (Sou et al., 2008).  
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Golgi-associated ATPase enhancer of 16 kDa (GATE16) and γ–aminobutyric-acid-type-A-
receptor-associated protein (GABARAP), two other mammalian homologues of yeast Atg8, 
have similarly been found to exist in two forms: cytosolic form I and the autophagosomal 
membrane-bound PE-conjugated form II (Kabeya et al., 2004). Like LC3, formation of PE-
conjugated GABARAP and GATE-16 have been proposed to be modified by subsequent 
actions of Atg7 and Atg3 (Tanida et al., 2003). Although all of these Atg8 homologues have 
been found to be essential for autophagosome formation, they act at different stages of this 
process. In particular, LC3 has been found to regulate membrane elongation, whereas GATE-
16 and GABARAP have been shown to be required at later stages of autophagosome 
maturation (Weidberg et al., 2010). 
 
1.4.2 Sequestosome 1 
Sequestosome 1 (p62/SQSTM1) was first identified as a 62 kDa protein that bound the 
lymphocyte-specific protein tyrosine kinase (LCK), a member of the Src family of kinases 
which regulates T-cell signalling  (Park et al., 1995). Later, two groups independently showed 
that p62/SQSTM1 binds atypical protein kinases C (aPKCs) and p62/SQSTM1 has been 
proposed to act as a scaffold protein bringing in close proximity aPKCs and other proteins 
(Puls et al., 1997; Sanchez et al., 1998). Further studies defined the roles for p62/SQSTM1 in 
activation of NFκB signalling, which regulates cellular inflammatory responses to tumor 
necrosis factor α (TNFα) and interleukin 1 (Sanz et al., 1999; Sanz et al., 2000). Since then, 
multiple functions of p62/SQSTM1 in cell signalling have been discovered.  
 
In the literature, p62/SQSTM1 has a well established role as a scaffold protein and is well 
recognised for its function in bone remodelling. This came into light when p62/SQSTM1 
knockout mice treated with an osteoclastogenic stimulus had severely reduced number of 
Chapter 1 - Introduction 
 
60 
 
osteoclasts. Further studies in vitro and in vivo confirmed the role for p62/SQSTM1 in 
induced osteoclastogenesis (Duran et al., 2004). Another study with p62/SQSTM1 knockout 
mice revealed its role in cell metabolism through inhibition of adipogenesis, and 
p62/SQSTM1 has been identified as a protective factor against obesity and insulin resistance 
(Rodriguez et al., 2006). Intensive studies into the structure and function of p62/SQSTM1 
revealed that it can bind ubiquitylated proteins through its UBA domain (Vadlamudi et al., 
1996; Geetha and Wooten, 2002). This led to identification of the p62/SQSTM1 functions in 
the autophagosomal degradation of ubiquitylated cargo (Vadlamudi et al., 1996; Bjorkoy et 
al., 2005). In particular, p62/SQSTM1 has been proposed to act as an autophagic receptor that 
recruits autophagic machinery to the poliubiquitylated cargo and is degraded alongside in the 
process. Thus, p62 has a well established function in selective autophagy of the ubiquitylated 
cargo, both as an autophagic receptor and a substrate. Interestingly, p62/SQSTM1 has been 
proposed to have a protective effect against protein aggregate-induced neurodegeneration, 
such as Huntington‟s disease, as p62/SQSTM1 downregulation in cells expressing mutant 
huntingtin resulted in increased cell death (Bjorkoy et al., 2005). 
 
The structure of p62/SQSTM1 was further analysed and an LC3-interacting region (LIR) has 
been identified, which mediates direct interaction with LC3 and related Atg8 homologues 
(Pankiv et al., 2007). Additionally, the domain structure of p62, shown in Figure 1.11, also 
includes the Phox and Bem (PB1) domain, which regulates protein oligomerisation and 
protein-protein interactions, ZZ-type zinc finger domain and TRAF6 binding domain (Moscat 
and Diaz-Meco, 2009). 
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Figure 1.11. Domain structures of p62/SQSTM1 and NBR1 
Despite the size differences, the domain structures of p62/SQSTM1 and NBR1 are similar, 
including N-terminal Phox and Bem 1 (PB1) domain which regulates protein-protein 
interaction and polymerisation, zinc finger domain (ZZ), LC3-interacting region (LIR) and the 
C-terminal ubiquitin-association domain (UBA). p62/SQSTM1 also contains TRAF6 binding 
domain (TB), and NBR1 has two coiled-coil (CC) domains which enable protein 
oligomerisation. Adapted from  (Lamark et al., 2009; Moscat and Diaz-Meco, 2012).   
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1.4.3 Neighbour of BRCA 1 
Neighbour of BRCA1 (NBR1) was originally isolated in a screen with a polyclonal antiserum 
against ovarian carcinoma antigen, and was identified to have ZZ-type zinc finger and coiled-
coil domains. The NBR1 gene locus was found in the close proximity to the BRCA1 gene, 
mutation of which is a predisposing factor for development of breast and ovarian cancer (Hall 
et al., 1990; Campbell et al., 1994; Teng et al., 2008). Studies into the functions of NBR1 
identified several proteins as NBR1 interactors in yeast two-hybrid screen. For example, 
NBR1 has been found to bind fasciculation and elongation protein zeta-1 (FIZ1), which is a 
PKC-δ interacting partner, and thus NBR1 has been proposed to act in PKC-δ signalling 
pathway. Another example include calcium and integrin binding protein (CIB), which binds 
Fnk/Snk and FIZ1 (Whitehouse et al., 2002). NBR1 was further identified as a substrate for 
the kinase domain of the giant muscle protein titin, thus has been proposed to regulate 
signalling pathway which controls muscle gene expression (Lange et al., 2005).  
 
Further studies revealed that the PB1 domain present within NBR1 mediates its interaction 
with p62/SQSTM1, as well as enables self-association (Lamark et al., 2003). Computational 
analysis also predicted the presence of the C-terminal UBA domain within NBR1 (Dimitrov 
et al., 2001), which was later shown to bind ubiqutin (Kirkin et al., 2009). NBR1 has been 
also found to bind the Atg8 homologues via the LIR motif and, like p62/SQSTM1, has been 
proposed to regulate autophagosomal degradation of ubiquitylated cargo (Kirkin et al., 2009). 
NBR domain structure is shown in Figure 1.11. Interestingly, NBR1 also localizes to late 
endosomes, and Mardakheh et al. showed that NBR1 autophagosomal and late endosomal 
localizations are independent of each other, suggesting that the function of NBR1 in each 
context may be different (Mardakheh et al., 2010). Additionally, they also showed that NBR1 
association with Sprouty-related EVH1 domain-containing protein (Spred2) promotes ligand-
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mediated RTK degradation, whereas NBR1 on its own acts as an RTK degradation inhibitor 
(Mardakheh et al., 2009; Mardakheh et al., 2010). 
  
1.5 Activated Cdc42-associated kinase 1 (Ack1/TNK2) 
To fully understand how growth factors and their receptors function within the cell, it is 
important to investigate binding partners and proteins that regulate RTK internalization and 
trafficking. One such protein is activated Cdc42-associated kinase 1 (Ack1) alternatively 
known as tyrosine kinase non-receptor 2 (TNK2); TNK2 being its official gene name 
(www.uniprot.org) (UniProt, 2012). The name TNK2 was first reported by Howlin et al. 
(Howlin et al., 2008) in a study on breast cancer cells, in which Ack1 depletion reduced the 
number of cell-surface EGFRs, cell migration and invasion. Manser et al. who identified the 
protein first (Manser et al., 1993) referred to it as Ack1 and, as this is the term that is most 
widely accepted, the name Ack1 will be used throughout this thesis. Ack1 is a non-RTK 
(NRTK) that has been implicated in signalling and trafficking of several RTKs, in particular 
EGFR, but the mechanisms underlying regulation of growth factor signalling and trafficking 
by Ack1 remain poorly understood (Shen et al., 2007; Grovdal et al., 2008; Lin et al., 2010).  
 
1.5.1 Structure 
Ack1 was first identified as a protein specifically interacting with GTP-bound Cdc42 (cell 
division cycle 42), but not with other members of the same family of Rho GTPases, such as 
Rac or Rho (Manser et al., 1993). The Ack1 messenger RNA (mRNA) was isolated from the 
human hippocampus (Manser et al., 1993), where it has been shown to be the most abundant; 
other tissues with high Ack1 expression include spleen, thymus and liver, although Ack1 has 
been shown to be ubiquitously expressed (Galisteo et al., 2006).  
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Ack1 is a relatively large protein with a molecular weight identified as approximately 120 
kDa (Mahajan et al., 2005) to 140 kDa (Shen et al., 2007) and it consists of multiple domains, 
as shown in Figure 1.12. For example, Ack1 has been shown to contain a tyrosine kinase 
domain allowing substrate phosphorylation, and an N-terminal sterile α motif (SAM) enabling 
protein oligomerization (Mahajan and Mahajan, 2010; Prieto-Echaguee et al., 2010). In 
addition, the SAM domain has been proposed to mediate membrane localization, as a mutant 
Ack1 comprising only the SAM and the kinase domain localizes predominantly at the plasma 
membrane (Prieto-Echaguee et al., 2010). In contrast, full-length protein has been identified 
to display cytoplasmic localization; however, some reports also describe a potential nuclear 
translocation of Ack1 (Ahmed et al., 2004; Mahajan et al., 2010). Apart from the tyrosine 
kinase domain and SAM, Ack1 also contains an SH3 domain (Prieto-Echague and Miller, 
2011), which enables binding to proline-rich regions of other proteins. Additionally, the large 
C-terminal proline-rich region within Ack1 has been identified to bind SH3 domains of other 
proteins (Prieto-Echague and Miller, 2011).  
 
Interestingly, Ack1 has a unique domain composition among other NRTKs, with the SH3 
domain being located C-terminal to the kinase domain (Figure 1.12). In other NRTKs, such 
as Src, the SH3 domain is located N-terminal to the kinase domain, and so it may interact 
with the C-terminal proline-rich region within the same protein. This comprises an 
autoinhibitory mechanism which may be abolished, for example, upon phosphorylation 
(Prieto-Echague and Miller, 2011). It is unclear whether Ack1 in autoinhibited by a similar 
mechanism. For example, the studies on the crystal structure of Ack1 showed that Ack1 is in 
an active conformation independently of phosphorylation (Lougheed et al., 2004); however, 
phosphorylation would slightly increase kinase activity (Yokoyama and Miller, 2003). 
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Figure 1.12. Domain structure of human Ack1 (isoform 1)  
N-terminal sterile-α motif (SAM) followed by the tyrosine kinase domain, Src homology 3 
(SH3) domain, clathrin box (clathrin binding domain), Mig6-homology domain (EGFR 
binding domain) and the C-terminal ubiquitin-associated (UBA) domain. Underlined is the 
proline-rich region within the C-terminal portion of Ack1. From UniProt (www.uniprot.org) 
(UniProt, 2012) and (Teo et al., 2001). 
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In contrast, a recent study by Lin et al. suggests that the SH3 domain of Ack1 interacts with 
the Mig6-homology domain leading to autoinhibition of the kinase activity, and that the 
interaction with Grb2 or Cdc42 would release the autoinhibitory state and activate Ack1 (Lin 
et al., 2012).  
 
Ack1 also contains a Cdc42/Rac interacting binding (CRIB) domain and binds specifically to 
GTP-bound Cdc42, but not Rac or Rho (Prieto-Echague and Miller, 2011; Miller, 2011). 
Recently, a clathrin binding domain (CBD) has been identified in the central region of the 
protein, and Ack1 has been shown to bind clathrin heavy chain (Teo et al., 2001). 
Additionally, a Mig6-homology domain (Mig6) has been identified within the C-terminal 
proline-rich region of Ack1, and the Mig6 domain has been shown to be important for  EGFR 
binding (Shen et al., 2007). Finally, a ubiquitin-associated (UBA) domain has been 
determined at the C-terminus of Ack1 (Prieto-Echague and Miller, 2011), which has been 
shown to be crucial for mediating interactions with ubiquitin and ubiquitylated proteins, and 
may potentially be important for targeting ubiquitylated proteins for degradation (Chan et al., 
2009). 
 
The Ack family comprises human and murine Ack1, human Tnk1, murine Ack1 (TNK2) and 
Kos1 (TNK1), bovine Ack2, Drosophila melanogaster DACK and DPR2 and Caenorhabditis 
elegans Ark-1 (Galisteo et al., 2006; Miller, 2011). These are schematically shown in Figure 
1.13 a. There exist three isoforms of human Ack1 and three isoforms of mouse Ack1, shown 
in Figure 1.13 b, which are described at the Universal Protein Resource (UniProt) database 
(www.uniprot.org) (UniProt, 2012). In humans, isoforms 1 and 3 are relatively similar. In 
contrast, isoform 2 is much smaller as it is approximately half the size of the full-length 
protein.  
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Figure 1.13. Ack1 orthologues and isoforms of human and mouse Ack1 
a) Orthologues of human Ack1 (TNK2) and TNK1; b) isoforms of human (Homo sapiens) 
and mouse (Mus musculus) Ack1; human and mouse isoforms 2 (underlined) were expressed 
throughtout the study presented. Adapted from (Miller, 2011) and from www.uniprot.org 
(UniProt, 2012).  
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There do not exist any experimental data regarding this isoform, and it is speculated that it 
may be produced at very low levels due to an aberrant mRNA splicing and a premature stop 
codon within the open reading frame of the Ack1 gene (www.uniprot.org) (UniProt, 2012). In 
mouse, all three Ack1 isoforms are relatively similar. For the purpose of the work presented in 
this thesis, the expression of mouse Ack1 isoform 2 was employed along with  human Ack1 
isoform 2 (truncated Ack1) (Figure 1.13 b).  
 
1.5.2 Function 
There are a number of proteins identified to interact with Ack1, some of which are involved in 
endocytosis and trafficking, e.g. clathrin (Teo et al., 2001), sorting nextin 9 (SNX9) and 
synaptojanin (Yeow-Fong et al., 2005). In addition, Ack1 has been found to interact, directly 
or indirectly, with several RTKs such as EGFR (Shen et al., 2007), platelet-derived growth 
factor receptor (PDGFR) (Galisteo et al., 2006) and Mer (Mahajan et al., 2005). Other Ack1 
interactors include transcription activators, e.g. androgen receptor (AR) (Mahajan et al., 2005; 
Mahajan and Mahajan, 2010) and adaptor proteins, e.g. Grb2 (Pao-Chun et al., 2009). Of 
note, Grb2 has also been shown to mediate an interaction between Ack1 and several other 
RTKs, such as Axl, leukocyte receptor tyrosine kinase and anaplastic lymphoma kinase (Pao-
Chun et al., 2009). All these interactions reveal a wide range of functions that Ack1 may 
potentially exert within the cell, e.g. during endocytosis, trafficking or signalling. 
Additionally, Ack1 has also been found to promote carcinogenesis, and both high expression 
and activation of Ack1 have been linked to cancer development (Mahajan et al., 2005; 
Mahajan and Mahajan, 2010). Moreover, the Ack1 gene has been identified as anti-apoptotic 
when profiling of human kinases, and Ack1 has been shown to promote growth of Ewing‟s 
sarcoma, a type of bone cancer (Arora et al., 2010). The carcinogenic properties of Ack1 are 
described later in Chapter 1.5.4. 
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 Looking into the role of Ack1 in more detail, upon interaction with active Cdc42, Ack1 has 
been shown to phosphorylate p130Cas and promote integrin-mediated cell migration 
(Modzelewska et al., 2006). Additionally, upon activation by RTKs, Ack1 has been found to 
phosphorylate Akt, leading to Akt membrane translocation and activation (Mahajan et al., 
2010). Ack1 has also been identified to colocalize with clathrin and α-adaptin, a component of 
AP2 complexes (Teo et al., 2001), thus indicating a potential function in endocytosis. 
Additionally, moderately overexpressed Ack1 and a kinase-dead Ack1 mutant have been 
found to stimulate uptake of transferrin (Teo et al., 2001), which is internalised through CME 
(Le Roy and Wrana, 2005). These results indicate that Ack1 may play a pivotal role in 
regulating clathrin-dependent internalization e.g. via stimulation of clathrin assembly at the 
plasma membrane. In contrast, highly expressed Ack1 has been shown to inhibit transferrin 
uptake as a result of clathrin aggregation, thus suggesting that the level of Ack1 expression 
may influence transferrin internalisation (Teo et al., 2001). In addition to a potential function 
in endocytosis, Ack1 has also been identified to bind both mono- and polyubiquitin via the 
UBA domain (Shen et al., 2007), and to be ubiquitylated by Nedd4 ubiquitin ligases in 
response to EGF stimulation (Chan et al., 2009; Lin et al., 2010). These features of Ack1 
have been further shown to be essential for regulation of ligand-induced EGFR degradation, 
as expression of the UBA domain-deletion mutant of Ack1 significantly reduced EGFR 
degradation when compared to WT Ack1 (Shen et al., 2007). 
 
1.5.3 Ack1 in EGFR trafficking and degradation 
Ack1 has been implicated in the regulation of EGFR trafficking and degradation  (Shen et al., 
2007; Grovdal et al., 2008); however, the precise mechanism of regulation remains unclear. 
For example, Grøvdal et al. (Grovdal et al., 2008) showed that Ack1 partially colocalizes with 
fluorescently labelled EGF on early endosomes following EGF stimulation. They also found 
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that high levels of Ack1 expression reduce EGFR internalisation, and this was proposed to be 
the result of clathrin aggregation. Interestingly, knockdown of the Ack1 gene expression also 
inhibited EGFR endocytosis (Grovdal et al., 2008). These data therefore suggest that the level 
of Ack1 expression is critical for EGFR internalisation. In addition, both overexpression and 
knockdown of Ack1 led to accumulation of EGF on early endosomes upon EGF stimulation, 
whereas in control cells the majority of EGF localized to the internal vesicles of late 
endosomes, thus indicating that Ack1 may play a role in lysosomal sorting of EGFR (Grovdal 
et al., 2008). Finally, Ack1 knockdown resulted in increased EGF recycling and decreased 
degradation (Grovdal et al., 2008). These data therefore indicate that Ack1 functions in EGFR 
trafficking and potentially plays important regulatory roles during EGFR endocytosis, 
trafficking and sorting for lysosomal degradation. 
 
Another study by Shen et al. (Shen et al., 2007) showed that endogenous Ack1 co-precipitates 
with endogenous EGFR following EGF stimulation, but not pre-EGF treatment. In particular, 
the interaction first occurs at 5 to 10 minutes following EGF stimulation and is still 
distinguishable upon three hours of EGF stimulation. In contrast, an interaction between 
ectopically expressed Ack1 and EGFR is observed much quicker, within one minute of EGF 
stimulation (Shen et al., 2007). Furthermore, Shen et al. also found that ectopically expressed, 
and not endogenous, Ack1 interacts with activated EGFR at the plasma membrane (Shen et 
al., 2007). These data therefore indicate that endogenous Ack1 may be restricted within 
subcellular compartments, from which it may be released following EGF stimulation. In 
contrast, when Ack1 is overexpressed, it may be readily available for interaction with EGFR 
close to the plasma membrane (Shen et al., 2007). Importantly, the EGFR tyrosine kinase 
activity has been found to be essential for this interaction, as both the kinase-inactive mutant 
of EGFR failed to bind Ack1 and the EGFR tyrosine kinase inhibitor blocked this interaction 
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(Shen et al., 2007). Additionally, an interaction between Ack1 and EGFR is preceded by 
EGFR association with Cbl, a ubiquitin ligase, and EGFR ubiquitylation (Shen et al., 2007). 
This may suggest that EGFR ubiquitylation is required for interaction with Ack1; however, 
the EGFR mutant unable to bind Cbl has also been shown to bind Ack1, thus indicating that 
EGFR ubiquitylation may not play a major role and other mechanisms regulate the 
association between Ack1 and EGFR (Shen et al., 2007). Nevertheless, as mentioned in 
Chapter 1.5.2, expression of the UBA domain-deletion mutant of Ack1 reduced EGFR 
degradation thus indicating that binding of ubiquitin or ubiquitylated proteins by Ack1 
promotes EGFR degradation. 
 
Another important outcome from the work by Shen et al. (Shen et al., 2007) is an indication 
that the Mig6-homology domain of Ack1 is required for EGFR binding (Shen et al., 2007). 
As described in Chapter 1.2.5, Mig6 is an adaptor protein which inhibits EGF signalling 
(Zhang et al., 2007). Whether Ack1 plays a similar role to Mig6 in this context remains 
elusive. Further investigation revealed that Grb2 regulates the association between Ack1 and 
EGFR through binding to the SH3 domain of Ack1 and releasing the autoinhibited 
conformation (Lin et al., 2012).  
 
1.5.4 Ack1 in cancer 
Apart from the important roles that Ack1 may potentially play in endocytosis, trafficking and 
signalling, the studies also reveal that Ack1 contributes to cancer development and cancer 
progression. For example, constitutively active Ack1 has been identified to induce 
tumorigenesis in vivo (Mahajan et al., 2005).  Additionally, Ack1 has been found to promote 
cancer metastasis, as Ack1 knockdown inhibited migration of breast cancer cells (Howlin et 
al., 2008). Furthermore, Ack1 has been shown to bind and phosphorylate tumor suppressor 
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WW domain-containing oxidoreductase (Wwox), which then may become polyubiquitylated 
and degraded. This has been shown to result in downregulation of Wwox and hence Ack1 
would contribute to carcinogenesis (Mahajan et al., 2005). Phosphorylation of androgen 
receptor, a transcription factor, by Ack1 has been proposed as another mechanism 
contributing to cancer progression via activation of transcription of genes involved in cancer 
progression (Mahajan et al., 2007).  
 
Further reports show that Ack1 knockdown results in upregulation of E-cadherin, an indicator 
of the epithelial phenotype, and downregulation of N-cadherin, an indicator of mesenchymal 
phenotype (Chua et al., 2010). Epithelial-mesenchymal transition (EMT) is a process in 
which cells lose their epithelial characteristics, such as polarisation or remaining within the 
epithelial layer, and acquire mesenchymal characteristics, such as fibroblast-like morphology 
and high motility. EMT is often observed during malignant transformation and is considered 
as a hallmark of cancer (Thiery and Sleeman, 2006). Thus, Ack1 has been proposed to 
contribute to tumorigenesis through promoting EMT (Chua et al., 2010). Interestingly, Ack1 
knockdown has been found to sensitize renal carcinoma cells, which express high levels of 
EGFR, to treatment with EGFR inhibitor, and led to increased cell apoptosis (Chua et al., 
2010). These data therefore potentially provide a novel therapeutic approach in cancers with 
high levels of EGFR expression, to combine the therapy against EGFR and Ack1 in tumors 
that are resistant for treatment with EGFR inhibitors. 
 
Sequencing of the genome of human cancers revealed several somatic and germline mutations 
within the Ack1 gene (Greenman et al., 2007). In particular, somatic mutation Met409Ile has 
been found in gastric cancer, Arg34Leu in lung cancer, and Arg99Gln and Glu346Lys in 
ovarian cancer (Greenman et al., 2007). The effects of these mutations on Ack1 function were 
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further investigated (Prieto-Echaguee et al., 2010). All four mutations have been shown to 
promote Ack1 autophosphorylation and activation, and Arg34Leu, Met409I and Glu346Lys 
also resulted in increased cell migration. Additionally, the Glu346Lys mutation has been 
found to promote anchorage-independent cell growth. This mutation, which is located within 
the C-lobe of the kinase domain, has been proposed to disrupt the inhibitory interaction 
between the kinase domain and the Mig6-homology domain, leading to Ack1 activation 
(Prieto-Echaguee et al., 2010). Another somatic mutation within the UBA domain, the 
Ser985Asn substitution, has been found to promote cell migration, proliferation and 
mitogenic signalling. The Ser985Asn mutant was unable to bind ubiquitin and has been 
shown defective in EGFR downregulation due to reduced EGFR ubiquitylation (Chua et al., 
2010). 
 
Interestingly, although Ack1 knockout mice are not currently available 
(www.mousephenotype.org), knockout of the TNK1 gene in mice has been shown to result in 
formation of spontaneous tumours (Hoare et al., 2008). Therefore, surprisingly, TNK1 has 
been proposed to function as a tumour suppressor through inhibition of Ras signalling. 
 
1.5.5 Rationale for investigation of Ack1 
Previous work by Cunningham et al. identified proteins that are phosphorylated downstream 
of FGFR activation in a Src family kinase (SFK)-dependent manner (Cunningham et al., 
2010). Specifically, cells isotopically labelled using stable isotope labelling of amino acids in 
cell culture (SILAC) technique (described in more detail in Chapter 7) were treated with 
FGF in the presence or absence of the SFK inhibitor. The proteins phosphorylated in FGF-
treated cells whose phosphorylation decreased in the presence of the inhibitor were 
recognised as those implicated in FGF signalling pathway which require SFKs for activation. 
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Prior to these SILAC experiments, preliminary non-quantitative experiments were performed 
in which phosphorylated peptides were enriched from FGF-treated cells (D. L. Cunningham, 
S. M. M. Sweet and J. K. Heath, unpublished work). Ack1 was identified and selected as an 
interesting molecule to research in the context of FGF due to its known role in EGF signalling 
pathway (Shen et al., 2007; Grovdal et al., 2008); however, further quantitative studies by Dr. 
D. L. Cunningham did not confirm Ack1 functions downstream of FGFR activation, neither 
did the work presented within this thesis (Chapter 4). 
 
1.6 Confocal Laser Scanning Microscopy 
Current cell biology uses multiple imaging techniques to study the localization, function and 
dynamics of molecules and compartments of interest. There are a vast number of microscopy 
techniques which enable understanding of the processes which take place both at the cell 
membrane and within the cell, e.g. total internal reflection fluorescent (TIRF) microscopy, 
epi-fluorescence microscopy, confocal microscopy, two-photon microscopy and super 
resolution microscopy. Each of these techniques has its advantages and disadvantages and 
may be used for a specific purpose, e.g. TIRF microscopy allows visualisation of events 
taking place at the adherent plasma membrane. Throughout this project confocal fluorescent 
microscope has been used to study subcellular dynamics, a schematic of which is shown in 
Figure 1.14.  
 
The term „confocal‟ arises from the conjugation of the focal point („confocal‟) of the lens 
within an objective with a pinhole, which largely improves image quality by blocking out of 
focus light. The first confocal microscope was invented by Marvin Minsky in the 1950s 
(Semwogerere and Weeks, 2005). As a light source he used a zirconium arc lamp, which 
delivered an intensely bright white light.  
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Figure 1.14. Schematic of Confocal Microscope 
A laser beam passes through the pinhole and reflects from the dichromatic mirror, and follows 
through the system of lenses within an objective. The beam excites fluorophores within the 
specimen, both within the focal plane and outside. The fluorescent light passes through the 
dichromatic mirror and an emission filter, which selects the emission wavelength and 
eliminates the excitation light. Adapted from  (Semwogerere and Weeks, 2005). 
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Minsky incorporated two pinholes into his microscope: first after the light source to eliminate 
scattered light, and the second before the detector to eliminate out-of-focus light. Further 
elimination of scattered light was obtained by point-by-point illumination of a specimen, due 
to moving the stage with the specimen. From then, confocal microscopes have developed 
while retaining the pinhole system and the point-by-point illumination of the specimen, which 
is typically obtained by the horizontal and vertical scanning mirrors that regulate the light 
source, a laser beam. Currently the confocal microscopes work either by reflecting the light 
from the specimen or by promoting fluorescence from the fluorophores present within the 
specimen. The main drawback is the limitation of the resolution of the confocal microscope 
images, typically around 200 nm, due to the diffraction of light (Semwogerere and Weeks, 
2005).  
 
1.7 Mass spectrometry 
Mass spectrometry is an analytical technique that enables ion separation depending on mass-
to-charge (m/z) ratio. The positively or negatively charged ions are formed during ionisation 
and are separated by electrical or magnetic field according to their m/z ratio. In the mass 
spectrum, the m/z ratio is presented on the x axis, and the abundance of an ion on the y axis 
(El-Aneed et al., 2009). There are many different isonisation techniques used in mass 
spectrometry, ranging from electron impact (EI), chemical ionization (CI), plasma desorption 
(PD), fast atom bombardment (FAB), liquid secondary ion mass spectrometry (LSIMS), 
matrix-assisted laser-desorption isonisation (MALDI) and electrospray ionization (ESI). Ions 
formed through these techniques are analysed according to their m/z ratio by a mass analyser 
(El-Aneed et al., 2009). Additional analysis is achieved by the use of tandem mass 
spectrometry (MS/MS) techniques, in which a specific ion is selected and undergoes 
fragmentation. The most common MS/MS techniques used for proteomic analysis include 
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collision-induced dissociation (CID) and electron transfer dissociation (ETD) (Jones and 
Cooper, 2011). 
 
CID technique excites ions to collide with the neutral gases, such as helium or nitrogen. This 
collision results in an increase in an internal vibrational energy leading to the cleavage of the 
weakest bond within the ion. In peptides and proteins, CID typically results in amide bond 
cleavage (N-CO) leading to formation b and y ions. In CID, labile PTMs, such as 
phosphorylation , ubiquitylation or nitrosylation (attachment of the nitric oxide group), are 
cleaved thus limiting localization of the site of modification (Jones and Cooper, 2011).  
 
Unlike in CID, in ETD the cleavage is radical, not thermal, resulting in the preservation of 
labile PTMs. A trapped gas-phase ion collides with a radical anion (e.g. anthracene) resulting 
in the transfer of a low energy electron. Typically the backbone bond N-Cα is cleaved leading 
to the formation of c and z ions, or disulfide bonds. Since its development, ETD (and the 
similar electron capture dissociation (ECD)) has been widely used for the successful 
identification of labile PTMs (Jones and Cooper, 2011). In the work presented in this thesis, 
ESI has been used for ionization, and CID and ETD tandem MS/MS techniques were 
employed. 
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2 Thesis Aims 
The aim of this thesis is to understand the molecular mechanisms by which Ack1 regulates 
EGFR trafficking and degradation. As described above, due to extensive actions that EGF 
signalling exerts within the cell, signal attenuation through endocytosis and degradation of 
EGF receptor is fundamental for proper cellular function. When these controlling measures 
are not efficient, this could potentially create a perfect envioronment for neoplastic 
transformation. In this context, Ack1 implication into EGFR trafficking and degradation have 
been described previously; nevertheless, the more precise mechanisms of the action remains 
elusive and incomplete. 
 
Specifically, this work aims to investigate the following: 
 Ack1 association with EGFR, whether it is a specific feature of the kinase, or whether 
 it can interact also with other RTKs, such as FGFR (Chapter 4) 
 Ack1 subcellular localization in steady-state cells, upon serum-starvation and 
 stimulation with EGF (Chapter 5) 
 Ack1 association with autophagic proteins and its potential involvement in the process 
 of selective autophagy (Chapter 6) 
 Identification of novel post-translational modifications and Ack1 binding partners 
 through mass spectrometry (Chapter 7). 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Buffers and solutions 
Bacterial culturing: 
 Lysogeny broth (LB): 20 % LB broth (Sigma-Aldrich) (w/v) 
 Ampicilin plates: LB, 15 g/l bactoagar (BD) 100 mg/l ampicilin (Sigma-Aldrich) 
 Kanamycin plates: LB, 15 g/l bactoagar (BD). 50 mg/l kanamycin (Sigma-Aldrich) 
DNA manipulation: 
 DNA loading buffer (6X) (Invitrogen) 
 Tris, borate, ethylenediaminetetraacetic acid (EDTA) (TBE) buffer (5X): 54 g/l Tris 
(Thermo Fisher Scientific), 27.5 g boric acid (Thermo Fisher Scientific), 0.01 M EDTA pH 
8.0 (Sigma-Aldrich) 
Protein manipulation: 
 Triton X-100 cell lysis buffer: 0.05 M tris (Thermo Fisher Scientific)-hydrochloric 
acid (HCl) (Thermo Fisher Scientific), 0.15 M sodium chloride (NaCl) (Thermo Fisher 
Scientific), 1 % triton X-100 (Sigma-Aldrich) (v/v), 0.001 M sodium orthovanadate (Na3VO4) 
(Sigma-Aldrich), 0.05 M sodium fluoride (NaF) (Sigma-Aldrich), 0.025 M β-
glycerophosphate (Sigma-Aldrich), complete protease inhibitor cocktail tablets (Roche 
Applied Science): 1 tablet per 10 ml (contains EDTA; final concentration 0.001 M) 
 SDS Sample buffer (2X): 0.125 M tris (Thermo Fisher Scientific)-HCl (Thermo Fisher 
Scientific) pH 6.8, 20 % glycerol (Thermo Fisher Scientific) (v/v), 4 % SDS (Thermo Fisher 
Scientific) (w/v), 0.1 % bromophenol blue (Sigma-Aldrich) (w/v), 10 % β-mercaptoethanol 
(Sigma-Aldrich) (v/v) 
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 LDS sample buffer (4X) (Invitrogen) 
 Reducing agent (10X) (Invitrogen) 
 MOPS/SDS running buffer (20X) (Invitrogen) 
 Tris-glycine transfer buffer: 0.025 M tris (Thermo Fisher Scientific), 0.2 M glycine 
(Thermo Fisher Scientific), 10 % methanol (Thermo Fisher Scientific) (v/v) 
 Phosphate buffered saline (PBS): PBS pH 7.2 tablets (Oxoid) made up according to 
manufacturer‟s instructions 
 PBST washing buffer: PBS (Oxoid), 0.1 % tween 20 (Sigma-Aldrich) (v/v) 
 PVDF stripping buffer (Li-Cor) 
 Immunoblotting blocking buffer: PBS (Oxoid), 50 % odyssey blocking buffer (Licor) 
(v/v), 0.1 % tween 20 (Sigma-Aldrich) (v/v) 
Immunoprecipitation: 
for Protein G-Sepharose Fast Flow beads (Sigma-Aldrich) 
 Stock solution (2X): 0.1 M tris (Thermo Fisher Scientific)-HCl (Thermo Fisher 
Scientific) pH 7.4, 0.1 % triton X-100  (Sigma-Aldrich) (v/v), 0.3 M NaCl (Thermo Fisher 
Scientific) 
for Dynabeads Protein G (Invitrogen) 
 Wash buffer: PBS (Oxoid), 0.02 % tween 20 (Sigma-Aldrich) (v/v) 
for GFP-Trap (Chromotek) 
 Dilution buffer: 0.01 M tris (Thermo Fisher Scientific)-HCl (Thermo Fisher Scientific) 
pH 7.5, 0.15 M NaCl (Thermo Fisher Scientific), 0.0005 M EDTA (Sigma-Aldrich), complete 
protease inhibitor cocktail tablets (Roche Applied Science): 1 tablet per 10 ml (contains 
EDTA; final concentration 0.001 M) 
 Wash buffer: 0.001 M tris (Thermo Fisher Scientific)-HCl (Thermo Fisher Scientific) 
pH 7.5, 0.5 M NaCl (Thermo Fisher Scientific), 0.0005 M EDTA (Sigma-Aldrich), complete 
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protease inhibitor cocktail tablets (Roche Applied Science): 1 tablet per 10 ml (contains 
EDTA; final concentration 0.001 M) 
Antibody cross-linking: 
 Wash buffer: 0.2 M triethanolamine (TEA) (Sigma-Aldrich) pH 8.2 
 Cross-linking buffer: 0.02 M dimethyl pimelidate dihydrochloride (Sigma-Aldrich), 
0.2 M TEA (Sigma-Aldrich) pH 8,2 
 Quenching buffer: 0.05 M tris (Thermo Fisher Scientific)-HCl (Thermo Fisher 
Scientific) pH 7.5 
 Elution buffer: 1 M glycine (Thermo Fisher Scientific) pH 3.0 
Immunofluorescence: 
 Fixation solution: PBS (Oxoid), 4 % paraformaldehyde (Electron Microscopy 
Sciences) (v/v) 
 Alternative fixation solution: methanol (Thermo Fisher Scientific) (-20 °C) 
 Wash buffer: PBS (Oxoid) 
 Permeabilisation  buffer: PBS (Oxoid), 0.1 % triton X-100 (Sigma-Aldrich) (v/v) 
 Alternative permeabilisation buffer: PBS (Oxoid), 0.2 % triton X-100 (Sigma-Aldrich) 
(v/v) 
 Blocking buffer: PBS (Oxoid), 10 % goat serum (Invitrogen) (v/v),  5 % bovine serum 
albumin (BSA) (Sigma-Aldrich) (w/v) 
 Antibody solution: PBS (Oxoid), 1 % goat serum (Sigma-Aldrich) (v/v) 
Live-cell imaging: 
 Cell imaging medium: 10 mM HEPES (Sigma-Aldrich)-Hank‟s balanced salt solution 
(HBSS) (Sigma-Aldrich) pH 7.4 
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In-gel digestion: 
 Gel fixation solution: 55 % methanol (Thermo Fisher Scientific) (v,v), 11 % acetic 
acid (Thermo Fisher Scientific) (v,v) 
 Gel staining with Coomassie: 0.1 % brilliant blue R (Sigma-Aldrich) in gel fixation 
solution 
 Gel destain solution: 7.5 % acetic acid (Thermo Fisher Scientific) (v,v), 5 % methanol 
(Thermo Fisher Scientific) (v,v) 
 Destaining solution: 30 % acetonitrile (JT Baker) (v/v) 
 Dehydration and washing buffer: 50 % acetonitrile (JT Baker) (v/v), 25 mM 
ammonium bicarbonate (Fluka) 
 Rehydration and washing buffer: 0.025 M ammonium  bicarbonate (Fluka) 
 Reduction buffer: 0.01 M dithiothreitol (DTT) (Sigma-Aldrich), 0.025 M ammonium 
bicarbonate (Fluka) 
 Alkylation buffer: 0.055 M iodoacetamide (Sigma-Aldrich), 0.025 M ammonium 
bicarbonate (Fluka) 
 Trypsin resuspension solution: 0.05 M acetic acid (Thermo Fisher Scientific) 
 Trypsin digestion solution: 12.5 mg/l trypsin (Promega), 0.025 M ammonium 
bicarbonate (Fluka) 
 Peptide extraction solutions: 50 % and 100 % acetonitrile (JT Baker)  (v/v) 
TiO2 enrichment: 
 Conditioning solution: 0.4 % trifluoroacetic acid (TFA) (Thermo Fisher Scientific)  
(v/v), 80 % acetonitrile (JT Baker)  (v/v) 
 Equilibration solution: 25 % solution B (lactic acid) (Hichram) (v/v), 75 % 
conditioning solution (v/v) 
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Desalting: 
 Wetting solution: 100 % acetonitrile (JT Baker)   
 Equilibration and washing solution: 0.1 % TFA (v/v) (Thermo Fisher Scientific)   
 Elution buffer: 0.1 % formic acid (Fisons, Ipswich, UK) (v/v), 50 % acetonitrile (JT 
Baker)  (v/v) 
Cell culture: 
 Poly-D lysine coating solution: 0.1 g/l poly-D-lysine (Sigma-Aldrich) 
 
3.1.2 Antibodies and Reagents 
Table 3.1 and Table 3.2 present primary and secondary antibodies used in this study, 
respectively. Additionally, anti-phospho-EGF receptor (Y1045) antibody raised in rabbit was 
provided by Dr. Elena Odintsova (University of Birmingham, Birmingham, UK) and normal 
mouse IgG was purchased from Santa Cruz Biotechnology. Alexa Fluor 488- and 568-
transferrin conjugates and Lysotracker Red DND-99 were purchased from Invitrogen. The 
FGF2 was made in-house (work by Miss S. Brewer). Briefly, the protein (155 amino acids; 18 
kDa) was expressed in E.coli from the bacterial expression vector pFC80 (provided by Dr 
Antonella Isacchi, Pharmacia & Upjohn, Milan, Italy) and purified by heparin-column 
chromatography. EGF, heparin sodium salt, albumin from bovine serum (BSA), glycerol-2-
phosphate and leptomycin B were from Sigma-Aldrich. FGFR inhibitor SU5402 and EGFR 
inhibitor BIBX 1382 were from Calbiochem. Fetal bovine serum (FBS) was from Biosera, 
donor bovine serum (DBS), goat serum (GS) were from Invitrogen. Bafilomycin A1 was 
purchased from Merck Millipore. Small interfering RNA (siRNA) against TNK2 and non-
targeting iRNA control were from Dharmacon. Human cancer cell line blot was purchased 
from G. Biosciences. 
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Primary Antibody Species Manufacturer Dilution 
GFP (D5.1) RM Cell Signalling Technology 1:1000 (WB) 
Phospho FGF Receptor 
(Tyr 653/654) 
MM Cell Signalling Technology 1:1000 (WB) 
HA-Tag (C29F4) MM Cell Signalling Technology 1:1000 (WB) 
EGFR RP Cell Signalling Technology 1:1000 (WB) 
EEA1 RP Cell Signalling Technology 1:100 (IF) 
Ack1 (A-11) MM Santa Cruz Biotechnology 1:25 (IF) - 1:250 (WB) 
PLCγ1 RP Santa Cruz Biotechnology 1:1000 (WB) 
Bek (C-17) RP Santa Cruz Biotechnology 1:1000 (WB) 
Ack1 (C20) RP Santa Cruz Biotechnology 1:25 (IF) - 1:1000 (WB) 
Flg (C-15) RP Santa Cruz Biotechnology 1:1000 (WB) 
EGFR (R-1) MM Santa Cruz Biotechnology 1:50 (IF) 
SQSTM1 RP Santa Cruz Biotechnology 1:50 (IF) - 1:1000 (WB) 
SQSTM1 (clone 2C11) MM Abnova 1:50 (IF) - 1:1000 (WB) 
Ack1 (phospho Y284) RP Abcam 1:1000 (WB) 
LBPA MM Echelon Biosciences 1:500 (IF) 
Rab11 RP Invitrogen 1:12.5 (IF) 
Atg16L RP MBL International 1:500 (IF) 
Phosphotyrosine 4G10 MM Millipore 1:2000 (WB) 
Phosphotyrosine PY20 MM MP Biomedicals 1:2000 (WB) 
Myc (clone 9E10) MM Roche Applied Science 1:2000 (WB) 
α-tubulin MM Sigma-Aldrich 1:10,000 (WB) 
 
Table 3.1. Primary antibodies used in the study 
Table presents primary antibodies used in the study. MM-mouse monoclonal, RP-rabbit 
polyclonal, RM-rabbit monoclonal. IF-immunofluorescence, WB-Western blotting. 
 
Secondary Antibody Species Manufacturer Dilution 
Alexa Fluor 488 Conjugated  Goat anti-mouse Invitrogen 1:200 (IF) 
Alexa Fluor 488 Conjugated  Goat anti-rabbit Invitrogen 1:200 (IF) 
Alexa Fluor 568 Conjugated  Goat anti-mouse Invitrogen 1:200 (IF) 
Alexa Fluor 568 Conjugated  Goat anti-rabbit Invitrogen 1:200 (IF) 
Alexa Fluor 633 Conjugated  Goat anti-mouse Invitrogen 1:200 (IF) 
Alexa Fluor 633 Conjugated  Goat anti-rabbit Invitrogen 1:200 (IF) 
HRP-conjugated IgG (FC) Goat anti-human Pierce 1:10,000 (WB) 
Odyssey 680 Goat anti-mouse Li-Cor 1:10,000 (WB) 
Odyssey 680 Goat anti-rabbit Li-Cor 1:10,000 (WB) 
Odyssey 800CW Goat anti-mouse Li-Cor 1:10,000 (WB) 
Odyssey 800CW Goat anti-rabbit Li-Cor 1:10,000 (WB) 
 
Table 3.2. Secondary antibodies used in the study 
Table presents secondary antibodies used in the study. IF: immunofluorescence, WB: Western 
blotting. 
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3.1.3 Plasmid constructs 
The murine Ack1 isoform 2 (1008 a.a.) amino terminal myc-tagged in pcDNA3 vector and 
GFP-tagged in pEGFP-C1 vector were provided by Dr. Wannian Yang (Geisinger, Danville, 
PA, USA). For mCherry-Ack1, Open Reading Frame (ORF) was subcloned into pmCherry-
C1 vector (Clontech). ORF of human Ack1 isoform 2 (528 aa; truncated Ack1) (UniProt 
Identifier: Q07912-2) in a Gateway (Invitrogen) pDONR vector (Open Biosciences) was 
subcloned into GFP-pcDNA3 and myc-PRK5 vectors. Human FGFR2-pEGFR-N2 was 
provided by Prof. John Ladbury (University of Texas M. D. Anderson Cancer Center, 
Houston, TX). hFGFR1-pcDNA3.1 was provided by Associate Prof. Pamela Maher (Scripps 
Research Institute, CA, USA), human IgG1 Fc-fused FGFR1 constructs (kinase active, kinase 
dead, transmembrane and VT-) in pEF-BOS-ires-Topaz vectors were described previously 
(Burgar et al., 2002). EGFR-pEGFP-N1 was provided by Prof. Alexander Sorkin (University 
of Pittsburgh, Pittsburgh, PA, USA), pcDNA-3 L61-Cdc42-GFP encoding GFP-tagged 
constitutively active Cdc42 (caCdc42) was provided by Dr. Neil Hotchin (University of 
Birmingham, Birmingham, UK). pEGFP-C3-Rab4a and pEGFP-C2-Rab11a were gifts from 
Prof. Marino Zerial (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, 
Germany), vector encoding GFP-tagged Rab7 was provided by Dr. Simon Johnston 
(University of Birmingham, Birmingham, UK). Rab5-EGFP and Eps15-pEGFP-C2 were 
provided by Dr. Alexandre Benmerah (Cochin Institute, Paris, France). Ubiquitin/HA fusion 
in pMT123 vector was provided by Prof. Ronald Hay, University of St. Andrews, North 
Haugh, St. Andrews, Fife, UK). Flag-p62/SQSTM1 in pcDNA3.1 vector was provided by 
Prof. Robert Layfield (University of Nottingham, Nottingham, UK). Rat pEGFP-LC3 was 
kindly provided by Prof. Tamotsu Yoshimori (Osaka University, Osaka, Japan). 
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3.2 Methods 
3.2.1 Molecular cloning 
Transformation of competent cells: 
1 µl of plasmid cDNA (pcDNA) was added to 50 µl of Escherichia coli strain DH5α and 
bacteria were incubated for 30 minutes on ice, following by a heat-shock for 45 sec at 42 °C 
and 2 minutes incubation on ice. 600 µl of LB was added and bacteria were incubated for 1 
hour at 37 °C, with agitation, to allow for expression of an antibotic-resistance gene. 100 to 
250 µl of the cells were then plated onto ampicilin or kanamycin plate and incubated 
overnight at 37 °C, allowing for growth of the antibiotic-resistant clones. 
 
Miniprep and Maxiprep: 
A bacterial colony was chosen from an agar plate and cultured for additional ~8 hours for 
Mini-prep or overnight for Maxiprep in LB with relevant antibiotic at the same 
concentrations. Bacteria were harvested by centrifuging for 15 minutes at 6,000 g at 4 °C. 
Plasmid cDNA was purified with Plasmid Maxiprep or Miniprep kits from Qiagen. Briefly, 
bacteria were resuspended and lysed, plasmid cDNA was loaded onto the column, then 
washed and eluted. Plasmid cDNA was precipitated with isopropanol, washed with 70 % 
ethanol and resuspended in distilled H2O. pcDNA concentration was determined by 
measuring absorbance at 260 nm using M501 UV/Visible Spectrophotometer (Camspec), and 
the purity of pcDNA was determined by 260 nm/ 280 nm absorbance ratio. 
 
Ack1 C-terminal truncation mutants (work performed by Miss S. Brewer): 
C-terminal truncations of murine Ack1 isoform 2 were generated via PCR from a full-length 
construct using forward and reverse primers with EcoR1 and BamH1 digestion sites, 
respectively. The linear products were digested with EcoR1 and BamH1 restriction enzymes 
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(New England Biolabs, Ipswich, MA, USA) and ligated with pmCherry-C1 vector using T4 
ligase (New England Biolabs). The following primers were used: forward primer for all 
mutants: TGAGTCCGTAGAATTCGATGCAGCCGGAGGAGGGA and reverse primers for 
ΔUBA mutant (1-910 a.a.) TAGCCTAAGTGGATCCTCATCTGACGGTGGCAGT, ΔMIG6 
mutant (1-680 a.a.) TAGCCTAAGTGGATCCTCAGGGCATCTGCGCCTG, ΔPRD mutant 
(1-610 a.a.) TAGCCTAAGTGGATCCTCACCGTGTGGGGCTCTG. 
 
3.2.2 Cell culture, transfection, treatment, stimulation and lysis 
Cell culture: 
Human Embryonic Kidney epithelial 293T (293T) and human cervival adenocarcinoma 
(HeLa) cells were cultured in Dulbeco‟s Modified Eagle Medium (DMEM) supplemented 
with 10% FBS (v/v) with 100 I.U./ml penicillin and 0.1 mg/ml streptomycin (Sigma-Aldrich), 
with addition of 2 mM L-glutamine (Sigma-Aldrich), at 37 °C with 5% CO2. Cells were 
generally split every three to four days using 0.05 % Trypsin-EDTA (Invitrogen). Androgen-
sensitive human prostate adenocarcinoma (LNCaP) cells were cultured in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 10% FBS (v/v) with 100 I.U./ml 
penicillin and 0.1 mg/ml streptomycin (Sigma-Aldrich), with addition of 2 mM L-glutamine 
(Sigma-Aldrich), at 37 °C with 5% CO2. Cells were generally split once a week. Since cells 
were weakly adherent, no trypsinisation was required prior to splitting, and flasks could be 
knocked gently by hand to detach the cells. 
 
Transfection: 
293T and HeLa cells transfection using GeneJuice 
Cells were transfected with GeneJuice Transfection Reagent (Novagen), according to the 
manufacturer‟s instructions. Briefly, the cells were plated in 35 mm dish at 3x10 5 cells/ml 
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concentration in the case of HeLa cells and at 4x10
5
 cells/ml concentration in the case of 
293T cells. The next day, 3 µg cDNA, 6 µl GeneJuice and 100 µl antibiotic- and serum-free 
medium was added drop-wise to the cells. Incubation was continued for further 48 hours to 
allow for protein expression. 
 
LNCaP cells transfection using Lipofectamine 2000 
Cells were transfected with Lipofectamine according to manufacturer‟s instructions. Briefly, 
cells were plated at 5x10
5
 cells/ml concentration in 35 mm dish. The next day, 3-4 µg cDNA 
and/or 100 pmol RNAi, 10 µl Lipofectamine 2000 and 500 µl antibiotic- and serum-free 
medium was added drop-wise to the cells. Incubation was continued for further 48 hours to 
allow for protein expression and/or siRNA knockdown. 
 
Treatment: 
Bafilomycin A (inhibitor of lysosomal acidification): cells were incubated with 400 nM 
bafilomycin A1 for four hours prior to EGF stimulation.  
BIBX 1382 (EGFR kinase inhibitor): cells were serum-starved for four hours, the final hour 
in the presence of BIBX 1382 (10 µM unless otherwise stated). 
Leptomycin B (inhibitor of nuclear export): cells were serum-starved for four hours following 
EGF stimulation in the presence of leptomycin B (10 ng/ml). 
 
Stimulation: 
Cells were serum-starved for 4 hours, unless otherwise stated. Following serum-starvation, 
cells were stimulated with FGF2 to the final concentration of 20 ng/ml and heparin to the final 
concentration 10 µg/ml, for 20 minutes. In the case of EGF, cells were stimulated for different 
times (as indicated), and the final concentration of EGF was 100 ng/ml in HeLa and 293T 
cells, and 20 ng/ml in LNCaP cells.  
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Cell lysis: 
Cells were washed with PBS and lysed with triton X-100 lysis buffer for 30 minutes on ice. 
Lysed cells were cleared by centrifugation at 14,000 g for 25 minutes at 4 °C, and the pellets 
were discarded. Total protein concentration of the cleared lysate was determined by 
Coomassie (Bradford) Protein Assay Kit (Pierce) according to the manufacturer‟s 
instructions, with E max spectrophotometer (Molecular Devices). Cell lysates were adjusted 
to the same protein concentration per experiment. 
 
3.2.3 Immunofluorescence and confocal microscopy 
Immunofluorescence: 
Cells were plated onto coverslips 24 hours prior to immunostaining. In the case of LNCaP 
cells, coverslips were coated with poly-D-lysine to enable the cells to attach to coverslips. 
Cells were washed twice with ice-cold PBS and fixed in 4 % paraformaldehyde (PFA; 
Electron Microscopy Sciences). Fixed cells were permeabilised with 0.1 % triton X-100 
(Sigma-Aldrich) in ice-cold PBS for 5 minutes at room temperature (RT) or with 0.2 % triton 
X-100 (Sigma-Aldrich) in ice-cold PBS for 3 minutes at RT. The cells were subsequently 
incubated with blocking buffer for one hour at RT, following by overnight incubation with 
primary antibodies at 4 °C, and one hour incubation with secondary antibodies at RT. 
Coverslips with cells were mounted using either HydroMount (National Diagnostics), 
ProLong Gold (Invitrogen) or Vectashield Mounting Medium with DAPI (Vector 
Laboratories). All images were acquired through Nikon A1R Confocal/TIRF Microscope 
(Nikon) with the NIS-Elements Software (version 3.1 and 4.0) (Nikon). For transferrin-488 or 
transferrin-568 data, cells were serum starved for 10 minutes and incubated with transferrin at 
the final concentration of 10 µg/ml for indicated times prior to fixation. For lysotracker data, 
HeLa cells were incubated for two hours with lysotracker at the final concentration of 100 nM 
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prior to fixation, whereas LNCaP cells were incubated 30 minutes with lysotracker prior to 
live-cell imaging. 
 
Confocal Microscopy: 
Single section images were acquired by Nikon A1R confocal microscope using 60X objective 
lens, with pinhole size 1 µm. All images were analysed with NIS Elements software. Two 
methods of quantification were employed: quantification using the Pearson‟s Correlation 
Coefficient (PCC) and as a percentage (described below). The PCC method was particularly 
useful when the fluorescent signal from one or both channels was diffused and thus would be 
difficult to quantify using the other method (described below). Quantification as a percentage 
was employed when the fluorescent signal from both channels was clear to distinguish. 
Additionally, as the PCC method turned out to be much quicker, it was additionally employed 
throughout the study presented within this thesis. In both cases, minimum three cells were 
quantified per experiment, from minimum three experiments. 
 
Quantification using Pearson‟s Correlation Coefficient: 
A line was drawn around a cell, and the value of PCC (the correlation between two channels) 
was taken (Zinchuk et al., 2007; Adler and Parmryd, 2010). In the case of pixel movement, 
one channel was shifted one pixel at time relatively to the other channel, up to ten pixels. 
Gradual decrease in the value of PCC was perceived as a genuine colocalization between two 
channels, whereas no change in this value was assument as no colocalization between 
channels. 
 
Quantification as a percentage: 
The puncta within one channel representing a particular protein within the cell were circled, 
and the colocalization with another channel was quantified. As a control, the circles were 
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moved into the areas absent in the particular protein, and the random colocalization with 
another channel was quantified. 
 
Statistical analysis: 
All the data were analysed in Microsoft Excell using two-tailed Student t-Test, from 
minimum three experiments, with at least three cells being counted per experiment. 
 
3.2.4 Protein analysis 
Immunoprecipitation: 
For Protein G-Sepharose beads (Sigma-Aldrich), cell lysates were incubated for 1 hour with 
an antibody followed by one hour incubation with the beads. In the case of IgG-conjugated 
FGFR1, cell lysates were incubated for one hour with Protein G-Sepharose beads only. Beads 
were subsequently separated by short centrifugation, washed five times with stock solution 
(2X) and resuspended in SDS sample buffer (2X). For GFP-trap, cell lysates were incubated 
one hour with GFP-conjugated beads, followed by separation by short centrifugation (agarose 
beads) or magnetic separation (magnetic beads). Beads were washed succesively with dilution 
and wash buffer and resuspended in SDS sample buffer (2X) or in NP LDS sample buffer 
(4X) (Invitrogen) with sample reducing buffer (10X) (Invitrogen). For Dynabeads 
(Invitrogen), magnetic beads were incubated with primary antibody in wash buffer for 10 
minutes at RT and subsequently with cell lysates for 30 minutes at 4 °C. Beads were 
separated on magnet and washed three times with ice-cold PBS and resuspended in NP LDS 
sample buffer (4X) with sample reducing buffer (10X). All samples in sample buffer were 
boiled for 10 minutes at 95 °C. 
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SDS PAGE and Western blotting: 
For analysis of whole cell lysate, SDS sample buffer (2X) or LDS sample buffer (4X) with 
sample reducing agent (10X) was added to lysates and the samples were boiled for 5 minutes 
at 95 °C. Otherwise, the samples were used after performing immunoprecipitation. For SDS 
PAGE analysis, samples were resolved on NuPAGE 4-12 % pre-cast Bis-Tris Gels 
(Invitrogen) using MOPS/SDS running buffer. For immunoblotting (western blotting), 
proteins were transferred to Immobilon-FL PVDF membranes (Milipore) at 4 °C using Tris-
Glycine transfer buffer at 100 V for 1:15 hours. The membranes were then incubated with 
methanol for two minutes and air-dried. Dried membranes were incubated overnight with 
primary antibody diluted in immunoblotting blocking buffer, washed three times for 5 
minutes with PBST, followed by incubation with secondary antibody in the same buffer. 
Membranes were washes again three times for 5 minutes with PBST, placed in PBS and 
imaged via Odyssey Application Software version 3.0 with Odyssey Imaging System (Li-
Cor). In the case of Fc-conjugated FGFR1, the proteins were transferred onto nitrocellulose 
membranes (Li-Cor), which were then blocked for one hour in 5 % dried milk powder in 
PBST. The membranes were incubated with HRP-conjugated secondary goat anti-human 
antibody diluted in 5 % dried milk powder in PBST. The membranes were washed with PBST 
and following by a final wash with PBS. The membranes were then incubated with ECL 
Western blotting substrate (Pierce) according to manufacturer‟s instructions. Finally, the 
proteins were visualised on Hyperfilm (Amersham Biosciences Inc.). 
 
Antibody cross-linking: 
Dynabeads were incubated with antibody for 10 minutes at RT. The beads were then washed 
with 0.02 % tween 20 in PBS, followed by two additional washes in wash buffer. The beads 
were then resuspended in cross-linking buffer and incubated for 30 minutes at RT. This was 
followed by washing for 15 minutes with quenching buffer and 5 minutes with elution buffer. 
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The beads were then washed three times with 0.02 % tween 20 in PBS and resuspended in 
this buffer. This was followed by incubation with cell lysates and further stages of 
immunoprecipitation with Dynabeads (described earlier). 
 
3.2.5 Real time quantitative polymerase chain reaction 
LNCaP cells were transfected with short interfering RNA (siRNA) targeting Ack1 mRNA 
(Dharmacon), or non-targeting RNAi (control) (Dharmacon). 48 hours post-transfection cells 
were trypsinised, centrifuged and total RNA was purified using RNeasy Mini kit (Qiagen), 
according to the manufacturer‟s instructions. RNA concentration was determined by 
measuring absorbance at 260 nm and 280 nm using a NanoDrop. The ratio of absorbance at 
260 nm to 280 nm determined the purity of RNA. cDNA was synthesized with Veriti Thermal 
Cycler (Applied Biosystems) using High Capacity cDNA Reverse Transcription kit 
(Invitrogen), as shown in Table 3.3 The thermal cycler conditions are shown in Figure 3.1 a. 
 
Upon synthesis, cDNA was diluted with distilled H2O to the final concentration 25 ng/µl. The 
reaction mix was prepared as shown in Table 3.4 and the real-time quantitative polymerase 
chain reaction (RT-qPCR) was performed with TNK2 primers (Applied Biosystems) and 
TaqMan Universal Master Mix (Applied Biosystems) using ABI Prism 7000 Sequence 
Detection System (Applied Biosystems). Ribosomal 18S (r18S) (Applied Biosystems) was 
used as a control. The thermal cycler conditions are shown in Figure 3.1 b. The data were 
analysed using ABI Prism 7000 SDS Software. To analyse the level of Ack1 knockdown, 
statistical analysis was performed in Microsoft Excell using two-tailed Student t-Test from 
three experiments. 
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cDNA synthesis mix Supplier Volume per sample 
RT buffer (10X) Invitrogen 2 µl 
25X deoxiribonucleotide triphosphates Invitrogen 0.8 µl 
10X random primers Invitrogen 2 µl 
MultiScribe Reverse Transcriptase (50 U/µl) Invitrogen 1 µl 
RNase-free H2O Qiagen 4.2 µl 
RNA (0.2 µg/µl) - 10 µl 
 
Table 3.3. cDNA synthesis mix 
The table shows the components of the cDNA synthesis mix as volume per sample. 
 
Reaction mix Supplier Volume per sample 
2X TaqMan Universal Master Mix Applied Biosystems 10 µl 
20X primers (TNK2 or r18S) Applied Biosystems 1 µl 
RNase-free H2O Qiagen 9 µl 
cDNA (25 ng/µl) - 1 µl 
 
Table 3.4. Reaction mix for RT-qPCR 
The table presents the components of the reaction mix for RT-qPCR as volume per sample. 
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Figure 3.1. Thermal cycler conditions for cDNA synthesis and RT-qPCR 
The schematic presents the thermal cycler conditions used for cDNA synthesis (a) and when 
performing RT-qPCR (b).  
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3.2.6 SILAC sample preparation 
Stable isotope labelling of amino acids in cell culture (SILAC) labeling: 
For SILAC labeling, 293T cells were cultured in amino acid deficient SILAC DMEM 
(Thermo Fisher Scientific) supplementd with 0.1 mg/ml isotopically normal L-arginine and L-
lysine (R0K0) (Sigma-Aldrich) (“light”), with 13C6 L-arginine and 4,4,5,5-D4 L-lysine 
(R6K4) (Goss Scientific) (“medium”), or with 13C6 
15
N4 L-arginine and 
13
C6 
15
N2 L-lysine 
(R10K8) (Goss Scientific) (“heavy”), 0.1 mg/ml streptomycin and 100 I.U./ml penicillin, and 
0.5 mg/ml proline (Sigma-Aldrich) and 10 % dialyzed FBS (Labtech International). The cells 
were cultured in SILAC medium for at least five doubling times to allow for incorporation of 
labeled amino acids (Cunningham et al., 2010). 
 
Cell transfection, cell treatment and immunoprecipitation: 
Labeled 293T cells in “light” medium were untransfected, whereas cells in “medium” and 
“heavy” media were transfected with myc-Ack1, shown in Figure 3.2. The cells were serum-
starved for four hours and “heavy” cells were stimulated with EGF for 15 minutes. The cells 
were lysed and cell lysates were incubated with α-myc antibody, or with α-myc antibody 
previously cross-linked to the beads. Immunoprecipitates were mixed and subjected to trypsin 
digestion (Chapter 3.2.7). Two independent experiments were performed, each with and 
without antibody cross-linking, as summarized in Table 3.5.  
 
Experiment Amount of proteins 
per sample 
α-myc antibody Dynabeads Cross-linking 
1 10 mg 20 µg/10 µl beads 160 µl Yes 
10 g 20 µg/10 µl beads 160 µl No 
2 10 mg 20 µg/10 µl beads 160 µl Yes 
10 mg 20 µg/10 µl beads 160 µl No 
 
Table 3.5. The amounts of protein, antibody and beads used for immunoprecipitation 
The table shows the approximate amounts of proteins, the antibody and Dynabeads used for 
immunoprecipitation of isotopically labelled 293T cells. 
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Figure 3.2. Simplified diagram of SILAC experiment 
293T cells were cultured in “light”, “medium” or “heavy” SILAC media. “Medium” and 
“heavy” cells were transfected with myc-Ack1. Subsequently, the cells were serum-starved 
for four hours and “heavy” cells were stimulated with EGF for 15 minutes. The cells were 
lysed and cell lysates were incubated with α-myc antibody (alone or cross-linked to the 
beads). Immunoprecipitates were washed, mixed, washed again and subjected to SDS PAGE 
(Chapter 3.2.4) followed by Coomassie staining, in-gel trypsin digestion, desalting and LC-
MS/MS (described in Chapter 3.2.7).  
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3.2.7 Mass spectometry 
In-gel trypsin digestion: 
Immunoprecipitates were separate on the NuPAGE 4-12 % pre-cast Bis-Tris gels. The gels 
were fixed for 10 minutes in gel fixation solution followed by staining in Coomassie gel 
staining solution to enable visualization of proteins. The gels were next destained with gel 
destain solution for several hours at RT. The gels were divided into multiple pieces and 
destained with destaining solution for 15 minutes with agitation. Gel pieces were washed with 
dehydration and washing buffer until no staining remained followed by vacuum centrifugation 
for 5 minutes. Gel pieces were rehydrated in reduction buffer and subsequently resuspended 
in Alkylation buffer for 45 minutes protected from light. This allowed for alkylation of 
reduced cysteine side chains. Gel pieces were washed for 5 minutes with rehydration and 
washing buffer, and twice for 5 minutes with dehydration and washing buffer, and 
subsequently dried by vacuum centrifugation for 5 minutes. Trypsin digestion solution was 
added to the gel pieces and allowed to rehydrate for 10 minutes on ice. Excess of trypsin was 
removed and gels were covered with rehydration and washing buffer, and left overnight at   
37 °C. The next day, formic acid was added to the final concentration of 0.5 % and the 
supernatant was transferred into a new tube. Further extraction was done with Peptide 
extraction solutions. The supernatants were dried with vacuum centrifuge, and the remaining 
peptides were resuspended in 0.1 % formic acid. The samples were stored at -20 °C. 
 
TiO2 enrichment: 
For phosphopeptide enrichement, titanium dioxide columns were conditioned with 
conditioning solution and equilibrated with equilibration solution. Samples were loaded onto 
the column with equilibration solution and centrifuged. The flow-through was loaded back   
on to the column and centrifuged again to maximize the binding of the peptides. The column 
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was washed with equilibration and conditioning solution and centrifuged. Peptides were 
eluted with 1.75 % ammonia solution upon centrifugation. The flow-through was re-loaded on 
the column to maximize elution of the peptides, and centrifuged. The samples were dried in 
vacuum centrifuge and phosphor-enriched peptides were resuspended in 0.1 % formic acid.   
 
Desalting using Zip-Tips: 
Zip-tip was wetted in wetting solution and equilibrated in equilibration and washing solution. 
Peptides in 0.1 % formic acid were loaded onto the tip, aspirated and dispensed several times 
to allow for maximum binding. The tip was washed with equilibration and washing solution, 
and the peptides were eluted with elution buffer. The sample was then dried in a vacuum 
centrifuge and the peptides were resuspended in 0.1 % formic acid. 
 
Liquid chromatography (work performed by Dr. A. J. Creese): 
Peptides were loaded onto a 150 mm Acclaim PepMap100 C18 column (LC Packings, 
Sunnyvale, CA, USA) in mobile phase A (water and 0.1 % formic acid) (JT Baker and 
Sigma-Aldrich). Peptides were separated over a linear gradient from 3.2 % to 44 % mobile 
phase B (acetonitrile and 0.1 % formic acid) (JT Baker and Sigma-Aldrich) with a flow rate of 
350 nl/min. The column was then washed with 90 % mobile phase B before re-equilibrating at 
3.2 % mobile phase B. The column oven was heated to 35 
o
C. The LC system was coupled to 
an Advion Triversa Nanomate, which infused the peptides with a spray voltage of 1.7 kV. 
Peptides were infused directly into the LTQ-Orbitrap Velos ETD (Thermo Fisher Scientific). 
 
Tandem mass spectrometry MS/MS (work performed by Dr. A. J. Creese): 
The mass spectrometer performed a full FT-MS scan (m/z 380-1600) and subsequent collision 
induced dissociation (CID) MS/MS scans of the seven most abundant ions above a threshold 
of 1,000. Survey scans were acquired in the Orbitrap with a resolution of 60,000 at m/z 400. 
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Precursor ions were subjected to CID in the linear ion trap. Width of the precursor isolation 
window was m/z 2 and only multiply charged precursor ions were subjected to CID. CID was 
performed with helium gas at normalized collision energy of 35 % (target 5 x 10
4
, maximum 
fill time 100 ms). CID activation was performed for 10 ms.  Dynamic exclusion repeat count 
was set to 1 with duration of 60 s. Data acquisition was controlled by Xcalibur 2.1 (Thermo 
Fisher Scientific). 
 
Identificatication of PTMs (work performed by Dr. A. J. Creese): 
The database search was performed in Proteome Discoverer (V1.2.0.208). The search engine 
was Mascot (version 2.2.4) and the database used was the mouse International Protein Index 
(IPI) database (version 3.84). The parameters for the searches were as follows: precursor mass 
tolerance 10 ppm, fragment mass tolerance 0.5 Da, a maximum of 2 missed cleavages, the 
enzyme was specified as trypsin. The cleavage was restricted when adjacent to proline. 
Carbamidomethylation (Cys) was set as a static modification. The variable modifications 
were phosphorylation (Ser, Thr, Tyr), oxidation (Met), deamidation (Asn, Gln) and 
ubiquitylation (Lys). The data were filtered with 0.01 (1 %) false discovery rate (FDR) using 
a reversed database.  
 
Analysing SILAC data (work performed by Dr. A. J. Creese): 
Mass spectra were processed using the MaxQuant software (version 1.3.0.5). Data were 
searched using the Andromeda search engine against a human Swiss Prot database 
(downloaded 9
th
 Jan 2013) containing forward and reverse sequences, supplemented with 
common contaminants (including keratin, trypsin, BSA). The human database contained 
174,900 protein entries (87,450 of which were reversed-sequence versions). The search 
parameters were: minimum peptide length 7, precursor ion mass tolerance 7 ppm, fragment 
ion mass tolerance 0.5 Da, cleavage enzyme trypsin/P, and a total of 2 missed cleavages were 
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allowed. Carbamidomethylation (Cys) was set as a fixed modification and oxidation (Met), 
acetylation (peptide N-terminus) were set as variable modifications. The appropriate SILAC 
labels were selected and the maximum labelled amino acids was set to 3. The peptide and 
protein false-discovery rate (FDR) was set to 0.01 (1%).  
 
Further analysis of SILAC data: 
Further analysis of SILAC data was performed in Perseus (version 1.4.0.8). Normalised ratios 
were filtered for reverse peptide sequence and contaminants, and log-transformed. Only 
proteins identified in a minimum of two out of four experiments (two independent 
experiments, each with and without antibody cross-linking to the beads) were considered as 
potential binding partners for Ack1. Significance A was applied with Benjamini-Hochberg 
FDR multiple testing correction-adjusted p-values calculated from Mann-Whitney-Wilcoxon 
tests. 
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4 Ack1 functions in EGFR, but not FGFR, 
trafficking 
4.1 Introduction 
Understanding the mechanisms underlying growth factor signalling and receptor tyrosine 
kinase (RTK) trafficking could potentially greatly improve the methods of treatment of 
patients with growth factor signalling-related diseases, such as cancer. Much research has 
been carried out in order to specify the pathways of RTK trafficking and the outcomes of 
RTK activation; however, due to the number and diversity of growth factor and growth factor 
receptors, and the complexity of the signalling networks downstream of RTK activation, there 
are still many unanswered questions and areas that require more in-depth investigation. 
 
Ack1 belongs to the Ack family of non-receptor protein kinases. Other similar families 
include Src family, focal adhesion kinase (FAK) and Abl family, and a total of ten families of 
non-receptor tyroskine kinases have been identified to date (Blume-Jensen and Hunter, 2001). 
Ack1 is activated following stimulation with EGF, PDGF and insulin (Galisteo et al., 2006). 
Ack2, an alternatively spliced isoform of Ack1, has been found to bind SNX9, which 
regulates receptor trafficking and degradation (Lin et al., 2002). Furthermore, Ack1 binds 
clathrin and thus it may regulate CME (Teo et al., 2001).  The Mig6-homology domain within 
the C-terminal portion of Ack1 has been proposed to regulate an interaction between Ack1 
and active EGFR (Shen et al., 2007). It has been shown that Mig6 binds directly ligand-bound 
EGFR and inhibits EGFR activation (Zhang et al., 2007). However, a recent study has shown 
that in the case of Ack1, the interaction with EGFR involves Grb2 (Lin et al., 2012). In 
particular, it has been proposed that Ack1 is autoinhibited by an interaction between the SH3 
domain and Mig6 domain, and that EGFR activation promotes Grb2 binding to Mig6 domain 
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of Ack1 and disrupts Ack1 autoinhibition. An indirect interaction between Ack1 and other 
RTKs, such as Axl, LTK and ALK, has also been reported and similarly has been shown to be 
mediated by Grb2 (Pao-Chun et al., 2009). Thus, Ack1 has been identified as an important 
player in subcellular trafficking.  
 
In this chapter the nature of the association between Ack1 and EGFR is further investigated. 
Both endogenous and ectopically expressed Ack1 colocalizes with EGFR following EGF 
stimulation. Similarly, Ack1 colocalizes with constitutively active Cdc42, a known Ack1 
interactor. In contrast, no colocalization or interaction is found in the case of FGFR. The 
Ack1 domains regulating the colocalization with EGFR have been determined. Surprisingly 
and in contrast to other studies, Ack1 knockdown (KD) does not dramatically influence the 
level of EGFR degradation; however, Ack1 KD accelerates EGFR localization to lysosomes, 
thus indicating that Ack1 regulates EGFR trafficking.  
 
4.2 Optimising experimental conditions 
4.2.1 Time courses of EGF and FGF stimulation in HeLa and 293T cells 
The activation of RTKs and downstream signalling molecules is both time and concentration 
sensitive. Following stimulation with a particular ligand, various proteins are being modified 
depending on the time, concentration and the cellular context. For example, in human 
epithelial type 2 cells, EGFR ligands have been shown to differentially influence EGFR 
trafficking depending on ligand concentration and the duration of stimulation (Roepstorff et 
al., 2009). In particular, at low EGF concentrations (0.01 nM) very little EGFR internalisation 
may be observed, whereas at higher concentrations (10 nM and above) approximately half of 
the cell surface EGFRs are internalised. Additionally, stimulation with a particular ligand 
differently influences EGFR ubiquitylation, e.g. BTC treatment promotes much stronger 
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EGFR ubiquitylation than EGF or TGF-α (Roepstorff et al., 2009). In the case of Hrs, it has 
been shown in B16-F1 cells that the strongest Hrs phosphorylation takes places shortly after 
HGF stimulation (2.5-15 min), and almost disappears after 1 hour of stimulation (Komada 
and Kitamura, 1995). In HeLa cells, stimulation with EGF at low concentrations (0.125 
ng/ml) results in the most pronounced Erk phosphorylation at 10-15 minutes of stimulation, 
and at 30-60 minutes the phosphorylation almost disappears. In contrast, at higher 
concentrations (50 ng/ml) strong Erk phosphorylation can be observed between 3 and 30 
minutes (Schoeberl et al., 2002). Therefore, determination of the cell responses to the 
particular ligand in every cell line is extremely important.  
 
In the study presented in this thesis, the experiments were predominantly performed on HeLa, 
293T and LNCaP cells, and EGF and FGF2 were the only ligands used. In the case of HeLa 
and 293T cells, previously described ligand concentrations have been employed (Row et al., 
2006; Row et al., 2007; Mardakheh et al., 2009; Mardakheh et al., 2010). These include the 
final concentration of 100 ng/ml in the case of EGF and 20 ng/ml in the case of FGF2, with 
addition of 10 µg/ml of heparine. For LNCaP cells, the determination of the optimal 
conditions for EGF stimulation is described in Chapter 4.2.3. 
 
In order to determine the best timing conditions for EGF and FGF2 stimulation, the cells were 
incubated with ligand for various times, lysed and the samples were analysed via Western 
blotting.  In addition, similar experiments were performed on the cells ectopically expressing 
EGFR and FGFR2, as these conditions have also been employed throughout the study 
presented in this thesis. The data are collected and shown in Figure 4.1.  
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Figure 4.1. Time courses of EGF and FGF stimulation for HeLa and 293T cells 
HeLa and 293T cells transfected with EGFR-GFP or FGFR2-GFP or untransfected, were 
serum-starved for four hours and stimulated with EGF (100 ng/ml) or FGF2 (20 ng/ml) and 
heparin (10 µg/ml) for indicated times. The cells were lysed and the cell lysates were 
subjected to SDS PAGE and Western blotting with α-phospho EGFR, α-EGFR, α-phospho 
Akt, α-Akt, α-phospho Erk and α-Erk antibodies. 
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EGFR phosphorylation in both HeLa and 293T cells can be distinguished in every condition 
(Figure 4.1). Strong EGFR phosphorylation following EGF treatment is observed in HeLa 
cells expressing EGFR at the endogenous level, as well as in cells with ectopically expressed 
EGFR. In 293T cells, strong EGFR activation post-EGF treatment is seen at the endogenous 
level, whereas ectopically expressed EGFR exhibits strong phosphorylation independently of 
ligand stimulation. In the case of Erk activation, strong Erk phosphorylation is observed in 
both cell lines in every condition following EGF stimulation. Surprisingly, no changes in Akt 
phosphorylation are seen in any conditions. 
 
HeLa cells have been found to express only a minor level of endogenous FGFRs and therefore 
the FGF response is expected to be minimal (Francavilla et al., 2009). Consistently, no 
detectable levels of FGFR2 can be found in HeLa cells, and only minimal Erk 
phosphorylation is noted (Figure 4.1). In contrast, FGF treatment of HeLa cells ectopically 
expressing FGFR2 has been found to promote phosphorylation and activation of downstream 
signalling cascades (Auciello et al., 2013). Accordingly, in the case of ectopically expressed 
FGFR2, strong FGFR2 phosphorylation is observed and Erk activation can be distinguished 
following EGF treatment. In 293T cells, relatively strong expression of endogenous FGFR2 
has been reported (Mardakheh et al., 2010). Indeed, endogenous FGFR2 can be detected in 
293T cells. Although its phosphorylation upon FGF stimulation is minimal, strong Erk 
activation can be observed following FGF treatment. In the case of ectopically expressed 
FGFR2 in 293T cells, strong FGFR2 phosphorylation is observed independently of ligand 
stimulation, and Erk activation is detected following FGF stimulation. A subtle increase in 
Akt phosphorylation following FGF stimulation can be distinguished in 293T cells expressing 
endogenous FGFR2 and the cells with ectopically expressed FGFR2. 
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Considering the results presented in Figure 4.1, the optimal timing of stimulation with EGF 
and FGF2 would be between 5 and 20 minutes of ligand stimulation in both cell lines, as the 
most pronounced phosphorylation of RTKs and Erk can be observed between these time 
points; however, at the early stages of ligand stimulation RTKs are likely to be present in a 
close proximity to the plasma membrane and therefore unable to interact with proteins that are 
present within intracellular compartments, e.g. late endosomes. Therefore, in the case of HeLa 
and 293T cells ectopically expressing FGFR2, the cells were stimuilated with FGF2 for 20 
minutes, at which stage FGFR1 and Erk phosphorylation are still strong. In the case of EGF, 
the most common time point used is 30 minutes in both cell lines. At this time point 
phosphorylation of EGFR and Erk are still distinguishable, and a portion of EGFR should be 
present within intracellular compartments and thus be able to associate with other intracellular 
molecules (Roepstorff et al., 2009); however, some signal may be lost due to possible EGFR 
recycling. Therefore, in many instances, several time points have been employed to enable for 
the most precise determination of the localization, interactions or modifications of particular 
proteins. 
 
4.2.2 Optimising conditions of Ack1 expression 
Further optimisation was applied to determine the most efficient transfection with Ack1. For 
this purpose, HeLa cells were transfected with mCherry-Ack1 and cultured for further 24, 48 
or 72 hours to allow for protein expression. Fixed cells were then imaged via confocal 
microscopy. As shown in Figure 4.2 a, similarly high Ack1 expression can be distinguished 
both at 24 and 48 hours post-transfection. Thus, the cells were incubated for 48 hours post-
transfection to get optimal expression. 
  
Chapter 4 – Ack1 functions in EGFR, but not FGFR, trafficking 
 
108 
 
 
 
Figure 4.2. Optimising Ack1 transfections in HeLa cells 
a) HeLa cells transfected with mCherry-Ack1 were fixed 24, 48 or 72 hours post-transfection 
and imaged via confocal microscopy; b) HeLa cells co-transfected with GFP-Ack1 and 
mCherry-Ack1 were fixed 48 hours post-transfection and imaged via confocal microscopy. 
Scale bars 10 µm.  
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Additionally, as different Ack1 constructs are available, it is important to validate whether 
they colocalize with each other. In particular in the case of mCherry-Ack1, which was 
constructed in our lab, verifying its functionality is crucial. For this purpose, mCherry- and 
GFP-tagged Ack1 were co-expressed in HeLa cells, and their colocalization was assessed via 
confocal microscopy. As shown in Figure 4.2 b, these two fusion proteins colocalize with 
each other. Although there is a possibility that the observed colocalization is due to 
dimerisation between mCherry- and GFP-tagged Ack1, since Ack1 has been shown to 
dimerise via N-terminal SAM domains (Prieto-Echaguee et al., 2010), no major differences in 
subcellular distribution can be distinguished. Therefore, various Ack1 constructs were used 
interchangeably to provide the most optimal conditions for a particular experiment. 
Additionally, uptake of transferrin is not affected by low or moderate expression of Ack1, 
whilst it is inhibited in cells expressing high Ack1 levels (shown in Chapter 5.3) (Teo et al., 
2001). Thus, throughout the study presented in this thesis the cells expressing low or 
moderate levels of Ack1 have been employed.  
 
4.2.3 Optimising conditions of EGF stimulation in LNCaP cells 
Neither HeLa nor 293T cells are optimal for looking at endogenous Ack1, as detection of 
endogenous Ack1 within these two cell lines was very poor, both via biochemical studies and 
microscopy. Therefore, I searched for another the cell line that would be a good platform for 
studying endogenous Ack1 at the cellular level. 
 
The membrane containing whole cell lysates from 13 various cancer cell lines was purchased 
and probed with antibodies against Ack1 and its phosphorylated form. As shown in Figure 
4.3, total Ack1 is poorly distinguishable in the cell lines tested.  
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Figure 4.3. Identification of potentially phosphorylated Ack1 in LNCaP cells 
The membrane purchased from G. Biosciences contains 50 µg of proteins from each cell line 
loaded, along with the protein marker. The membrane was incubated with α-Ack1 and α-
phospho Ack1 (phospho Y284) antibodies. The arrow indicates potentially phosphorylated 
Ack1 in LNCaP cells. Predicted molecular weight of Ack1 is approximately 120 kDa. 
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Importantly, a relatively high level of potentially phosphorylated Ack1 can be found in 
prostate adenocarcinoma LNCaP cells, as the molecular weight of the protein identified is 
similar to Ack1. Additionally, Ack1 has been widely studied in LNCaP cells in the context of 
androgen receptor (AR) signalling (Mahajan et al., 2005; Mahajan et al., 2007). Therefore, 
this cell line has been chosen for studying endogenous Ack1. Interestingly, multiple 
phosphorylated proteins can be identified following incubation with an antibody against 
phosphorylated Ack1. The nature of those proteins is unknown: some of them are likely to be 
background proteins which are non-specifically recognised by the antibody, whereas others 
may be Ack1 isoforms or dimers. 
 
To determine the optimal EGF concentration in LNCaP cells which promotes EGFR 
internalisation and degradation, the cells were stimulated with a range of different 
concentrations for up to three hours and EGFR degradation was assessed by Western blotting. 
As shown in Figure 4.4, the lowest concentration used (2 ng/ml) results in a delayed and 
decreased EGFR degradation compared to the other two concentrations employed (20 ng/ml 
and 50 ng/ml), both of which resulted in a similar level of EGFR degradation. This indicates 
that 20 ng/ml of EGFR is sufficient to promote EGFR internalisation and degradation. 
Additionally, a range of the EGF concentrations between 2 ng/ml and 20 ng/ml was applied to 
LNCaP cells ectopically expressing EGFR-GFP, and the cells were analysed via confocal 
microscopy using live-cell imaging to visualise EGFR endocytosis. As shown in Figure 4.5, 
the internalisation of EGFR is difficult to distinguish under these conditions, although EGF 
stimulation promotes cell movement and membrane „blebbing‟. Together with the data on 
EGFR degradation (Figure 4.4), the EGF concentration of 20 ng/ml was employed for further 
studies. 
  
Chapter 4 – Ack1 functions in EGFR, but not FGFR, trafficking 
 
112 
 
 
 
Figure 4.4. EGFR degradation upon treatment with various EGF concentrations 
LNCaP cells were serum-starved for four hours and stimulated with various EGF 
concentrations for indicated times. The cells were lysed and cell lysates were subjected to 
SDS PAGE and Western blotting with α-Ack1, α-EGFR and α-tubulin antibodies. The 
densitometric analysis from three experiments is shown on the graph. The level of EGFR 
presented is obtained from a ratio of EGFR to tubulin. 
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Figure 4.5. EGFR trafficking upon treatment with various EGF concentrations 
LNCaP cells transfected with EGFR-GFP were serum-starved for four hours and imaged for 30 minutes (one frame every 30-60 seconds) upon 
stimulation with various EGF concentrations. Scale bars 10 µm.  
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4.3 Ack1 interacts with EGFR, but not FGFR2 
The main aim of this chapter is to explore the potential roles of Ack1 in growth factor 
signalling and trafficking. As described in Chapter 1.5.3, it is well documented that Ack1 is 
involved in EGFR trafficking and degradation (Shen et al., 2007; Grovdal et al., 2008), yet 
the exact functions remain elusive. To investigate whether interaction of Ack1 with growth 
factor receptors is a general feature of the kinase, or whether it specifically binds EGFR and 
not other RTKs, I investigated a potential interaction between Ack1 and FGFR2. As shown in 
Figure 4.6 upon Ack1 immunoprecipitation activated EGFR co-precipitates with Ack1, and 
this is not seen with FGFR2. These results are additionally validated when compared to the 
well described interaction between Ack1 and constitutively active Cdc42 (caCdc42) (Manser 
et al., 1993). These data indicate that Ack1 specifically interacts with EGFR and not with 
FGFR2. This suggests that the interaction may be mediated through motifs within EGFR, 
which are absent in FGFR2, or through different binding proteins that recognise EGFR, but 
not FGFR2.  
 
4.4 Ack1 colocalizes with EGFR, but not FGFR2 
Consistent with the biochemical studies, Ack1 colocalizes with EGFR, but not with FGFR2, 
as shown in Figure 4.7. This colocalization has been quantified using Pearson‟s Correlation 
Coefficient (PCC). PCC is a relatively recent but very efficient method of quantification of 
colocalization between two channels (e.g. green and red) (Zinchuk et al., 2007; Adler and 
Parmryd, 2010). Its values range from -1 to 1, with -1 indicating negative correlation, 0 
showing no correlation and 1 designating complete colocalization. On the graph in Figure 
4.7, the value of PCC for EGFR is relatively high and it decreases upon pixel movement, 
when one channel (i.e. green) has been shifted relatively to the other (i.e. red).  
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Figure 4.6.Ack1 interacts with EGFR and Cdc42, but not with FGFR2 
293T cells transfected with myc-Ack1 and GFP-tagged EGFR, FGFR2 or caCdc42 were 
serum-starved for four hours (apart from cells transfected with Ack1 and caCdc42) and 
stimulated with EGF or FGF2 and heparin for 20 minutes, as indicated. The cells were lysed 
and cell lysates were incubated with α-myc antibody to imunoprecipitated Ack1. 
Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-Ack1 and α-
GFP antibodies. 
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Figure 4.7. Ack1 colocalizes with EGFR, but not FGFR2 
HeLa cells transfected with mCherry-Ack1 and EGFR-GFP or FGFR2-GFP were serum-starved for four hours and stimulated with EGF or FGF2 
and heparin for 20 minutes, fixed and imaged via confocal microscopy. For quantification, the PCC values were obtained using NIS Element 
software and one channel was shifted relatively to the other, up to 10 pixels (explained in Chapter 3.2.3). The gradual decrease in PCC upon 
pixel movement is perceived as a genuine colocalization, whereas no change in PCC indicates lack of colocalization. Scale bars 10 µm. Error 
bars represent standard error of the mean (SEM).  
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Therefore, gradual decrease in PCC upon pixel movement as in the case of EGFR indicates 
genuine colocalization, rather than random alignment of pixels.   
 
In the case of FGFR2, however, PCC is low and remains low irrespective of pixel movement, 
thus indicating the lack of colocalization between Ack1 and FGFR2. Similarly, the 
colocalization between Ack1 and EGFR can be seen in Cos7 cells following EGF stimulation, 
(Figure 4.8). Therefore, the association between Ack1 and EGFR is not cell type-specific and 
can be found in different cell lines. Altogether, these data indicate that Ack1 specifically 
colocalizes with EGFR and not with FGFR2, thus suggesting divergent endocytic pathways of 
EGFR and FGFR2. 
 
4.5 Ack1 does not interact with FGFR1  
Showing that Ack1 does not interact with FGFR2, I investigated whether it associates with 
other members of the FGFR family. 293T cells transfected with myc-Ack1 and FGFR1 were 
serum-starved and stimulated with FGF2, since FGF2 has been shown to activate FGFR1  
(Lefevre et al., 2009). Cell lysates were subjected to immunoprecipitation with α-myc 
antibody and analysed by immunoblotting. As shown in Figure 4.9 a, FGFR1 does not co-
precipitate with Ack1, thus indicating that similarly to FGFR2, FGFR1 does not interact with 
Ack1. The experiment was duplicated, but the lysates were incubated with α-FGFR1 antibody 
rather than α-myc antibody. As shown in Figure 4.9 b, Ack1 does not co-precipitate with 
FGFR1 following FGF2 stimulation, further emphasizing that Ack1 and FGFR1 do not 
associate in vitro.  
 
Furthermore, I used the FGFR1 constructs conjugated to the Fc fragment (Fragment, 
crystallizable) of the immunoglobulin G heavy chain.   
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Figure 4.8. Ack1 colocalizes with EGFR in COS7 cells 
Cos7 cells transfected with mCherry-Ack1 and EGFR-GFP were serum-starved for four hours 
and stimulated with EGF for 30 minutes, fixed and imaged via confocal microscopy. Scale 
bars 10 µm. 
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Figure 4.9. Ack1 does not interact with FGFR1 upon FGF2 stimulation 
293T cells transfected with myc-Ack1 and FGFR1 were serum-starved for four hours and 
stimulated with FGF2 and heparin. The cells were lysed and cell lysates were incubated with 
α-myc (a) or α-FGFR1 (b) antibodies to immunoprecipitate Ack1 or FGFR1, respectively. 
Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-Ack1 and α-
FGFR1 antibodies.  
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Conjugation with Fc fragment enables direct binding to the beads during 
immunoprecipitation, without the requirement of an antibody (Burgar et al., 2002), The 
following constructs were used: FcFGFR1 kinase active (KA), kinase dead (KD), 
transmembrane domain only (TM) and VT- (lacks two amino acids in its JM domain hence 
does not bind FGFR substrate 2, FRS2) (Burgar et al., 2002). The receptors were co-
expressed along with myc-tagged Ack1 in 293T cells. As a control, GFP was co-expressed 
along with myc-Ack1. The cells were serum-starved and lysed, and cell lysates were 
incubated with beads alone (in the case of FcFGFR1s) or with α-myc antibody (in a control). 
As shown in Figure 4.10, in the control sample Ack1 immunoprecipitates with α-myc 
antibody; howeve, it does not co-precipitate with either of the FcFGFR1 constructs. 
Additionally, the association between FGFR1s and phospholipase C gamma (PLCγ), which 
binds kinase active, but not kinase dead FGFR (Vecchione et al., 2007), was veryfied. As 
expected, PLCγ co-precipitates with KA FGFR1, but not KD FGFR1, thus confirming that 
KA FcFGFR1 is functional. Altogether, these data further support the observation that Ack1 
does not bind FGFR1 and suggest that Ack1 is not directly involved in FGFR1 trafficking. 
 
4.6 Ack1 C-terminal truncation mutants 
Ack1 is a relatively large protein with multiple domains which interact with various motifs 
within other proteins. In particular, the Mig6-homology domain has been previously shown to 
regulate the interaction with EGFR following EGF stimulation (Shen et al., 2007; Lin et al., 
2012); however, other domains could potentially also contribute to this interaction. Therefore 
C-terminal truncation mutants of Ack1 were generated by Miss S. Brewer. These include the 
UBA domain deletion mutant (ΔUBA),  the UBA and Mig6 domain deletion mutant (ΔMig6) 
and the UBA, Mig6 and proline rich domain deletion mutant (ΔPRD), as presented in Figure 
4.11 a and b.  
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Figure 4.10. Ack1 does not co-precipitate with kinase-active FGFR1 
293T cells transfected with myc-Ack1 and human IgG1 Fc-conjugated FGFR1 (VT-, TM, 
KA, KD) or GFP (control) were lysed and cell lysates were incubated with α-myc antibody 
(control) to immunoprecipitated Ack1, or with G protein agarose beads only (FcFGFR1 
samples) to immunoprecipitate FcFGFRs. Immunoprecipitates were subjected to SDS PAGE 
and Western blotting with α-human IgG(Fc), α-Ack1 and α-PLCγ antibodies. n/a – non 
applicable; VT- – lacks two amino acids, valine and threonine, in its JM domain and does not 
bind FRS2; TM – truncated, transmembrane domain only; KA – kinase active; KD – kinase 
dead. From (Burgar et al., 2002).  
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Figure 4.11. Ack1 C-terminal truncation mutants 
 
a) Full-length mouse Ack1 (isoform 2) was amplified by polymerase chain reaction (PCR) 
with a common forward primer for all mutants and with different reverse primers constructed 
to omit particular domains (described in Chapter 3.2.1). The PCR product was linearised by 
digesting with restriction enzymes and ligated with pmCherry-C1 vector; b) 293T cells 
transfected with mCherry-tagged Ack1, tAck1 and Ack1 mutants were lysed and cell lysates 
were subjected to SDS PAGE and Western blotting with  α-mCherry and α-tubulin antibodies.   
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The mutant lacking UBA, Mig6, PRD and clathrin binding domain (ΔCBD) was also 
constructed (Figure 4.11 b); however, for further experiments the truncated form of human 
Ack1 (tAck1) was used instead. The mutants were additionally N-terminally tagged to 
mCherry to facilitate imaging via confocal microscopy. These mutants were employed in 
several experiments to analyse the importance of the various domains in association between 
Ack1 and other proteins.  
 
4.7 Mig6 and CBD both contribute to the colocalization with EGFR 
It has been proposed that the UBA domain of Ack1 is required for EGFR degradation, 
whereas the Mig6 domain regulates EGFR binding (Shen et al., 2007; Lin et al., 2012). To 
analyse more precisely whether other Ack1 domains also contribute to the association with 
EGFR, I employed the mCherry-tagged C-terminal truncation mutants of Ack1 and human 
truncated Ack1. Using these constructs I carried out a series of colocalization studies with 
EGFR-GFP upon EGF stimulation. As shown in Figure 4.12, deletion of the UBA domain 
alone does not alter the colocalization between Ack1 and EGFR, which is similar to the full-
length protein (~90%). In contrast, deletion of both UBA and Mig6 domains dramatically 
decreases this colocalization (~43%). Additional removal of the PRD does not have any 
further effects on the colocalization with EGFR; however, the absence of the clathrin binding 
domain, which is represented by tAck1, abolishes any remaining colocalization (Figure 4.12). 
These data emphasize the importance of the Mig6 domain in this context and suggest that 
Ack1 association with clathrin may also contribute to the colocalization between Ack1 and 
EGFR.
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Figure 4.12. The Mig6 domain and CBD regulate colocalization with EGFR  
HeLa cells transfected with mCherry-tagged Ack1, tAck1 and C-terminal truncation mutants and EGFR-GFP were serum-starved and stimulated 
with EGF for 30 minutes, fixed and imaged via confocal microscopy. For quantification, the Ack1, tAck1 or the Ack1 mutant puncta were 
circled and the colocalization with EGFR was quantified (described in Chapter 3.2.3). As a control, the circles were moved into the areas absent 
for Ack1, tAck1 or the Ack1 mutants and the random colocalization with EGFR was quantified. Scale bars 10 µm. Error bars represent SEM. 
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4.8 Endogenous Ack1 colocalizes with endogenous EGFR upon EGF stimulation 
Showing that ectopically expressed Ack1 and  EGFR colocalize in HeLa cells, I investigated 
this colocalization at the endogenous level in LNCaP cells, in which I identified endogenous 
Ack1 through immunostaining with α-Ack1 antibody (Chapter 4.2.3). As shown in Figure 
4.13, endogenous Ack1 colocalizes with endogenous EGFR upon EGF stimulation. To my 
knowledge this is the first report of imaging the colocalization between Ack1 and EGFR at 
the endogenous level. These results validate that Ack1 and EGFR colocalize under 
physiological conditions. 
 
4.9 Ack1 knockdown does not influence EGFR degradation 
To further investigate the roles of Ack1 in EGFR trafficking, I investigated whether Ack1 
influences EGFR degradation in LNCaP cells. A study by Grøvdal et al. shows that 
ectopically expressed Ack1 in HeLa cells inhibits EGFR sorting into the inner vesicles of late 
endosomes resulting in reduced EGFR degradation, whereas Ack1 knockdown increases 
EGFR recycling and thus decreases degradation (Grovdal et al., 2008). Another study by 
Shen et al. also shows that EGFR degradation is inhibited following Ack1 knockdown in 
293T cells (Shen et al., 2007). Similarly in 1483 head and neck cancer cells, Ack1 
knockdown inhibits EGFR degradation and ectopically expressed Ack1 in cells with 
downregulated Ack1 can rescue this inhibition (Kelley and Weed, 2012).  
 
To determine whether Ack1 regulates EGFR signalling and degradation in LNCaP cells, the 
cells were treated with small interfering RNA (siRNA) against Ack1 or with non-targetting 
RNAi (control). The cells were then serum-starved for four hours and stimulated with EGF 
for up to three hours, and EGFR degradation was assessed by Western blotting, as shown in 
Figure 4.14 a.  
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Figure 4.13. Endogenous Ack1 colocalizes with endogenous EGFR upon EGF treatment 
LNCaP cells plated onto poly-D-lysine covered coverslips were serum-starved for four hours 
and stimulated with EGF for indicated times. The cells were fixed and immunostained with α-
Ack1 and α-EGFR antibodies, and imaged via confocal microscopy. Scale bars 10 µm. 
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Figure 4.14. EGFR degradation in LNCaP cells following Ack1 knockdown 
a) LNCaP cells transfected with siRNA against Ack1 or non-targeting RNAi (control) were 
serum-starved for four hours, the final hour in the presence or absence of the EGFR kinase 
inhibitor BIBX 1382, and stimulated with EGF for indicated times. The cells were lysed and 
cell lysates were subjected to SDS PAGE and Western blotting with α-Ack1, α-EGFR, α-
phopsho Akt, α-Akt, α-phospho-Erk, α-Erk and α-tubulin antibodies; b) LNCaP cells were 
serum-starved for four hours, the final hour in the presence of BIBX 1382 at the indicated 
concentrations and stimulated with EGF for 30 minutes. The cells were lysed and cell lysates 
were subjected to SDS PAGE and Western blotting with α-phospho EGFR, α-EGFR, α-
phospho Akt, α-Akt, α-phopsho-Erk and α-Erk antibodies.  
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As an additional control, cells were pre-treated with EGFR kinase inhibitor to prevent EGF-
dependent EGFR degradation. Prior to this experiment, the optimal concentration of the 
EGFR inhibitor was tested and 10 µM  has been found to sufficiently inhibit EGFR activation, 
as shown in Figure 4.14 b. Surprisingly, Ack1 knockdown does not influence EGFR 
degradation, as compared to control cells (Figure 4.14 a). Additionally, downstream 
signalling cascades are not affected by Ack1 knockdown, as represented by Erk and Akt 
phosphorylation which is similar to control cells. Therefore, these data indicate that in LNCaP 
cells, unlike in other cell lines, EGFR degradation is not affected by Ack1 depletion. 
Interestingly, although in the control Ack1 is degraded following EGF stimulation, this is not 
the case in the presence of the EGFR inhibitor (Figure 4.14 a). These data suggests that 
EGFR kinase activity is important for EGF-mediated Ack1 degradation.  
 
4.10 Ack1 knockdown results in accelerated lysosomal localization of EGFR 
Since Ack1 does not appear to influence EGFR signalling and degradation in LNCaP cells, I 
hypothesized that Ack1 may function in EGFR trafficking. Therefore I investigated whether 
EGFR localization to lysosomes is affected in cells depleted of Ack1. Thus, LNCaP cells 
expressing EGFR-GFP and treated with siRNA against Ack1 or with non-targetting RNAi 
(control) were serum-starved in the presence of lysotracker, a fluorescent dye that stains 
lysosomes (Chazotte, 2011). The cells were then imaged for 30 minutes upon EGF 
stimulation. As shown in Figure 4.15 a, when compared to the control, Ack1 knockdown 
promotes enhanced colocalization of EGFR and lysotracker following EGF stimulation. 
Additionally, average Ack1 knockdown in these conditions is approximately 80 %, as verified 
by real-time quantitative polymerase chain reaction (Figure 4.15 b).  
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Figure 4.15. Ack1 knockdown increases EGFR lysosomal localization 
a) LNCaP cells transfected with siRNA against Ack1 or non-targetting RNAi (control) and EGFR-GFP were serum-starved for four hours, the 
final 30 minutes in the presence of lysotracker (100 nM). The cells were washed with PBS and placed in cell imaging medium to enable live-cell 
imaging. Images were acquired upon 30 minutes of EGF treatment (one frame every 30-60 seconds). PCC was quantified at indicated times 
following EGF treatment; b) LNCaP cells transfected with siRNA against Ack1 or with non-targetting RNAi (control) were trypsinised and total 
RNA was isolated and used to synthesize cDNA. RT-qPCR was performed using primers for TNK2 or control r18S (Chapter 3.2.5).
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Therefore, these results indicate that in the presence of Ack1, EGFR recruitment to lysosomes 
in reduced, thus suggesting that Ack1 functions in EGFR trafficking by preventing EGFR 
targetting to lysosomes following EGF stimulation. 
 
4.11 Conclusions 
The main aim of this chapter was to investigate the functions of Ack1 in RTK signalling and 
trafficking. So far numerous studies identified an involvement of Ack1 in signalling and 
trafficking of several RTKs. In particular, multiple lines of evidence implied on involvement 
of Ack1 implication in EGFR signalling, trafficking and degradation, and describe association 
between PDGFR, Axl, LTK and ALK (Shen et al., 2007; Grovdal et al., 2008; Pao-Chun et 
al., 2009; Lin et al., 2012). Interestingly, a screen for Ack1 interacting proteins showed that 
the C-terminal proline-rich portion of Ack1, including Mig6 domain, does not bind FGFR1 
nor FGFR2 (Pao-Chun et al., 2009). Therefore, the specificity of the interactions between 
Ack1 and EGFR, PDGFR and other RTKs is likely to depend on the motifs present within 
these RTKs, on interacting proteins or on the proximal subcellular localization.  
 
The data presented in this chapter further characterise the association between Ack1 and 
EGFR. Immunoprecipitation of Ack1 results in co-precipitation of EGFR following EGF 
stimulation, whereas FGFR2 does not co-precipitate with Ack1 following FGF2 stimulation. 
Similar results are observed in the case of Fc-conjugated FGFR1 constructs, since Ack1 does 
not co-precipitate with any of these proteins, including kinase-active FcFGFR1.  Furthermore, 
although an interaction between endogenous Ack1 and EGFR has been previously shown via 
biochemical approaches (Shen et al., 2007), I believe that the imaging of the Ack1 and EGFR 
colocalization is shown for the first time at the physiological, endogenous level. Investigating 
the association between proteins at the cellular level can be very challenging, as some proteins 
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may not be very abundant and therefore difficult to identify. This often results in shifting 
towards the ectopically expressed proteins, which are usually easier to detect; however, this 
approach raises the question of the physiological relevance of identified associations. 
Therefore, detecting EGF-dependent colocalization between Ack1 and EGFR at the cellular 
level adds further evidence for their association in vivo and opens up the possibility of further 
research in these conditions. In summary, I conclude that Ack1 specifically interacts with 
EGFR, but not with FGFR, which potentially indicates the divergence in the endocytic 
trafficking of these RTKs. 
 
Another outcome of the studies presented in this chapter comes from the work on the Ack1 C-
terminal truncation mutants. This particular work has been performed to characterise the 
association between Ack1 and EGFR more precisely. Previous studies defined the regions 
within the Mig6 domain of Ack1 that interact with EGFR following EGF stimulation (Shen et 
al., 2007) and in the presence of an adaptor protein Grb2 (Lin et al., 2012). Mig6 has been 
shown to bind directly to activated EGFR and inhibit EGFR autophosphorylation, thus acting 
as a feedback EGFR inhibitor (Zhang et al., 2007). Nevertheless, to my knowledge and 
according to the data presented in this chapter, Ack1 does not inhibit EGFR activation. The 
reason may be that another region within Mig6 is required for EGFR inhibition, and this 
region is absent in Ack1 (Zhang et al., 2007). In this chapter I confirm the importance of the 
Mig6 domain in the association between Ack1 and EGFR. I also identify the clathrin binding 
domain as another region that contributes to this association. This is likely to be an indirect 
effect of EGFR being present within clathrin-coated vesicles and Ack1 association with 
clathrin through CBD. 
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Although other studies demonstrate that Ack1 regulates EGFR degradation, my work fails to 
demonstrate Ack1 function in this context. One of the reasons for this discrepancy may be 
that this function of Ack1 is cell-type specific, as my work was performed on prostate cancer 
cells, whereas the other studies employed cervical adenocarcinoma, head and neck cancer 
cells and human embryonic kidney cells (Shen et al., 2007; Grovdal et al., 2008; Kelley and 
Weed, 2012). As each cell line has its own specific proteome, EGFR degradation may be 
affected in different ways depending on cell context. In particular, I observe that in LNCaP 
cells the amount of endogenous EGFR is relatively high, whereas there is very little Ack1 
(Figure 4.14 a). Therefore, it is possible that this discrepancy between the amount of 
endogenous Ack1 and EGFR may prevent observation of any influence of Ack1 depletion on 
EGFR degradation. In other cells, the difference may be smaller and thus Ack1 depletion 
could potentially exert a much more striking effect in this context. Additionally, other studies 
have shown that Ack1 is involved in Akt and Erk activation, e.g. Ack1 has been found to 
promote Erk phosphorylation downstream of activation of Axl RTK in Cos7 cells, and 
purified Ack1 has been shown to phosphorylate purified Akt (Pao-Chun et al., 2009; Mahajan 
et al., 2010). In contrast, I do not observe dramatic changes in Erk or Akt phosphorylation 
upon Ack1 knockdown. The reason may similarly be the cell-type specific differences; 
however, it is possible that activation of other signalling cascades may be affected by Ack1, 
e.g. those involved in autophagosomal degradation (described in Chapter 6). Interestingly, I 
show that Ack1 functions in EGFR trafficking and demonstrate that Ack1 knockdown 
promotes accelerated lysosomal localization of EGFR. Therefore, I propose that Ack1 
interaction with EGFR following EGF stimulation may prevent EGFR trafficking through the 
classical endo-lysosomal pathway. 
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5 Ack1 endo-lysosomal localization 
5.1 Introduction 
The subcellular localization of a protein can potentially be very informative and shed a light 
on protein functions. For example receptor tyrosine kinases, such as EGFR, which are located 
at the plasma membrane, sense the extracellular environment and translate the signals from 
the outside into the cell (Lemmon and Schlessinger, 2010). Non-receptor tyrosine kinases are 
predominantly cytoplasmic, although some can associate with membranes, e.g. Src, and 
transduce signals upon RTKs activation (Blume-Jensen and Hunter, 2001; Roskoski, 2004; 
Mahajan and Mahajan, 2010). Other protein kinases, such as Akt, translocate to the nucleus to 
activate transcription factors, whereas STATs are themselves transcription factors and 
translocate to the nucleus to regulate gene expression (Blume-Jensen and Hunter, 2001).  
 
Ack1 is a non-receptor tyrosine kinase and therefore is expected to be predominantly 
cytoplasmic. Consistently, the reports show that Ack1 partially localizes to early endosomes 
following EGF stimulation (Shen et al., 2007; Grovdal et al., 2008). Apart from the 
endosomal localization, reports exist suggesting that Ack1 translocates to the nucleus 
following activation (Ahmed et al., 2004; Mahajan et al., 2010). The N-terminal SAM 
domain has been found to promote plasma membrane localization; however, the other 
domains present within full-length protein prevent membrane localization (Prieto-Echaguee et 
al., 2010). Other structures found to partially colocalize with Ack1 include clathrin-containing 
vesicles and AP2 complexes (Teo et al., 2001), as well as amorphous intracellular structures 
(Prieto-Echaguee et al., 2010) or a tubulo-reticular membrane compartments (Grovdal et al., 
2008). Nevertheless, the precise Ack1 subcellular localization has not yet been characterised. 
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In this chapter I investigate Ack1 localization in serum-starved cells and upon EGF 
stimulation. Consistently with previous reports, I find that Ack1 partially colocalizes to early, 
but not late or recycling, endosomes following EGF treatment; however, in contrast to other 
studies, I show that Ack1 does not translocate to the nucleus following EGF stimulation, even 
when nuclear export is inhibited. I also find association between Ack1 and Rab5, which 
localizes to early endosomes, but can also be found at the plasma membrane and in other 
intracellular structures, e.g. early autophagosomes (Stenmark, 2009). 
 
5.2 Cytoplasmic localization of Ack1 
Since Ack1 subcellular localization is poorly characterised and inconclusive, I investigated 
this more precisely. As mentioned above, some proteins and protein kinases translocate to the 
nucleus following activation and they regulate gene expression, e.g. it has been shown that 
Akt translocates to the nucleus upon phosphorylation, to activate downstream proteins and 
transcription factors (Nguyen et al., 2006). In contrast the endocytic protein Eps15, which 
contains an identified nuclear export signal (NES), has been found to shuttle between the 
cytoplasm and nucleus in a phosphorylation-independent manner. In particular, when nuclear 
export was inhibited by treatment with leptomycin B, ectopically expressed Eps15 
accumulated within the nucleus in both serum-starved and EGF treated cells (Vecchi et al., 
2001). Ack1 has been proposed to interact with androgen receptor (AR) and translocate to the 
nucleus to promote DNA binding of AR and regulate gene transcription in prostate cancer 
cells (Mahajan et al., 2007). Additionally, Ack1 has been proposed to translocate to the 
nucleus in semi-confluent, but not confluent, glioblastoma cells through interaction with 
Cdc4, and a putative NES sequence has been identified within the N-terminal portion of Ack1 
(Ahmed et al., 2004). 
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In order to determine whether Ack1 translocates to the nucleus following EGF stimulation, 
HeLa cells expressing GFP-Ack1 were serum-starved for four hours followed by an overnight 
incubation with EGF in the presence of leptomycin B. Additionally, truncated Ack1 has been 
employed to determine whether the C-terminal portion, which is present in full-length but not 
tAck1, is important for a potential nuclear localization. Eps15 was used as a positive control. 
As shown in Figure 5.1, Ack1 does not accumulate within the nucleus following EGF 
treatment, even in the presence of leptomycin B. In contrast, Eps15 exhibits strong nuclear 
localization when nuclear export is inhibited. This possibly indicates that although the 
putative NES motif may be present within the N-terminus of Ack1, additional features, e.g. 
conformation of a full-length protein or interacting partners, prevent Ack1 nuclear 
translocation. Surprisingly, tAck1 shows leptomycin-independent nuclear localization. These 
results suggest that the N-terminal portion of Ack1 does not comprise NES sequence, as 
tAck1 would accumulate within the nucleus in the presence of leptomycin B. Although it is 
possible that nuclear localization of tAck1 is an artefact, the molecular size of GFP-tagged 
tAck1 (approximately 100 kDa) prevents it from diffusing freely through nuclear pores 
(Marfori et al., 2011). Therefore, the nuclear localization potentially indicates that tAck1 may 
play a role within the nucleus, e.g. in a process of DNA replication or gene transcription. 
 
Additionally, to exclude the possibility that aquired images do not focus entirely on the 
nucleus and thus the observed nuclear localization of Eps15 and tAck1 may be the result of 
imaging of the perinuclear region rather than nucleus, the images were taken at various depths 
within the sample (Z-stack). As shown in Figure 5.2, the nuclear localization of both Eps15 
and tAck1 can be distinguished. In contrast, no Ack1 can be found within the nucleus. 
Therefore I conclude that in HeLa cells, ectopically expressed Ack1 does not translocate to 
the nucleus following EGF treatment, even when nuclear export is inhibited.
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Figure 5.1. Ack1 does not translocate the nucleus 
HeLa cells transfected with Eps15-GFP, GFP-Ack1 or GFP-tAck1 were serum-starved for four hours and stimulated overnight with EGF in the 
presence of leptomycin B (10 ng/ml). The cells were fixed and mounted with Vectashield with DAPI, which stains the nucleus. The cells were 
imaged via confocal microscopy. Scale bars 10 µm. 
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Figure 5.2. Z-stack of cells expressing Eps15-GFP, GFP-Ack1 and GFP-tAck1 
The cells were treated as in Figure 5.1. Presented Z-stack cover 5.6 µm of the cell (each frame every 0.8 µm). Scale bars 10 µm. 
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5.3 Ack1 partially colocalizes with transferrin  
Considering that Ack1 does not localize within the nucleus, I investigated other potential 
intracellular localizations. Firstly, I assessed Ack1 colocalization with transferrin (Tf), an 
iron-binding protein that undergoes clathrin-mediated endocytosis following binding to Tf 
receptor (TfR). Tf-TfR traffics to early endosomes to deliver iron and then recycles back to 
the plasma membrane (Mayle et al., 2012). HeLa cells expressing GFP-Ack1 were briefly 
serum-starved and incubated with Tf for 30 min, fixed and imaged. As shown in Figure 5.3 a, 
partial colocalization between Ack1 and Tf can be distinguished suggesting that Ack1 may 
localize to clathrin-coated vesicles, early endosomes or recycling endosomes, all of which are 
characterised by Tf; however, a substantial portion of Ack1 is present within structures devoid 
of Tf, indicating that Ack1 also localizes to compartments other than early or recycling 
endosomes. Interestingly and consistently with previous reports, I find that high levels of 
Ack1 expression inhibit Tf uptake, shown in Figure 5.3 b, likely as a result of perturbation of 
clathrin distribution (Teo et al., 2001). Therefore, for all studies presented, low or moderate 
levels of Ack1 expression were employed. 
 
I also investigated the colocalization between Ack1 and acidic compartments, such as late 
endosomes and lysosomes using lysotracker, which permeates plasma membrane and 
accumulates within acidic compartments (Chazotte, 2011). HeLa cells expressing GFP-Ack1 
and incubated with lysotracker were fixed and imaged via confocal microscopy. As shown in 
Figure 5.3 c, no colocalization can be distinguished suggesting that Ack1 does not localize to 
acidic compartments; however, the fluorescence of GFP has been shown to decrease in low 
pH (Patterson et al., 1997). Since this study employed GFP-tagged Ack1, it is possible that 
the fluorescence of GFP-Ack1 was decreased in acidic compartments.  
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Figure 5.3. Ack1 partially colocalizes with transferrin 
HeLa cells transfected with GFP-Ack1 were serum-starved for 10 minutes and incubated with 
Alexa Fluor-568 transferrin for 30 minutes (a) or 5 minutes (b). The cells were fixed and 
imaged via confocal microscopy, c) HeLa cells transfected with GFP-Ack1 were incubated 
with lysotracker for two hours, fixed and imaged via confocal microscopy. Scale bars 10 µm.  
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Therefore the late endosomal or lysosomal localization of Ack1 cannot be excluded on the 
basis of this experiment 
 
5.4 Ack1 partially localizes to early endosomes upon EGF stimulation 
Previous reports demonstrate that upon EGF treatment, Ack1 partially colocalizes with EGF 
on early endosomes which are the initial delivery sites for membrane proteins upon 
endocytosis (Maxfield and McGraw, 2004; Grovdal et al., 2008). Early endosome antigen 1 
(EEA1) is a peripheral membrane protein that localizes to early endosomes (Mu et al., 1995). 
I therefore employed α-EEA1 antibody to confirm the previous reports on early endosomal 
localization of Ack1. HeLa cells expressing mCherry-Ack1 were serum-starved followed by 
incubation with EGF for various times, fixed and immunostained with α-EEA1 antibody. As 
shown in Figure 5.4, Ack1 poorly colocalizes with EEA1 in serum-starved cells (0 minutes 
EGF), which is manifested by a very low PCC (Figure 5.4, graph). Consistently with the 
previous reports, upon EGF stimulation Ack1 colocalization with EEA1 significantly 
increases. These results confirm that Ack1 partially translocates to early endosomes following 
EGF treatment.  
 
5.5 Ack1 partially colocalizes with Rab5 upon EGF stimulation 
In addition to early endosomes, I also investigated whether Ack1 may localize to other 
subcellular compartments. As explained in Chapter 1.3.4, Rab GTPases localize to various 
endocytic compartments, e.g. Rab4 predominantly to early and recycling endosomes, Rab5 to 
early endosomes, autophagosomes and clathrin-coated pits, Rab7 to late endosomes, 
autophagosomes and autolysosomes and Rab11 to recycling endosomes (Stenmark, 2009). 
Therefore I investigated the colocalization between Ack1 and these Rab GTPases. 
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Figure 5.4. Ack1 partially localizes to early endosomes upon EGF stimulation 
HeLa cells transfected with mCherry-Ack1 were serum-starved for four hours and stimulated with EGF for indicated times, fixed and 
immunostained with α-EEA1 antibody. The cells were imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. 
Error bars represent SEM.   
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Firstly, I examined the association between Ack1 and Rab5. HeLa cells expressing mCherry-
Ack1 and Rab5-GFP were serum-starved and stimulated with EGF for various times, fixed 
and imaged. As shown in Figure 5.5 a, Ack1 only marginally colocalizes with Rab5 in 
starved cells; however, the colocalization between Ack1 and Rab5 significantly increases 
following EGF stimulation. Additionally, I employed a mutant Rab5aQ79L-GFP, which is 
constitutively active and GTP-bound. This mutant has been shown to promote early 
endosomal fusion and its expression led to the accumulation of enlarged endosomes 
(Stenmark et al., 1994). As shown in Figure 5.5 b, mCherry-Ack1 colocalizes with 
Rab5aQ79L-GFP mutant following EGF stimulation. These results support the finding that 
Ack1 partially colocalizes with Rab5 upon EGF treatment. 
 
Subsequently, I examined whether Ack1 colocalizes with Rab4 and Rab11. These two Rab 
GTPases are found on recycling endosomes: Rab4 on vesicles derived from early endosomes, 
whereas Rab11 on vesicles trafficking through the perinuclear recycling compartment 
(PNRC) (Stenmark, 2009). As shown in Figure 5.6 a and b, very little colocalization between 
mCherry-Ack1 and GFP-tagged Rab4 or Rab11 can be distinguished in serum-starved cells. 
Following EGF stimulation, some colocalization can be found at 15 and 30 minutes post-EGF 
treatment in the case of Rab4 (Figure 5.6 a), and at 30 minutes post-EGF in the case Rab11 
(Figure 5.6 b). These data potentially suggest that Ack1 may regulate recycling following 
EGF stimulation. 
 
I also examined the colocalization between Ack1 and Rab7, which has been found enriched in 
late endosomes, lysosomes and autophagosomes (Stenmark, 2009). As shown in Figure 5.7, 
Ack1 does not colocalize with Rab7 in serum-starved cells. Following EGF stimulation, some 
level of colocalization can be distinguished at 15 and 30 minutes of EGF treatment.
Chapter 5 – Ack1 endo-lysosomal localisation 
 
143 
 
 
Figure 5.5 Ack1 partially localizes to Rab5 upon EGF stimulation (a) and (b) 
a) HeLa cells transfected with mCherry-Ack1 and Rab5-GFP were serum-starved for four hours and stimulated with EGF for indicated times, 
and fixed. The cells were imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. Error bars represent SEM. 
Chapter 5 – Ack1 endo-lysosomal localisation 
 
144 
 
 
 
Figure 5.5 Ack1 partially localizes to Rab5 upon EGF stimulation (a) and (b) 
b) HeLa cells transfected with mCherry-Ack1 and Rab5aQ79L-GFP mutant were serum-starved for four hours and stimulated with EGF for 30 
minutes, fixed and imaged via confocal microscopy. Scale bars 10 µm.  
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Figure 5.6. Ack1 partially colocalizes with Rab4 and Rab11 post-EGF treatment (a) and (b) 
a) HeLa cells transfected with mCherry-Ack1 and Rab4-GFP were serum-starved for four hours and stimulated with EGF for indicated times, 
and fixed. The cells were imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. Error bars represent SEM. 
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Figure 5.6. Ack1 partially colocalizes with Rab4 and Rab11 post-EGF treatment (a) and (b) 
b) HeLa cells transfected with mCherry-Ack1 and Rab11-GFP were serum-starved for four hours and stimulated with EGF for indicated times, 
and fixed. The cells were imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. Error bars represent SEM.  
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Figure 5.7. Ack1 partially colocalizes with Rab7 post-EGF treatment 
HeLa cells transfected with mCherry-Ack1 and Rab7-GFP were serum-starved for four hours and stimulated with EGF for indicated times, and 
fixed. The cells were imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. Error bars represent SEM.
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Therefore, these results indicate that following EGF treatment, a portion of Ack1 translocates 
to Rab7-enriched compartments. Taken together, these data raise the possibility that Ack1 
may partially regulate recycling through its association with Rab4 and Rab11, and 
degradation through association with Rab7. Nevertheless, these studies have been completed 
on ectopically expressed Rab GTPases, which may potentially disturb subcellular trafficking. 
Therefore, subsequent experiments have been carried out without ectopically expressed Rab 
GTPases. 
 
5.6 Ack1 does not localize to late endosomes or recycling endosome 
Following studies with ectopically expressed Rab GTPases, I further investigated Ack1 
localization to late endosomes and recycling compartment taking advantage of the specific 
characteristics of these compartments, i.e. late endosomes being enriched in 
lysobisphosphatidic acid (LBPA), whereas PNRC in Rab11 (Kobayashi et al., 1998; 
Kobayashi et al., 1999; Galve-de Rochemonteix et al., 2000; Stenmark, 2009). Therefore, I 
performed the colocalization studies between Ack1 and endogenous LBPA and Rab11. HeLa 
cells expressing mCherry-Ack1 were serum-starved and stimulated with EGF for various 
times. The cells were fixed and immunostained with α-LBPA or α-Rab11 antibodies. As 
shown in Figure 5.8 and Figure 5.9, Ack1 does not colocalize with endogenous LBPA or 
Rab11 in serum-starved cells or upon EGF stimulation. This is inconsistent with my data on 
ectopically expressed Rab GTPases, where Ack1 partially colocalized with GFP-tagged Rab4, 
Rab7 and Rab11 upon EGF treatment (Chapter 5.5). This discrepancy may reflect the 
differences between experiments completed at the physiological levels to those employing 
ectopically expressed proteins. Additionally, subcellular distribution of Rab7 may slightly 
differ from LBPA, which could additionally explain observed differences.  
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Figure 5.8. Ack1 does not localize to late endosomes post-EGF treatment 
HeLa cells transfected with mCherry-Ack1 were serum-starved for four hours and stimulated with EGF for indicated times, and fixed. The cells 
were immunostained with α-LBPA antibody and imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. Error 
bars represent SEM. 
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Figure 5.9. Ack1 does not localize to recycling endosomes post-EGF treatment 
HeLa cells transfected with mCherry-Ack1 were serum-starved for four hours and stimulated with EGF for indicated times, and fixed. The cells 
were immunostained with α-Rab11 antibody and imaged via confocal microscopy, and the colocalization was quantified. Scale bars 10 µm. Error 
bars represent SEM. 
Chapter 5 – Ack1 endo-lysosomal localisation 
 
151 
 
It seems reasonable that a portion of Ack1 may partially localize to late or recycling 
endosomes following EGF stimulation; however, taking into consideration the data on 
endogenous LBPA and Rab11, it is likely the minority of the Ack1 molecules. Importantly, 
the concordance of results obtained with GFP-Rab5 and anti-EEA1 suggest that the 
localization of Ack1 to early endosomes is genuine. 
 
5.7 Conclusions 
The study presented within this chapter explores Ack1 subcellular localization in more detail. 
To date the characterisation of the Ack1 location is rather limited, with indication on partial 
endosomal localization upon EGF treatment; Ack1 has also been found within 
uncharacterised tubulo-reticular compartments (Grovdal et al., 2008; Prieto-Echaguee et al., 
2010).  
 
In this study I confirm that Ack1 partially translocates to early endosomes following EGF 
stimulation. This is shown by an increase in colocalization between Ack1 and EEA1. 
Interestingly, early endosomes have also been shown to be essential during autophagy (Razi 
et al., 2009; Tooze and Razi, 2009). In particular, the fusion of early endosomes with 
autophagosomes has been found required for autophagosome maturation. Therefore, although 
Ack1 exhibits endosomal localization, this does not necessarily exclude the potential 
association between Ack1 and the autophagosomal compartments. 
 
Similar to the results on EEA1, an increased EGF-dependent colocalization can be seen 
between Ack1 and Rab5. This association has been further confirmed through studies with 
constitutively active Rab5 mutant, in which strong colocalization between Ack1 and Rab5 
mutant can be observed upon EGF treatment. As explained in Chapter 1.3.4, Rab5 is found 
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on several distinctive intracellular compartments; these include early endosomes, early and 
late phagosomes and clathrin-coated pits (Stenmark, 2009). Therefore an increase in 
colocalization between Ack1 and Rab5 following EGF stimulation suggests that Ack1 
partially translocates towards Rab5-enriched compartments, e.g. early endosomes or 
autophagosomes. 
 
I show that when investigating endosomal localization of Ack1, the outcomes of the studies 
vary depending on the experimental design. In particular, I can distinguish a partial 
colocalization between Ack1 and the ectopically expressed Rab4, Rab7 and Rab11 upon EGF 
treatment. More precisely, the colocalization with Rab4 increases at 15 minutes post-EGF, 
with Rab7 at 15 minutes and further at 30 minutes, and with Rab11 at 30 minutes post-EGF 
treatment. Therefore, it seems reasonable to interpret these data that following EGF 
stimulation, Ack1 partially translocates to early endosomes at 15 minutes of the EGF 
stimulation, from where a portion of Ack1 remains within endosomes which mature into late 
endosomes and another portion recycles via recycling endosomes. In contrast, the data on 
endogenous Rab11 and LBPA indicate no colocalization between Ack1 and late or recycling 
endosomes upon EGF treatment. Partial explanation may come from the possible influence of 
ectopically expressed proteins on cell functions. Additionally, non-physiological expression 
of proteins may promote the colocalization that does not occur in physiological conditions. 
For example, ectopically expressed Rab5 has been found to promote enlargement of 
endosomes and their mislocalization to the cell periphery (Trim, 2009). Finally, the 
differences in Ack1 colocalization with Rab7 and LBPA may be the result of slight 
differences in their subcellular distribution. 
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6 Ack1 autophagosomal localization 
6.1 Introduction 
I and others have shown that Ack1 partially localizes to early endosomes following EGF 
stimulation (Shen et al., 2007; Grovdal et al., 2008); however, Ack1 does not display 
endosomal localization in serum-starved cells. Additionally, uncharacterised tubulo-reticular 
compartments have also been identified where Ack1 resides (Shen et al., 2007; Grovdal et al., 
2008). Nevertheless, more precise Ack1 subcellular localization, in particular pre-EGF 
stimulation, is elusive. This chapter investigates Ack1 subcellular localization more precisely 
and with focus on the compartments outside the classical endo-lysosomal pathway, as I did 
not find Ack1 present within endosomes in serum-starved cells.  
 
Firstly I investigate Ack1 association  with ubiquitin, which is an important regulator of 
protein degradation and ubiquitylated proteins typically undergo proteasomal, lysosomal or 
autophagosomal degradation (Kraft et al., 2010; Lemmon and Schlessinger, 2010). Previous 
reports show that Ack1 interacts with mono- and polyubiquitin and with ubiquitylated 
proteins (Shen et al., 2007). Ack1 contains a UBA domain, which in other proteins recognises 
ubiquitylated cargo targeted for degradation (Lamark et al., 2009). Therefore I studied a 
potential localization of Ack1 to degradative compartments marked by the presence of 
ubiquitin.  
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6.2 Ack1 localizes to ubiquitin-rich compartments 
Since my attempts to identify Ack1 endosomal localization in serum-starved cells were 
unsuccessful, I searched for other compartments not directly connected to the endosomal 
pathway. As explained in Chapter 1.3.3, protein ubiquitylation is a common factor targeting 
proteins for degradation via several degradative pathways, e.g. ubiquitylated cargo is enriched 
and enclosed within double membranes during selective autophagy (Kraft et al., 2010). Since 
Ack1 has been previously shown to bind both mono- and polyubiquitin (Shen et al., 2007), I 
therefore examined the colocalization between ectopically expressed Ack1 and ubiquitin in 
HeLa cells. As shown in Figure 6.1 a, there is a striking colocalization between Ack1 and 
ubiquitin in steady-state cells and this is not the case for truncated Ack1 or GFP. This is 
particularly relevant considering that truncated Ack1 lacks the C-terminal portion, including 
the UBA domain. Therefore the C-terminus of Ack1 promotes the colocalization with 
ubiquitin. Since Ack1 has also been found to be ubiquitylated (Chan et al., 2009; Lin et al., 
2010), this may also reflect Ack1 ubiquitylation. Interestingly, I commonly observe large 
ubiquitin-rich structures to which Ack1 localizes, hereafter referred to as ubiquitin-rich 
compartments (Figure 6.1 b). I also observe that the subcellular distribution of ubiquitin is 
affected by the presence of ectopically expressed Ack1 when compared to truncated Ack1 or 
GFP. In the case of truncated Ack1 and GFP, a disperse staining for ubiquitin typically can be 
distinguished, whereas in the presence of full-length Ack1 ubiquitin often forms larger 
structures. These data indicate that Ack1 influences subcellular distribution of ubiquitin and 
promotes formation of condensed ubiquitin and ubiquitin-rich compartments.  
 
Consistently with the colocalization studies, ubiquitin associates only with the full-length 
protein following Ack1 or tAck1 immunoprecipitation, as shown in Figure 6.2, and this is 
independent of EGF treatment.  
Chapter 6 – Ack1 autophagosomal localisation 
 
155 
 
 
Figure 6.1. Ack1 localizes to ubiquitin-rich compartments 
a) and b) HeLa cells transfected with GFP-Ack1, GFP-tAck1 or GFP and HA-ubiquitin were 
serum-starved for four hours and stimulated with EGF for 30 minutes. The cells were fixed 
and immunostained with α-HA antibody, and imaged via confocal microscopy. Scale bars 10 
µm.  
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Figure 6.2. Ack1 binds ubiquitin 
293T cells transfected with GFP-Ack1 or GFP-tAck1 and HA-ubiquitin were serum-starved 
for four hours and stimulated with EGF for 30 minutes. The cells were lysed and cell lysates 
were incubated with GFP-trap to immunoprecipitate GFP-tagged proteins. 
Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-GFP and α-
HA antibodies. 
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These results indicate that Ack1 constitutively associates with ubiquitin, or is constitutively 
ubiquitylated, and confirm that the C-terminus is required for this association. 
 
Showing that Ack1 localizes to ubiquitin-rich compartments, and that EGFR colocalizes with 
Ack1 upon EGF treatment, I examined whether EGFR localizes with Ack1 to ubiquitin-rich 
compartments. HeLa cells expressing EGFR-GFP, mCherry-Ack1 and HA-ubiquitin were 
serum-starved and stimulated with EGF, fixed and immunostained with α-HA antibody. The 
cells were imaged via confocal microscopy. As shown in Figure 6.3, in starved cells EGFR is 
mainly present at the plasma membrane, whereas Ack1 colocalizes with ubiquitin. Following 
EGF stimulation, EGFR moves away from the plasma membrane and localizes with Ack1 to 
ubiquitin-rich compartments. These data further support the association between Ack1 and 
ubiquitin, which may be important for EGFR trafficking, and may reflect the ubiquitylation of 
Ack1 and/or EGFR. 
 
Subsequently, I examined the colocalization between ubiquitin and the C-terminal truncation 
mutants of Ack1 to determine more precisely which of the Ack1 domains promote association 
with ubiquitin. HeLa cells expressing mCherry-tagged Ack1, truncated Ack1 or the Ack1 
mutants and HA-ubiquitin were serum-starved and stimulated with EGF, fixed and 
immunostained with α-HA antibody. The cells were imaged via confocal microscopy. As 
shown in Figure 6.4 a, b and c, there is a striking colocalization between Ack1 and ubiquitin 
(approximately 70-80 %) and this is independent of EGF stimulation. This colocalization 
dramatically decreases upon deletion of the UBA domain (to approximately 40-50 %); 
however, the colocalization is not completely abrogated thus indicating that other domains 
also contribute to this colocalization.  
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Figure 6.3. EGFR colocalizes with Ack1 and ubiquitin post-EGF treatment 
HeLa cells transfected with mCherry-Ack1, EGFR-GFP and HA-ubiquitin were serum-starved for four hours and stimulated with EGF for 30 
minutes. The cells were fixed and immunostained with α-HA antibody, and imaged via confocal microscopy. For quantification, the Ack1 puncta 
were circled and the colocalization with EGFR and ubiquitin was quantified. As a control, the circles were moved into the areas absent for Ack1, 
and the random colocalization with EGFR and/or ubiquitin was quantified. Nuclear localization was excluded from analysis. Scale bars 10 µm. 
Error bars represent SEM.  
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Figure 6.4. Ack1 domains required for colocalization with ubiquitin (a), (b) and (c) 
a) HeLa cells transfected with mCherry-tagged Ack1, tAck1 or the Ack1 mutants and HA-ubiquitin were serum-starved for four hours and 
stimulated with EGF for 30 minutes. The cells were fixed and immunostained with α-HA antibody, and imaged via confocal microscopy. Scale 
bars 10 µm.  
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Figure 6.4. Ack1 domains required for colocalization with ubiquitin (a), (b) and (c) 
b) For quantification (Figure 6.4 a), the Ack1, tAck1 or Ack1 mutant puncta were circled and the colocalization with ubiquitin was quantified. 
As a control, circles were moved into the areas absent for Ack1, tAck1 or the Ack1 mutants and the random colocalization with ubiquitin was 
quantified. Error bars represent SEM; c) schematic structure of Ack1, tAck1 and the Ack1 mutants employed. 
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Deletion of the Mig6 domain does not have any influence on this colocalization, whereas 
deletion of the PRD further decreases the colocalization between Ack1 and ubiquitin 
(approximately 20-30 %). In the case of truncated Ack1, only minute colocalization can be 
distinguished (approximately 10 %). Interestingly, although no significant EGF-dependence 
can be found, a trend can be recognised that EGF stimulation slightly decreases the 
colocalization between Ack1 and ubiquitin. In conclusion, the UBA domain, PRD and CBD 
all contribute to the colocalization between Ack1 and ubiquitin. 
 
6.3 Ack1 associates with Eps15 and Hrs 
As explained in Chapter 1.3.1, Hrs is a component of the ESCRT-0 complex, which 
regulates incorporation of ubiquitylated cargo, such as RTKs, into the internal vesicles of late 
endosomes (Clague et al., 2012). I find that ectopically expressed Ack1 and Hrs colocalize 
with each other both in serum-starved and in EGF-treated HeLa cells, as presented in Figure 
6.5 a. Interestingly, ectopically expressed Hrs has been found to retain EGFR at the limiting 
membranes of early endosomes and thus inhibit EGFR degradation, whereas a UIM-deletion 
Hrs mutant with reduced ability to interact with ubiquitylated proteins failed to do so (Urbe et 
al., 2003). This could potentially indicate that Hrs overexpression prevents EGFR degradation 
via a classical endo-lysosomal pathway, and that the UIM is important for this function. 
Additionally, Hrs has been found to localize to autophagosomes and regulate autophagosomal 
maturation, which was impaired in cells depleted of Hrs (Tamai et al., 2007). These data 
suggest that Hrs potentially plays a role in autophagosomal degradation.  
 
Eps15 is another ubiquitin-binding protein with well-established role in endo-lysosomal 
trafficking that has also been proposed to regulate autophagosomal degradation. Eps15 
activation upon EGF stimulation is required for EGFR endocytosis (Confalonieri et al., 2000).  
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Figure 6.5. Ack1 colocalizes with Hrs and Eps15 
HeLa cells transfected with mCherry-Ack1 and Hrs-GFP (a) or mCherry-Ack1 and Eps15-GFP (b) were serum-starved for four hours and 
stimulated with EGF for 30 minutes. The cells were fixed and imaged via confocal microscopy. Scale bars 10 µm; c) 293T cells transfected with 
myc-Ack1 and Eps15-GFP were lysed and cell lysates were incubated with α-Ack1 antibody to immunoprecipitate Ack1. Immunoprecipitates 
were subjected to SDS PAGE and Western blotting with α-Ack1 and α-GFP antibodies. 
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Ubiquilin, a ubiquitin-like protein that localizes to ubiquitin-rich structures, has been found to 
associate with endogenous Eps15 and Hrs. Additionally, this association has been found 
dependent on UIMs of Eps15 and Hrs, as the UIM-deletion mutants did not associate with 
ubiquilin (Regan-Klapisz et al., 2005). I show that ectopically expressed Ack1 and Eps15 
colocalize in HeLa cells in EGF-independent manner, as shown in Figure 6.5 b. Furthermore, 
I found that Ack1 and Eps15 interact with each other, and Eps15-GFP co-precipitates with 
myc-Ack1 in steady-state 293T cells (Figure 6.5 c). 
 
6.4 Ack1 interacts and colocalizes with p62/SQSTM1 and NBR1 
The data presented so far on Ack1 subcellular localization suggest that Ack1 may be involved 
in ubiquitin-dependent degradation. Furthermore, Ack1 association with Hrs and Eps15 
supports this suggestion, since both Hrs and Eps15 have proposed roles in autophagosomal 
degradation (Regan-Klapisz et al., 2005; Tamai et al., 2007). Therefore, my studies have 
focused on the non-canonical degradative pathways. 
 
Sequestosome 1 (p62/SQSTM1) has been shown to target ubiquitylated proteins for 
degradation through selective autophagy, as explained in more detail in Chapter 1.4.2. In 
particular,  the UBA domain of p62/SQSTM1 recognises ubiquitylated cargo, whereas the 
LC3-interacting region (LIR) binds LC3 which is associated with autophagosomal 
membranes (Lamark et al., 2009). 
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Thus, I examined whether Ack1 interacts with p62/SQSTM1. 293T cells expressing myc-
Ack1 and p62/SQSTM1-flag were lysed and cell lysates were subjected to 
immunoprecipitation with α-Ack1 antiobody. As shown in Figure 6.6 a, p62/SQSTM1 co-
precipitates with Ack1, thus indicating that Ack1 and p62/SQSTM1 interact in these 
conditions.  
 
Subsequently, I investigated whether Ack1 and p62/SQSTM1 colocalize with each other. 
HeLa cells expressing GFP-Ack1 and p62/SQSTM-flag were serum-starved and stimulated 
with EGF, fixed and immunostained with α-SQSTM1 antibody. The cells were imaged via 
confocal microscopy. As shown in Figure 6.6 b, a strong colocalization can be distinguished 
particularly in serum-starved cells, whereas upon EGF stimulation the colocalization partially 
decreases. Therefore Ack1 and p62/SQSTM1 colocalize predominantly in serum-starved cells 
and EGF stimulation partially reduces this colocalization. 
 
Finally, I analysed whether the interaction between Ack1 and p62/SQSTm1 takes place at the 
physiological level. LNCaP cells were serum-starved in the presence or absence of 
bafilomycin, an inhibitor of lysosomal acidification and thus autophagy, and stimulated with 
EGF. The cells were lysed and cell lysates were incubated with α-Ack1. As a negative 
control, cell lystes were incubated with non-specific IgG. As shown in Figure 6.6 c, 
endogenous p62/SQSTM1 co-precipitates with Ack1 in serum-starved cells, but not in the 
control. This indicates that the interaction between Ack1 and p62/SQSTM1 is physiologically 
relevant. Furthermore, this interaction decreases following EGF treatment and this is 
consistent with my studies on colocalization between ectopically expressed Ack1 and 
p62/SQSTM1 in HeLa cells.  
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Figure 6.6. Ack1 interacts and colocalizes with p62/SQSTM1 (a), (b) and (c) 
a) 293T cells transfected with myc-Ack1 and p62/SQSTM1-flag were lysed and cell lysates were incubated with α-Ack1 antibody previously 
cross-linked to the beads, to immunoprecipitate Ack1. Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-Ack1 and 
α-SQSTM1 antibodies; c) LNCaP cells were serum-starved for four hours in the presence or absence of bafilomycin A (400 nM). The cells were 
stimulated with EGF for 10 minutes, lysed and cell lysates were incubated with α-Ack1 antibody previously cross-linked to the beads, to 
immunoprecipitate endogenous Ack1. Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-Ack1 and α-SQSTM1 
antibodies. 
  
Chapter 6 – Ack1 autophagosomal localisation 
 
166 
 
 
 
Figure 6.6. Ack1 interacts and colocalizes with p62/SQSTM1 (a), (b) and (c) 
b) HeLa cells transfected with GFP-Ack1 and p62/SQSTM1-flag were serum-starved for four hours and stimulated with EGF for 30 minutes. 
The cells were fixed and immunostained with α-SQSTM1 antibody. The cells were imaged via confocal microscopy, and the colocalization was 
quantified. Scale bars 10 µm. Error bars represent SEM. 
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Interestingly, the interaction between Ack1 and p62/SQSTM1 is retained upon EGF 
stimulation in bafilomycin treated cells, suggesting that this interaction may take place at the 
stages involving acidic lysosomes. 
 
NBR1 is another autophagic receptor that has been proposed to play a similar role to 
p62/SQSTM1. Although nearly twice the size of p62/SQSTM1, it shares a similar domain 
structure with a UBA domain recognising ubiquitylated proteins and a LIR motif interacting 
with LC3, as explained in more detail in Chapter 1.4.2. Additionally, NBR1 and 
p62/SQSTM1 interact with each other via their PB1 domains (Lamark et al., 2009). To 
examine whether Ack1 colocalizes with NBR1, HeLa cells expressing mCherry-Ack1 and 
NBR1-GFP were serum-starved and stimulated with EGF, fixed and imaged via confocal 
microscopy. As shown in Figure 6.7, partial colocalization between Ack1 and NBR can be 
seen; however, it is not as striking as in the case of p62/SQSTM1. When quantified, 
approximately 20-25 % of the Ack1 puncta colocalize with NBR1 (Figure 6.7, graph), but 
the colocalization between Ack1 and NBR1 is EGF-independent. This is in contrast with the 
data on the interaction between Ack1 and p62/SQSTM1, which decreases upon EGF 
treatment.  
 
6.5 p62/SQSTM1 promotes colocalization between Ack1 and NBR1 
As explained in Chapter 1.4.2 and Chapter 1.4.3, p62/SQSTM1 and NBR1 interact with 
each other via their PB1 domains (Lamark et al., 2003; Lamark et al., 2009). They also 
colocalize with each other within ubiquitin-rich compartments in autophagy-deficient cells; 
however, NBR1 has been shown to be degraded by autophagy independently of p62/SQSTM1 
(Kirkin et al., 2009). 
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Figure 6.7. Ack1 only partially colocalizes with NBR1 
HeLa cells transfected with mCherry-Ack1 and NBR1-GFP were serum-starved for four hours and stimulated with EGF for 30 minutes, fixed 
and imaged via confocal microscopy. For quantification, the Ack1 puncta were circled and colocalization with NBR was quantified. As a control, 
the circles were moved into the areas absent for Ack1 and the random colocalization with NBR1 was quantified. Scale bars 10 µm. Error bars 
represent SEM. 
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Additionally, the late endosomal and autophagosomal localization of NBR1 have been shown 
to be independent of each other, suggesting that NBR1 may play different roles in each 
context (Mardakheh et al., 2010). 
 
When comparing the colocalization between Ack1 and NBR1 to the colocalization between 
Ack1 and p62/SQSTM1, it is apparent that the latter is more striking. This suggests that Ack1 
may preferably interact with p62/SQSTM1. To compare the interaction between Ack1, NBR1 
and p62/SQSTM1, 293T cells expressing myc-Ack1, NBR1-GFP and p62/SQSTM1-flag 
were serum-starved followed by stimulation with EGF. The cells were lysed and cell lysates 
were incubated with α-Ack1 antibody. As shown in Figure 6.8, in these conditions Ack1 
interacts with both NBR1 and p62/SQSTM1 to a similar level and independently of EGF 
treatment. This is suprising, since previous data on HeLa and LNCaP cells show that Ack1 
association with p62/SQSTM1 decreases following EGF treatment. This discrepancy is likely 
to reflect the differences between different cell lines. Thus, subsequent experiments were 
designed to further explore the association between Ack1, NBR and p62/SQSTM1. 
 
To examine the colocalization between Ack1, NBR1 and p62/SQSTM1, HeLa cells 
expressing mCherry-Ack1, NBR1-GFP and p62/SQSTM1-flag were serum-starved and 
stimulated with EGF. The cells were fixed and immunostained with α-SQSTM1 antibody, and 
imaged via confocal microscopy. As shown in Figure 6.9 a and b, relatively strong 
colocalization between Ack1, NBR1 and p62/SQSTM1 can be distinguished in serum-starved 
cells (approximately 50 %), which decreases following EGF treatment (approximately 30 %). 
Additionally, when examining the colocalization between NBR1 and p62/SQSTM1 within the 
Ack1 puncta, it is strong both in serum-starved and in EGF-treated cells (approximately       
80 %) (Figure 6.9 c).   
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Figure 6.8. p62/SQSTM1 and NBR1 co-precipitate with Ack1 
293T cells transfected with myc-Ack1, NBR1-GFP and p62/SQSTM1-flag were serum-
starved for four hours and stimulated with EGF for 30 minutes. The cells were lysed and cell 
lysates were incubated with α-Ack1 antibody to immunoprecipitate Ack1. 
Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-Ack1, α-GFP 
and α-SQSTM1 antibodies. 
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Figure 6.9. The colocalization between Ack1, p62/SQSTM1 and NBR1 (a), (b) and (c) 
a) HeLa cells transfected with mCherry-Ack1, NBR1-GFP and p62/SQSTM1-flag were serum starved for four hours and stimulated with EGF 
for 30 minutes, fixed and immunostained with α-SQSTM1 antibody. The cells were imaged via confocal microscopy. Scale bars 10 µm. 
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Figure 6.9. The colocalization between Ack1, p62/SQSTM1 and NBR1 (a), (b) and (c) 
b) For quantification (Figure 6.9 a), the Ack1 puncta were circled and the colocalization with NBR1 and p62/SQSTM1 was quantified. As a 
control, the circles were moved into the areas absent for Ack1 and the random colocalization with NBR1 or p62/SQSTM1 was quantified; c) For 
quantification (Figure 6.9 a), the Ack1 puncta were circled and the colocalization between NBR1 and p62/SQSTM1 within Ack1 puncta was 
quantified (bottom right graph). As a control, the circles were moved into the areas absent for Ack1 and the random colocalization between 
NBR1 and p62/SQSTM1 was quantified. Error bars represent SEM. 
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Therefore, the colocalization between Ack1 and NBR1 is nearly doubled in the presence of 
ectopically expressed p62/SQSTM1 and acquires EGF sensitivity (Figure 6.9 a and b 
compared to Figure 6.7). Thus, p62/SQSTM1 promotes the association between Ack1 and 
NBR1 in serum-starved HeLa cells. 
 
6.6 The UBA domain regulates association with p62/SQSTM1, but not NBR1 
Showing that Ack1 colocalizes with p62/SQSTM1, I further examined which of the Ack1 
domains regulate this colocalization. HeLa cells expressing mCherry-tagged Ack1, truncated 
Ack1 or the C-terminal truncation mutants and p62/SQSTM1-flag were serum-starved and 
stimulated with EGF. The cells were fixed and immunostained with α-SQSTM1 antibody, and 
imaged via confocal microscopy. As shown in Figure 6.10 a and b, the colocalization 
between full-length Ack1 and p62/SQSTM1 is strong in serum-starved cells (approximately 
55 %) and decreases significantly following EGF stimulation (approximately 30 %). Deletion 
of the UBA domain dramatically reduces the colocalization between Ack1 and p62/SQSTM1 
(approximately 20 %) and desensitizes it to EGF treatment. Further deletion of the Mig6 
domain or PRD does not influence the colocalization between Ack1 and p62/SQSTM1, 
whereas any remaining colocalization is abrogated in the case of truncated Ack1. Therefore 
the UBA domain mediates the colocalization between Ack1 and p62/SQSTM1.  
 
Subsequently, I examined whether the UBA domain similarly promotes the association 
between Ack1 and NBR1. HeLa cells transfected with mCherry- tagged Ack1 or the UBA 
domain-deletion mutant and NBR1-GFP were serum-starved and stimulated with EGF. The 
cells were fixed and imaged via confocal microscopy.  
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Figure 6.10. The UBA domain mediates the colocalization with p62/SQSTM1 (a) and (b) 
a) HeLa cells transfected with mCherry-tagged Ack1, truncated Ack1 or the Ack1 mutants were serum-starved for four hours and stimulated 
with EGF for 30 minutes, fixed and immunostained with α-SQSTM1 antibody. Scale bars 10 µm. 
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Figure 6.10. The UBA domain mediates the colocalization with p62/SQSTM1 (a) and (b) 
b) For quantification (Figure 6.10 a), the Ack1, tAck1 or Ack1 mutant puncta were circled and the colocalization with p62/SQSTM1 was 
quantified. As a control, the circles were moved into the areas absent for Ack1, tAck1 or the Ack1 mutants and the random colocalization with 
p62/SQSTM1 was quantified. Error bars represent SEM. 
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As shown in Figure 6.11, deletion of the UBA domain does not influence the colocalization 
between Ack1 and NBR1, nor alters its EGF-independence. Thus, the UBA domain 
specifically mediates the colocalization between Ack1 and p62/SQSTM1.  
 
6.7 EGFR partially colocalizes with Ack1 and p62/SQSTM1 post-EGF treatment 
I and others show that Ack1 colocalizes with EGFR following EGF stimulation (Shen et al., 
2007; Grovdal et al., 2008). I also identify the association between Ack1 and the autophagy 
receptors, i.e. NBR1 and p62/SQSTM1. Therefore I examined whether EGFR colocalizes 
with Ack1 and p62/SQSTM1 upon EGF treatment. HeLa cells expressing mCherry-Ack1, 
EGFR-GFP and p62/SQSTM1-flag were serum-starved and stimulated with EGF. The cells 
were fixed and immunostained with α-SQSTM1 antibody, and imaged via confocal 
microscopy. As shown in Figure 6.12, upon EGF treatment approximately 90 % of the Ack1 
puncta colocalize with EGFR, whereas approximately 30 % colocalize with p62/SQSTM1. 
This relatively low colocalization with p62/SQSTM1 is expected, since EGF stimulation 
decreases the colocalization between Ack1 and p62/SQSTM1. Importantly, the majority of 
the Ack1 puncta which colocalize with p62/SQSTM1 also colocalize with EGFR 
(approximately 20 %). Therefore EGFR partially colocalizes with Ack1 and p62/SQSTM1 
following EGF stimulation. 
 
6.8 Ack1 partially localizes to early phagophores upon EGF stimulation 
Since I identified the interaction between Ack1 and the autophagy receptors, I examined 
whether Ack1 colocalizes with pre-autophagosomes. As explained in more detail in Chapter 
1.4.1, the Atg proteins are essential for autophagy as they are required for initiation and 
maturation of autophagosomes (Mizushima et al., 2011). 
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Figure 6.11. The UBA domain does not mediate the colocalization with NBR1 
HeLa cells transfected with mCherry-tagged Ack1 or ΔUBA Ack1 mutant and NBR1-GFP were serum-starved for four hours and stimulated 
with EGF for 30 minutes, fixed and imaged via confocal microscopy. For quantification, the Ack1 or ΔUBA Ack1 mutant puncta were circled 
and the colocalization with NBR1 was quantified. As a control, the circles were moved into the areas absent for Ack1 or ΔUBA Ack1 mutant and 
the random colocalization with NBR1 was quantified. Scale bars 10 µm. Error bars represent SEM.  
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Figure 6.12. EGFR partially colocalizes with Ack1 and p62/SQSTM1 post-EGF treatment 
Hela cells transfected with mCherry-Ack1, EGFR-GFP and p62/SQSTM1-flag were serum-starved for four hours and stimulated with EGF for 
30 minutes, fixed and immunostained with α-SQSTM1 antibody. The cells were imaged via confocal microscopy. For quantification, the Ack1 
puncta were circled and the colocalization with EGFR and p62/SQSTM1 was quantified. As a control, the circles were moved into the areas 
absent for Ack1, and the random colocalization with EGFR and p62/SQSTM1 was quantified. Scale bars 10 µm. Error bars represent SEM.  
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For example, Atg16 forms a multimeric complex with Atg5 and Atg12 at the initial stages of 
autophagosome formation, which dissociates when the autophagosome is formed, and 
disruption of the Atg16 gene decreases cell viability upon nitrogen starvation in yeast 
(Mizushima et al., 1999; Mizushima et al., 2011). 
 
To examine whether Ack1 colocalizes with Atg16, HeLa cells expressing GFP-Ack1 were 
serum-starved and stimulated with EGF for various times. The cells were fixed and 
immunostained with α-Atg16L antibody, and imaged via confocal microscopy. As shown in 
Figure 6.13 a, in serum-starved cells the antibody exhibits rather diffused staining, although 
some punctual staining can also be observed. Following EGF stimulation, the Atg16-positive 
structures can be distinguished, and Ack1 colocalizes to these structures upon EGF treatment. 
When quantified at 15 minutes post-EGF, approximately 25 % of the Ack1 puncta colocalizes 
with Atg16 (Figure 6.13 a, top right graph). Additional quantification with PCC shows a 
significant increase in colocalization between Ack1 and Atg16 at 15 and 30 minutes of EGF 
treatment (Figure 6.13 a, bottom right graph). Thus, EGF stimulation promotes 
colocalization between Ack1 and Atg16. 
 
To verify whether the interaction between Ack1 and Atg16 takes place at the physiological 
level, LNCaP cells were serum-starved and stimulated with EGF for various times. The cells 
were lysed and cell lysates were incubated with α-Atg16L antibody. Consistenly with the data 
from HeLa cells, endogenous Ack1 co-precipitates with endogenous Atg16 in LNCaP cells, 
as shown in Figure 6.13 b. Additionally endogenous LC3, another member of the Atg family 
crucial for autophagy (described in Chapter 1.4.1) (Mizushima et al., 2011) also co-
precipitates with Atg16, suggesting formation of a complex is formed between Ack1, Atg16 
and LC3.  
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Figure 6.13. Ack1 partially localizes to early phagosomes upon EGF stimulation (a) and (b) 
a) HeLa cells transfected with GFP-Ack1 were serum-starved for four hours and stimulated with EGF for indicated times, fixed and 
immunostained with α-Atg16L antibody. The cells were imaged via confocal microscopy. For quantification, top right graph: the Ack1 puncta at 
15 minutes post-EGF were circled and the colocalization with Atg16L was quantified. As a control, the circles were moved into the areas absent 
for Ack1 and the random colocalization with Atg16L was quantified. The PCC quantification was also completed, shown on the bottom right 
graph. Scale bars 10 µm. Error bars represent SEM. 
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Figure 6.13. Ack1 partially localizes to early phagoosomes upon EGF stimulation (a) and (b) 
b) LNCaP cells were serum-starved for four hour and stimulated with EGF for 10 minutes. The cells were lysed and cell lysates were incubated 
with α-Atg16L antibody to immunoprecipitate endogenous Atg16. Immunoprecipitates were subjected to SDS PAGE and. Western blotting with 
α-Atg16L, α-Ack1 and α-LC3B antibodies. 
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6.9 Ack1 colocalizes with LC3 
LC3, a mammalian homologue of yeast Atg8, associates with  isolation membranes 
downstream of Atg16 and remains within autophagosomes to undergo degradation, as 
described in Chapter 1.4.1 (Mizushima et al., 2011). LC3 association with autophagosomes 
is critical for the isolation membrane elongation and closure (Sou et al., 2008). To examine 
the colocalization between Ack1 and LC3, HeLa cells expressing mCherry-Ack1 and GFP-
LC3 (Kabeya et al., 2000) were serum-starved in the presence or absence of bafilomycin, 
which inhibits autophagy. The cells were stimulated with EGF and fixed, and imaged via 
confocal microscopy. As shown in Figure 6.14 a, the colocalization between ectopically 
expressed Ack1 and LC3 can be distinguished in serum-starved cells and upon EGF 
treatment; however, EGF stimulation may partially reduce this colocalization. Additionally, 
treatment with bafilomycin appears to positively influence the colocalization between Ack1 
and LC3, which may indicate that it takes place prior to fusion of autophagosomes with 
lysosomes.  
 
Subsequently, I tested the association between GFP-Ack1 and endogenous LC3 in the 
presence of bafilomycin to inhibit autophagosomal degradation of LC3 (Ravikumar et al., 
2010). As shown in Figure 6.14 b, nearly 30 % of the Ack1 puncta colocalize with 
endogenous LC3; however, in the case of endogenous LC3 the colocalization with Ack1 is 
EGF-independent.  
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Figure 6.14. Ack1 colocalizes with LC3 (a) and (b) 
a) HeLa cells transfected with mCherry-Ack1 and GFP-LC3 were serum-starved for four hours in the presence or absence of bafilomycin A (400 
nM) and stimulated with EGF for 30 minutes. The cells were fixed and imaged via confocal microscopy. Scale bars 10 µm. 
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Figure 6.14. Ack1 colocalizes with LC3 (a) and (b) 
b) HeLa cells transfected with GFP-Ack1 were serum-starved for four hours in the presence of bafilomycin A (400 nM) and stimulated with EGF 
for 30 minutes. The cells were fixed and immunostained with α-LC3B antibody. For quantification, the Ack1 puncta were circled and the 
colocalization with LC3B was quantified. As a control, the circles were moved into the areas absent for Ack1 and the random colocalization with 
LC3B was quantified. Scale bars 10 µm. Error bars represent SEM. 
Chapter 6 – Ack1 autophagosomal localisation 
 
185 
 
6.10 Conclusions 
The studies completed in this chapter suggest Ack1 implication in the autophagic machinery. 
The first indication of possible functions of Ack1 in selective autophagy is its association with 
ubiquitin, a protein commonly involved in several degradative pathways (Kraft et al., 2010). 
Previously Ack1 has been shown to bind mono- and polyubiquitin and interact with 
ubiquitylated proteins (Shen et al., 2007). Additionally, Ack1 has also been shown to be 
ubiquitylated (Chan et al., 2009; Lin et al., 2010). I show that Ack1 localizes to ubiquitin-rich 
compartments and the C-terminal portion of Ack1 is critical for this localization, as truncated 
Ack1 fails to do so. Additionally, through employing the C-terminal truncation mutants of 
Ack1 I identify several domains which regulate the association between Ack1 and ubiquitin; 
these include the UBA domain, the proline-rich domain and the clathrin-binding domain. 
These data further emphesize that Ack1 may interact with ubiquitylated proteins and/or may 
be ubiquitylated by ubiquitin ligases. 
 
I also find association between Ack1 and p62/SQSTM1, an autophagic receptor which 
recognises ubiquitylated cargo during autophagosomal degradation (Lamark et al., 2009). 
This association is enhanced in serum-starved cells and partially decreases following EGF 
stimulation. These data indicate that EGF treatment results in Ack1 translocation from 
p62/SQSTM1 compartments. Importantly, the UBA domain is critical for this association. 
Therefore, it appears that the ubiquitin binding mediated via the UBA domain contributes to 
the association between Ack1 and p62/SQSTM1. Interestingly, Ack1 association with NBR1, 
which plays a similar function to p62/SQSTM1 (Lamark et al., 2009), is much less evident 
and is independent on EGF treatment. Thus, it is likely that the interaction between Ack1 and 
p62/SQSTM1 is specific. Finally, ectopically expressed p62/SQSTM1 promotes association 
between Ack1 and NBR1 and confers EGF sensitivity to this association. This is likely due to 
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an interaction between NBR1 and p62/SQSTM1 via their PB1 domains (Lamark et al., 2009). 
This is schematically presented in Table 6.1. 
 
I also show that Ack1 interacts and colocalizes with Atg16, a protein that regulates the early 
stages of the autophagosome formation (Mizushima et al., 1999; Mizushima et al., 2011) and 
this is enhanced in EGF-treated cells. Interestingly, EGF treatment appears to stimulate the 
formation of the Atg16-positive structures thus suggesting that Atg16-positive phagophores 
(isolation membranes) are formed in these conditions. In addition to the interaction with 
Atg16, I find an association between Ack1 and LC3, which plays a critical role in 
autophagosomal membranes elongation (Sou et al., 2008). Interestingly, the colocalization 
between Ack1 and ectopically expressed LC3 appears to decrease upon EGF stimulation, 
whereas colocalization between Ack1 and endogenous LC3 is EGF-independent. These data 
again suggest that the colocalization studies at the physiological levels may differ from that 
on ectopically expressed proteins. In summary, the association between Ack1 and Atg16 is 
promoted upon EGF treatment, the colocalization between Ack1 and ectopically expressed 
LC3 appears to decrease upon EGF stimulation, whereas the colocalization between Ack1 and 
endogenous LC3 is independent of EGF stimulation. This is schematically presented in Table 
6.1. 
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Colocalization 
between Ack1 and: 
Colocalization (approximate) EGF 
sensitivity 
Colocalization 
post-EGF -EGF +EGF 
NBR1 25 % 20 % No No change 
p62/SQSTM1 55 % 30 % Yes Decreases 
NBR1 and 
p62/SQSTM1 
50 % and 
50 % 
35 % 
and 30 % Yes Decreases 
LC3 (endogenous) 30 % 30 % No No change 
Atg16 (endogenous) Less More Yes Increases 
 
 
Table 6.1. Summary of the studies on Ack1 colocalization with autophagic proteins 
The table presents the results of the studies performed to evaluate the association between 
Ack1 and the autophagic proteins, including the level of colocalization and the EGF 
sensitivity of a particular association. 
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7 Identification of novel PTMs and Ack1 
interactors via mass spectrometry 
7.1 Introduction 
Posttranslational modification (PTM) of proteins is a ubiquitous mechanism for regulation of 
cellular functions, as described in more detail in Chapter 1.3.2 and Chapter 1.3.3. PTMs 
provide a very efficient way for controlling cellular physiology, are important aspects of 
protein folding, structure and function, and allow the cell to rapidly react to an extracellular 
signal via transmitting the message throughout the cell (Deribe et al., 2010). PTMs involve 
attachment of a chemical group (e.g. phosphate in phosphorylation), a protein (e.g. ubiquitin 
in ubiquitylation), lipid (i.e. lipidation), sugar (i.e. glycosylation) or other molecules to amino 
acid residues within the modified protein and these modifications result in alteration of 
protein properties (Deribe et al., 2010).  
 
There are many different types of PTMs; some are stable and regulate protein folding and 
maturation (e.g. glycosylation and formation of disulfide bridges), others are reversible and 
control cellular signalling (e.g. phosphorylation, nitrosylation, ubiquitylation) (Hess et al., 
2005; Hjerpe and Rodriguez, 2008; Deribe et al., 2010). Among the latter, phosphorylation is 
ubiquitous and is considered central for correct cellular function (Cohen, 2002; Deribe et al., 
2010). In eukaryotic cells, phosphorylation is a process in which a phosphate group is 
attached to tyrosine, serine or threonine residue (Deribe et al., 2010). Phosphorylation is 
regulated by the enzymatic function of protein kinases, which add phosphate groups, and 
phosphatases, which remove phosphate groups (Deribe et al., 2010), as described in Chapter 
1.3.2. Therefore, identification of novel phosphorylation sites allows for better understanding 
of protein regulation. Mass spectrometry is currently one of the most used techniques for the 
Chapter 7 – Identification of novel PTMs and Ack1 interactors via mass spectrometry 
 
189 
 
identification of phosphorylation and other PTMs within the protein, due to a change in mass 
upon protein modification. 
 
Apart from identification of PTMs there are many other areas, in which mass spectrometry 
has been applied, e.g. identification of binding partners of a protein of interest. Typically, a 
particular protein is immunoprecipitated and the co-precipitating proteins are characterised by 
mass spectrometry. Additionally, in this context, stable isotope labelling of amino acids in cell 
culture (SILAC) may be used in order to quantitatively analyse the interactors that bind in 
response to a particular treatment. 
  
SILAC was first described by Ong et al. in 2002 (Ong et al., 2002). They used mouse 
myoblast cells which have a potential to differentiate into myotubes, and cultured the 
uninduced cells in normal medium (“light”), whereas cells undergoing differentiation induced 
by reduced concentration of serum, in medium with isotypically labelled leucine (“heavy”). 
Using mass spectrometry, they quantitatively compared the proteins obtained from uninduced 
cells to those obtained from differentiating cells and identified upregulation of several 
proteins in cells undergoing differentiation. This study opened up the possibility to employ 
the SILAC technique to study the quantitative changes in protein levels in cells in response to 
a particular treatment.  
 
7.2 Novel phosphorylation sites 
To identify potential novel phosphorylation sites within Ack1, 293T cells expressing myc-
Ack1 were lysed and cell lysates were subjected to immunoprecipitation with α-myc 
antibody. The immunoprecipitated proteins were resolved by SDS PAGE (Chapter 3.2.4) and 
the gel was stained with Coomassie in order to visualise separated proteins (Chapter 3.2.7). 
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(Figure 7.1). The section of the gel identified as containing myc-Ack1 (approximately 140 
kDa) was cut out along with a very thin section directly above myc-Ack1, at approximately 
150 kDa, which could potentially include modified Ack1, i.e. phosphorylated or 
ubiquitylated. These sections of the gel were cut into pieces, which were further destained and 
subjected to trypsin digestion and desalting (Chapter 3.2.7), and the samples were subjected 
to liquid chromatography (LC) mass spectrometry (MS/MS) (Chapter 3.2.7). The mass 
spectrometry-obtained data were analysed by Dr. A. J. Creese using Proteome Discoverer, as 
described in Chapter 3.2.7. In particular, phosphorylation of serine, threonine and tyrosine, 
and ubiquitylation of lysine were set as variable modifications. The experiment was repeated 
several times to improve Ack1 sequence coverage. The data from all experiments were 
collated resulting in 52.28 % protein sequence coverage, shown in Figure 7.2. Green regions 
indicate the sequences identified with high confidence and yellow indicate the sequences with 
medium confidence. The coverage obtained allows for confident identification of Ack1 within 
the sample; however, parts of Ack1 have not been characterised. These include the N-
terminus containing the SAM domain, some regions in the kinase domain, a large region 
containing the clathrin binding domain, a region containing the EGFR binding domain and the 
C-terminus with the UBA domain. 
 
Three novel phosphorylation sites of serine residues have been identified, which are shown in 
Figure 7.3 a and b and Figure 7.4 a. These modifications are defined as novel, since they are 
not described in an online database containing a comprehensive information on proteins 
phosphorylation sites (www.phosphosite.org) (Hornbeck et al., 2012). The identified novel 
PTMs include serine 102 (Ser102), Ser761 and Ser936. These novel PTMs along with known 
phosphorylation sites within mouse Ack1 (isoform 2) are shown in Figure 7.5. 
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Figure 7.1. Coomassie-stained gel with immunoprecipitated Ack1 
293T cells transfected with myc-Ack1 were lysed and cell lysates were incubated with α-myc 
antibody to immunoprecipitate Ack1. Immunoprecipitates were subjected to SDS PAGE 
followed by the staining of the gel with Coomassie. The red rectangle indicates the section of 
the gel containing myc-Ack1 (approximately 140 kDa) and potentially modified myc-Ack1 
(approximately 150 kDa), which was cut out and subjected to trypsin digestion and further 
mass spectrometric analysis (Chapter 3.2.7). 
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Figure 7.2. Ack1 sequence coverage 
The primary sequence of Ack1 identified by LC-MS/MS with 52.28 % sequence coverage. 
Green colour indicates the regions identified with high confidence, yellow colour with 
medium confidence. The following PTMs are indicated: A-acetylation (COCH3 addition to N-
terminus); C-carbamidomethylation (CH2CONH2 addition to Cys); G-ubiquitylation (Gly-Gly 
addition to Lys); O-oxidation (O addition to Met); P-phosphorylation (H2PO3 addition to Ser, 
Thr or Tyr). 
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a) 
 
b) 
 
Figure 7.3. Novel phosphorylation sites at Ser102 and Ser761 
Mass spectra of the peptides comprising novel phosphorylation sites identified by LC-
MS/MS: phospho-serine 102 (a) and phospho-serine 761 (b). The sequence of each peptide is 
shown above the spectrum, with b and y fragment ions. 
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a) 
 
b) 
 
Figure 7.4. Novel phosphorylation sites at Ser936 and the SSS region 
Mass spectra of a peptide comprising novel phosphorylation site identified by LC-MS/MS: 
phospho-serine 936 (a) and of a peptide comprising three consecutive serines (Ser808, 
Ser809, Ser810), one of which has been identified as phosphorylated (b). The sequence of 
each peptide is shown above the spectrum, with b and y fragment ions.  
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Figure 7.5. Known and novel phosphorylation sites within mouse Ack1 (isoform 2) 
Known phosphorylation sites are shown in black, whereas three novel phosphorylation sites 
identified are shown in red. T-Thr, S-Ser, Y-Tyr. From PhosphoSitePlus 
(www.phosphosite.org).  
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Ser102 does not localize within any specific domain within Ack1 and is located between the 
SAM and the kinase domains (Mahajan and Mahajan, 2010), Ser936 is located within the C-
terminal proline-rich region and is adjacent to two proline residues (Mahajan and Mahajan, 
2010), whereas Ser761 is located within the Mig6-homology domain (the EGFR binding 
domain) (Shen et al., 2007). This phosphoprylation may be important for the interaction with 
EGFR and a point mutation of Ser761 may potentially influence EGFR binding. Additionally, 
a region with three consecutive serine residues (SSS) is found to be phosphorylated, as shown 
in Figure 7.4 b. The precise identification of a specific phospho-serine in this case is not 
possible due to a lack of peptide fragmentation in this region. These serines (Ser808, Ser809, 
Ser810) are also localized within the EGFR binding domain.  
 
As described above, the 52.28 % sequence coverage indicates that 47.72 % of the Ack1 
sequence is not characterised. These uncharacterised regions are likely to be modified, as they 
contain numerous tyrosine, serine and threonine residues which could potentially be 
phosphorylated, and multiple lysine residues that could be ubiquitylated. Although trypsin is a 
highly efficient enzyme for protein digestion and cleaves the amide bond at the C-terminus of 
lysine and arginine, it does not cleave this bond when lysine or arginine is followed by a 
proline residue. The uncharacterised regions appear to have a great amount of Lys-Pro and 
Arg-Pro motifs, and therefore would not be cleaved. This would result in very large peptides 
which may be difficult to detect.  The peptide coverage could potentially be improved by 
using a different enzyme for digestion rather than, or additionally to, trypsin.  
 
Having identified three novel phosphorylation sites within Ack1, it is possible to predict 
which kinases could potentially phosphorylate these sites using software available online.  
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This information may be further used for investigation of the signalling pathways upstream of 
Ack1 phosphorylation. An integrative computational approach NetworKIN 
(www.networkin.info) has been developed in order to predict relationships between kinases 
and their substrates. It combines the information on the motifs that are preferentially targeted 
by a specific family of kinases with the protein network described in STRING database 
(string-db.org), an online database of known and predicted protein interactions. This should 
enhance the likelihood of identifying the kinase that targets a particular phosphorylation site 
(Linding et al., 2007). This approach allowed us to predict the potential kinases that 
phosphorylate Ack1 at the three novel phosphorylation sites identified. As shown in Table 
7.1, Ser102 is predicted to be phosphorylated by the cell-division protein kinases (CDKs) or 
by MAP kinases, Ser761 by casein kinases 2 (CK2), whereas Ser936 by PIM2 kinase. These 
can be further verified, e.g. through Western blotting and if confirmed, could potentially lead 
to characterisation of signalling cascades comprising Ack1 and the identified kinases. 
 
7.3 Novel ubiquitylation site 
Ubiquitylation is another common PTM which regulates cell signalling. Attachment of 
ubiquitin to a lysine residue is mediated by the subsequent action of E1, E2 and E3 ubiquitin 
ligases, described in more detail in Chapter 1.3.3 (Deribe et al., 2010). The proteins can be 
modified by attachment of a single ubiquitin (monoubiquitylation) or a chain of ubiquitin 
molecules (polyubiquitylation). Within Ack1, SAM and UBA domains have been proposed to 
contain potential ubiquitylation sites  (Chan et al., 2009; Lin et al., 2010); however, the 
precise localization remains uncovered.  
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Phosphosite Kinase Family Post. Prob. String Score Kinase Gene 
S102 CDK2_CDK3_group 0.2084 0.992 CDK2 
S102 CDK2_CDK3_group 0.2084 0.964 CDK3 
S102 p38_group 0.2602 0.993 MAPK14 
S102 p38_group 0.2602 0.993 MAPK11 
S102 p38_group 0.2602 0.99 MAPK13 
S102 p38_group 0.2602 0.98 MAPK12 
S761 CK2_group 0.5139 0.979 CSNK2A2 
S761 CK2_group 0.5139 0.979 CK2A1 
S936 Pim2 0.2047 0.98 PIM2 
 
     
 
 
    Table 7.1. Prediction of the kinases which phosphorylate novel sites within Ack1  
Prediction of the kinases which phosphorylate Ack1 at Ser102, Ser761 and Ser 936 
using NetworKIN. Additional information include NetPhorest posterior probability 
(probability that a phosphorylation site is a substrate of a kinase/phospho-binding 
domain) and string score (probability of the best association path between a kinase and 
substrate in string database). 
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The peptides extracted from the gel directly above Ack1 (potentially ubiquitylated Ack1) 
(Figure 7.1) were subjected to LC-MS/MS. This led to the identification of a potentially 
ubiquitylated peptide, whose spectrum is shown in Figure 7.6. A potential ubiquitylation 
(Lys539) is recognised as a presence of two consecutive glycine residues attached to a lysine 
residue (Gly-Gly-Lys; GGK). Surprisingly this potential ubiquitylation site is not localized 
within either the SAM nor the UBA domains, nor does it localize within any other 
characterised domain, but it is in close proximity to the clathrin binding domain (Teo et al., 
2001). The mass spectrum presented in Figure 7.6 shows 100 % peptide backbone sequence 
coverage for the identified peptide. Unfortunately, this ubiquitylated peptide was identified 
only once in one of the samples, possibly due to its low abundance, and therefore further 
confirmation of this PTM is required. Additionally, since the modified lysine residue is 
located at the N-terminus of the peptide (K in KPALPR) it is possible that the peptide 
sequence is GGKPALPR rather than KPALPR with GG-modified lysine residue. 
Nevertheless, searching of a database with known mouse proteins was unsuccessful in 
identifying a protein containing a GGKPALPR sequence. Therefore the identified peptide is 
likely to be ubiquitylated. Two other ubiquitylation sites have previously been identified 
within mouse Ack1, which are shown along with the site identified in this study, in Figure 
7.7. Importantly, Lys539 is not present within truncated Ack1, which is consistent with the 
observation that only full-length Ack1 associates with ubiquitin and/or is ubiquitylated 
(Chapter 6.2). This finding therefore may be useful for further characterisation of the precise 
functions of Ack1 ubiquitylation in cell signalling and trafficking.  
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Figure 7.6. Novel ubiquitylation site at Lys539 
Mass spectrum of a peptide comprising novel ubiquitylation site identified by LC-MS/MS at 
Lys539. The sequence of the peptide is shown abouve the spectrum, with b and y fragment 
ions. 
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Figure 7.7. Known and novel ubiquitylation sites within mouse Ack1 (isoform 2) 
Known ubiquitylation sites are shown in black, whereas the novel ubiquitylation site 
identified is shown in red. K-Lys. From Mammalian Ubiquitination Site Database 
(http://222.193.31.35:8000/mUbiSiDa.php).  
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7.4 Ack1 binding partners identified by SILAC 
In order to identify the proteins interacting with Ack1 in an EGF-dependent manner, 293T 
cells were first cultured for at least five doubling times in SILAC “light”, “medium” or 
“heavy” media (described in Chapter 3.2.6). This allowed the cells to fully incorporate the 
labelled amino acids into the proteins during protein synthesis (Cunningham et al., 2010). 
Subsequently, “medium” and “heavy” cells were transfected with myc-Ack1, whereas “light” 
cells were untransfected and later used as control. The cells were serum-starved, and the 
“heavy” cells were stimulated with EGF for 15 minutes (+EGF sample), whereas “light” 
(control) and “medium” (-EGF sample) cells were left untreated.  The cells were lysed and 
cell lysates were subjected to immunoprecipitation with α-myc antibody, or with α-myc 
antibody previously cross-linked to the beads. Antibody cross-linking is useful as it allows a 
formation of a covalent bond between antibody chains and the beads, and thus the antibody 
chains are not eluted into the sample (Sousa et al., 2011). On the other hand, I find that it may 
result in a decreased amount of immunoprecipitated proteins. For example, as shown in 
Figure 7.8, antibody cross-linking dramatically reduces the amount of endogenous Ack1 
immunoprecipitated from LNCaP cell lysates. Therefore, for optimal results each experiment 
was carried in both conditions, i.e. with and without antibody cross-linking. Following 
immunoprecipitation, the beads were washed extensively, mixed (“light”. “medium” and 
“heavy”) and washed again. Precipitated proteins were eluted and separated through SDS 
PAGE. The antibody cross-linking largely prevented coelution of antibody chains shown in 
Figure 7.9; however, fewer proteins were found co-precipitated with Ack1, as visualised 
following gel staining with Coomassie. Separated proteins were digested with trypsin and 
subjected to LC-MS/MS by Dr. A. J. Creese (described in Chapter 3.2.7).  
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Figure 7.8. Antibody cross-linking reduces the amount of immunoprecipitated proteins 
LNCaP cells were lysed and cell lysates were subjected to immunoprecipitation with α-Ack1 
antibody, which had been previously cross-linked to the beads (+), or with the antibody alone 
(-). The same amounts of proteins, antibody and beads were used in both experiments. 
Immunoprecipitates were subjected to SDS PAGE and Western blotting with α-Ack1 
antibody. 
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Figure 7.9. Immunoprecipitation of myc-Ack1 
SILAC labelled 293T cells transfected with myc-Ack1 were serum-starved for four hours and 
the “heavy” cells were stimulated with EGF for 15 minutes. The cells were lysed and cell 
lysates were incubated with α-myc antibody (either alone or previously cross-linked to the 
beads) to immunoprecipitate Ack1. Immunoprecipitates were mixed and subjected to SDS 
PAGE following by the staining of the gel with Coomassie. Ack1 and co-precipitated proteins 
were cut out off the gel and subjected to trypsin digestion and further mass spectrometric 
analysis (Chapter 3.2.7).  
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The data were analysed using MaxQuant and Perseus (Chapter 3.2.7). MaxQuant recognises 
sets of isotope patterns and compares them to the theoretical isotope patterns, and if the mass 
differences are within the accepted error, and if the intensity correlation of the patterns is 
sufficient, then the peaks are recognised as a SILAC set (Cox and Mann, 2008).  
 
As explained in Chapter 3.2.7, the data were searched against a human protein database 
containing the reverse peptides and common contaminants, both of which were removed from 
the dataset. The protein ratios were normalised, so that the median of log-transformed peptide 
ratios equals zero (Cox and Mann, 2008). The normalised protein ratios (“medium”/“light” 
(M/L), “heavy”/”light” (H/L) and “heavy”/”medium” (H/M)) were subsequently log-
transformed to ensure the equal treatment of up- and downregulation. As shown in Figure 
7.10, the majority of the log-transformed ratios spread around zero, which indicates that their 
ratios have a value of, or close to, one (natural logarithm of one is zero). Therefore, the 
majority of the proteins are background proteins which co-precipitate in a control (“light”), as 
well as in -EGF (“medium”) and +EGF (“heavy”) samples. Additionally, since the experiment 
was performed four times (two independent experiments, each performed with and without 
antibody crosslinking), as shown in Figure 7.10, only the proteins identified in at least two 
samples were considered as potential binding partners for Ack1. Using Perseus, the proteins 
enriched in -EGF or +EGF samples were identified. For every protein, the p-value is adjusted 
with Benjamini Hochberg false discovery rate (FDR) to correct for the false positives due to 
multiple hypothesis testing (Cox and Mann, 2012). The threshold value for FDR is 0.05. 
Importantly, there are proteins identified only in one or two samples (e.g. in “medium” and/or 
“heavy”, and not in “light”), resulting in ratios of infinity as they cannot be calculated (e.g. 
M/L and H/L”). These proteins may potentially be novel interactors; however, in the study 
presented in this thesis they were omitted due to a lack of validation.  
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Figure 7.10.Natural logarithm of ratios from two independent experiments 
Natural logarithm of the ratios M/L (-EGF), H/L (+EGF)  and H/M (+EGF/-EGF) from two 
independent experiments (each performed with or without antibody cross-linking to the 
beads). 
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Additionally, some proteins which are known Ack1 interactors (e.g. clathrin) were not 
retained using the parameters described above, indicating that these parameters appear strict 
and conservative. Therefore, due to these restrictions, any proteins significantly enriched in 
“medium” or “heavy” samples are likely to be genuine Ack1 interactors. 
 
Using these parameters, the graphs have been plotted, as presented in Figure 7.11. The graphs 
show the log-transformed ratios of proteins identified in -EGF to control sample (H/L) on x 
axis, and +EGF to control sample (M/L) on y axis. The gene names of the proteins which 
have been significantly enriched in -EGF or +EGF sample, as compared to the control sample, 
are shown in Figure 7.12 and Figure 7.13, respectively. The proteins whose H/M ratio was 
significantly increased or decreased are shown in Figure 7.14. Additional information, 
including protein names, the ratios and the p-values for the proteins enriched in -EGF or 
+EGF sample is shown in Table 7.2. Among the identified proteins, some are characterised as 
binding independently of EGF treatment (high M/L and H/L ratio), some which preferably 
bind Ack1 following EGF treatment (high H/M ratio), whereas others preferably interact with 
Ack1 in untreated cells (high M/L and low H/M ratio). This is shown in Table 7.3. 
 
As shown in Table 7.2 and Table 7.3, some proteins are enriched in both -EGF and +EGF 
samples, as their M/L and H/L ratios are significantly increased, i.e. Cdc42, Nck1 and Nck2, 
TCEB2 and HSP90-α. These proteins therefore can interact with Ack1 both under serum 
starvation and following EGF stimulation. Other proteins are enriched in the -EGF sample, as 
their M/L ratio is significantly increased, i.e. CPSF3, MCM7, CANX and KAT7. Another 
group of proteins interacts with Ack1 upon EGF stimulation, as their H/L ratio is significantly 
increased, i.e. PFKL, HSP90-β, ARHGEF12 and Cdc37.  
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Figure 7.11. Proteins enriched or depleted in -EGF or +EGF sample 
The distribution of the log-transformed ratios of -EGF to control (M/L) (a) and +EGF to 
control (H/L) (b); c) the colour scheme of the p-values (which have been further adjusted with 
Benjamini Hochberg FDR) (Cox and Mann, 2012).  
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Figure 7.12. Proteins enriched in -EGF sample 
The graph shows the gene names of the proteins enriched in -EGF sample as compared to the 
control (the M/L ratio increased).  
Chapter 7 – Identification of novel PTMs and Ack1 interactors via mass spectrometry 
 
210 
 
 
 
Figure 7.13. Proteins enriched in +EGF sample 
The graph shows the gene names of the proteins enriched in +EGF sample as compared to the 
control (the H/L ratio increased).  
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Figure 7.14. Proteins enriched in +EGF vs. –EGF sample and –EGF vs. +EGF sample 
The graph shows the gene names of the proteins enriched in +EGF vs. -EGF sample and                
-EGF vs. +EGF sample (the H/M ratio increased or decreased, respectively).  
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 Proteins enriched in -EGF sample Gene names Ratio M/L Significance 
Cleavage and polyadenylation specificity factor 
subunit 3 CPSF3 1.925 0.0003 
DNA replication licensing factor MCM7 MCM7 1.962 0.0002 
Heat shock protein HSP 90-alpha HSP90AA1 2.067 0.0001 
Calnexin CANX 2.447 0.0000 
Transcription elongation factor B polypeptide 2 TCEB2 4.096 0.0000 
Cytoplasmic protein NCK2 NCK2 4.888 0.0000 
Histone acetyltransferase KAT7 KAT7* 5.016 0.0000 
Cell division control protein 42 homolog;Rho-related 
GTP-binding protein RhoQ CDC42;RHOQ 5.607 0.0000 
Cytoplasmic protein NCK1 NCK1 6.651 0.0000 
Activated CDC42 kinase 1 TNK2 11.103 0.0000 
    Proteins enriched in +EGF sample Gene names Ratio H/L Significance 
6-phosphofructokinase, liver type PFKL 2.111 0.0031 
Heat shock protein HSP 90-beta;Putative heat shock 
protein HSP 90-beta-3 
HSP90AB1;HSP
90AB3P 2.154 0.0024 
Rho guanine nucleotide exchange factor 12 ARHGEF12* 2.240 0.0014 
Hsp90 co-chaperone Cdc37 CDC37* 2.460 0.0004 
Heat shock protein HSP 90-alpha HSP90AA1 2.863 0.0000 
Cytoplasmic protein NCK2 NCK2 6.231 0.0000 
Transcription elongation factor B polypeptide 2 TCEB2* 6.728 0.0000 
Cytoplasmic protein NCK1 NCK1 11.355 0.0000 
Cell division control protein 42 homolog;Rho-related 
GTP-binding protein RhoQ CDC42;RHOQ* 12.082 0.0000 
Activated CDC42 kinase 1 TNK2 20.687 0.0000 
    Table 7.2. Proteins enriched in –EGF or +EGF sample 
The table presents the proteins enriched in –EGF or +EGF sample as compared to the control. 
Gene names, the ratios (M/L or H/L) and the p-values are shown. Stars indicate proteins, 
whose binding to Ack1 is EGF-dependent, as assessed by significantly low or high H/M 
ratios; these proteins are presented in Table 7.3.   
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Proteins showing EGF sensitivity Gene names Ratio H/M Significance 
Histone acetyltransferase KAT7 KAT7 0.276 0.0000 
Rho guanine nucleotide exchange factor 12 ARHGEF12 2.759 0.0000 
Hsp90 co-chaperone Cdc37 CDC37 2.611 0.0000 
Transcription elongation factor B polypeptide 2 TCEB2 2.060 0.0001 
Cell division control protein 42 homolog;Rho-
related GTP-binding protein RhoQ  CDC42;RHOQ 3.974 0.0000 
 
Table 7.3. The proteins identified to bind Ack1 in an EGF-dependent manner 
The table presents the proteins preferably binding Ack1 in untreated cells (H/M ratio < 1) or 
in EGF-treated cells (H/M ratio > 1). Gene names, the H/M ratio and the p-values are shown. 
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Several proteins are identified as binding preferentially to Ack1 following EGF stimulation 
compared to serum-starved conditions, since their H/M ratio is significantly increased, i.e. 
ARHGEF12, Cdc37, TCEB and Cdc42. Interestingly, KAT7 is the only protein identified to 
specifically interact with Ack1 in serum-starved cells rather than upon EGF stimulation, and 
its H/M ratio is significantly reduced. Importantly, as explained below, some proteins 
identified are known Ack1 interactors, i.e. Cdc42, Nck and HSP90-β. This indicates that the 
employed method is reliable and that the identified novel Ack1 interactors are likely to be 
accurate. 
 
Additionally, clustering all of the proteins from Table 7.2 using STRING database (string-
db.org) allowed for identification with medium confidence a group of interactors, shown in 
Figure 7.15 a. Some of the interactions have been shown experimentally, whereas others are 
based on databases or textmining. Identification of this major protein network (Figure 7.15 a) 
strongly support the reliability of the results obtained, as the proteins involved in common 
signalling networks are likely to interact and co-precipitate with one another. Additionally, 
knwon and/or predicted Ack1 interactors described in STRING database are shown for 
comparison in Figure 7.15 b. 
 
Ack1 has been shown to bind GTP-bound Cdc42 and to regulate Cdc42-dependent migration 
of breast cancer cells (Manser et al., 1993; Modzelewska et al., 2006). Similarly, the 
interaction between Ack1 and Nck has been suggested (Teo et al., 2001; Galisteo et al., 
2006). Nck is an adaptor protein comprised of three SH3 domains and one SH2 domain 
(Lettau et al., 2009). In human two members of the Nck family have been identified: Nck1 
and Nck2. Nck has been found to be phosphorylated following EGF treatment, and the SH2 
domain of Nck has been shown to interact with activated EGFR (Li et al., 1992).  
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Figure 7.15. Protein clustering using STRING database 
Proteins identified as Ack1 (TNK2) interactors (Table 7.2) (a) and known/predicted Ack1 (TNK2) interactors from STRING database (no more 
than 20 interactors) (b), both identified with medium confidence. Proteins present in both (a) and (b) are shown in black rectangles.  
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Therefore it is unlikely that Nck mediates an interaction between Ack1 and EGFR, since the 
SH2 domain of Nck has been similarly shown to bind phosphorylated Ack1 (Galisteo et al., 
2006). Nevertheless, through interaction with adaptor proteins such as Nck and GTPases such 
as Cdc42, Ack1 is a proposed to coordinate multiple signalling pathways (Galisteo et al., 
2006).  
 
HSP90 is a chaperone which regulates protein folding, stabilisation and degradation (Vaughan 
et al., 2010). HSP90-β has been found to associate with Ack1, in particular with constitutively 
active Ack1 (caAck1) (Mahajan et al., 2005). Treatment of cells with geldanamycin, an 
HSP90 inhibitor, reduced the kinase activity of caAck1, indicating that HSP90 is involved in 
maintaining Ack1 activity. Cdc37 is a HSP90 cochaperone that facilitates substrate 
recognition and binding (MacLean and Picard, 2003). Since Cdc37 is found enriched in +EGF 
sample as compared to -EGF sample, this suggests that EGF treatment enhances the 
interaction between Ack1 and the HSP90 co-chaperone Cdc37, and potentially with HSP90 
itself. CANX, or calnexin, is a lectin chaperone that resides in endoplasmic reticulum (ER) 
and assists maturation and folding of newly synthesised proteins (Hebert and Molinari, 2007). 
An interaction between Ack1 and calnexin in serum-starved cells may indicate that Ack1 is 
being synthesised by ribosomes and targeted to ER, where calnexin assists in correct Ack1 
folding. 
 
ARHGEF12, or LARG (leukemia-associated RhoGEF) is a member of the Dbl family of 
GEFs (Zheng, 2001). They all share a conserved motif of Dbl homology (DH) domain 
followed immediately by a tandem pleckstrin homology (PH) domain. These domains are 
required for their GEF activity, and the DH domain is proposed to regulate the GDP to GTP 
exchange, whereas the PH domain is proposed to control intracellular targetting of the DH 
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domain and membrane association. ARHGEF12/LARG has been shown to specifically 
interact with and activate RhoA, but not Rac1 or Cdc42 (Reuther et al., 2001). In contrast, as 
explained above, Ack1 interacts with GTP-bound Cdc42, but not Rac1 or RhoA. Therefore, 
co-precipitation of ARHGEF12/LARG with Ack1 is surprising. The study completed on 
human squamous carcinoma cells revealed that EGFR is in complex with ARHGEF12/LARG 
and CD44 (hyaluronan receptor), and stimulation with hyaluronan promotes the association 
between EGFR, ARHGEF12/LARG and CD44, and activates EGFR and downstream 
signalling cascades (Bourguignon et al., 2006). Therefore, it is possible that EGF stimulation 
promotes an interaction between ARHGEF12/LARG and EGFR, as between Ack1 and 
EGFR, leading to an indirect association between Ack1 and ARHGEF12/LARG. 
 
PFKL, or phosphofructokinase, is an enzyme that catalyses phosphorylation of fructose-6-
phosphate to fructose-1,6-biphosphate in the process of glycolysis (Pelicano et al., 2006). 
Addition of serum, which contains growth factors, to quiescent (non-dividing) cells induces 
glycolysis, and the homogenates obtained from quiescent cells treated with serum or with 
EGF show increased glycolytic activity compared to untreated cells (Diamond et al., 1978). In 
addition, purified EGFR has been shown to phosphorylate PFK, with suggestion that PFK 
may be an EGFR substrate in vivo  (Reiss et al., 1986). An interaction between Ack1 and 
PFKL observed in cells treated with EGF may therefore indicate that EGFR phosphorylates 
PFKL and PFKL is in the complex with EGFR and Ack1. 
 
K (lysine) acetyltransferase KAT7 (MYST2/HBO1) has been proposed to acetylate histone 
H4 at the origin of replication, which then facilitates loading of MCM2-7 helicase complex 
and DNA replication (Chadha and Blow, 2010). Co-precipitation of KAT7MYST2/HBO1 and 
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MCM7 with Ack1 in -EGF sample could potentially indicate Ack1 implication in DNA 
replication process. 
 
TCEB2, or elongin, has been characterised as a transcription elongation factor (Aso et al., 
1995). Co-precipitation of TCEB2/elongin with Ack1, which is additionally enhanced upon 
EGF treatment, may indicate that Ack1 is implicated in RNA synthesis. CPSF3, or CPSF73 
(cleavage and polyadenylation specificity factor 73-kDa subunit), which also co-precipitates 
with Ack1, is an endonuclease that has been proposed to assemble in a precleavage complex 
to cleave newly synthesised precursor messenger RNA at the 3‟ end, in the process of mRNA 
maturation (Ryan et al., 2004; Mandel et al., 2006). This further supports a potential function 
of Ack1 in RNA synthesis. Alternatively, TCEB2/elongin has been found associated with von 
Hippel-Lindau tumour suppressor (VHL), cullin-2 and RING-box protein 1 (RBX1) in an E3 
ubiquitin ligase complex which marks proteins for proteasomal degradation (Pugh and 
Ratcliffe, 2003). Therefore, this potentially suggests that Ack1 associates with this complex 
and therefore Ack1 may play a role, either positive or negative, in ubiquitin-mediated 
degradation of proteins via proteasome. 
 
7.5 Conclusions 
The employment of the mass spectrometric techniques allowed for identification of novel 
PTMs within Ack1. These include three phosphorylation sites on serine residues (Ser102, 
Ser761 and Ser936), one ubiquitylation site (Lys539), as well as a phosphorylation of a serine 
residue within the SSS motif (Ser808, Ser809 and Ser810); in this case, the exact localization 
of the phosphorylation site is limited due to insufficient sequence coverage of this region. As 
described in Chapter 1.3.2 and Chapter 1.3.3, protein phosphorylation and ubiquitylation 
play major roles in trafficking and signalling, and identification of PTMs within a protein is 
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likely to further the knowledge on protein functions. Using an online available resource 
(NetworKIN) I identify several kinases which may potentially phosphorylate the identified 
phosphorylated serine residues. These include cell-division protein kinases (CDKs), MAP 
kinases, casein kinases 2 (CK2) and PIM2 kinase. These results provide an input into the 
understanding of the Ack1 functions, as it may be involved in signalling pathways mediated 
by these kinases. Identification of the ubiquitylation site within Ack1 may provide further 
knowledge of the proposed functions of Ack1 in ubiquitin-mediated degradation, and 
mutation of the identified lysine residue may lead to characterisation Ack1 functions in this 
context more precisely.   
 
In adition to characterisation of novel PTMs within Ack1, using mass spectrometry I also 
identify several proteins that interact with Ack1, some of which are well-known Ack1 
interactors, e.g. Cdc42 and Nck1/Nck2, whereas others are novel, e.g. ARHGEF12/LARG, 
MCM7 or PFKL. I employed the SILAC technique to analyse the binding in the presence or 
absence of EGF treatment. This led to identification of proteins that bind Ack1 independently 
of EGF stimulation: adaptor proteins Nck1 and Nck2 and chaperone HSP90α; proteins that 
bind Ack1 upon serum-starvation: histone acetyltransferase KAT7/MYST2/HBO1, 
endonuclease CPSF3/CPSF73, helicase MCM7 and lectin chaperone CANX/calnexin; 
proteins that bind Ack1 following EGF treatment: RhoGEF ARHGEF12/LARG, HSP90 co-
chaperone Cdc37, phosphofructokinase PFKL, and chaperone HSP90β; and proteins that bind 
Ack1 both in the absence and presence of EGF treatment, but their binding is enhanced 
following EGF stimulation: transcription elongation factor TCEB2 and a small GTPase 
Cdc42 (described in Chapter 7.4). To verify these interactions, further experiments may be 
employed, including biochemical studies and microscopy, to validate whether they take place 
at the physiological level. 
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8 Discussion and future plans 
The scientific field of growth factors has evolved significantly since their discovery in the 
1950s (Garfield, 1987). Novel growth factors and growth factor receptors are being frequently 
discovered, as are the mechanisms underlying growth factor functions; however, many of 
these still remain unresolved. Therefore, more research is still required in order to fully 
understand the mechanisms underlying growth factor roles within the cell. 
 
The implication of Ack1 in growth factor signalling and trafficking has been developing for 
the past two decades. It is well documented that Ack1 plays a role in RTK trafficking and 
degradation (Galisteo et al., 2006; Shen et al., 2007; Grovdal et al., 2008), but the precise 
mechanism remains elusive. In the work presented within this thesis, I have investigated the 
molecular mechanisms underlying Ack1 involvement in growth factor signalling and in RTK 
trafficking. The schematic representation of the function of Ack1 in EGFR trafficking is 
presented in Figure 8.1. 
 
In Chapter 4, the implication of Ack1 in RTK trafficking is investigated. The 
immunoprecipitation studies reveal that activated FGFR2 does not interact with Ack1. In 
contrast, both activated EGFR and constitutively active Cdc42 co-precipitate with Ack1. 
Further studies also reveal that activated FGFR2 does not colocalize with Ack1, thus Ack1 
and active FGFR2 are likely located within distinct compartments/microdomains within the 
same compartment. In the study presented in Chapter 4, the colocalization of Ack1 with 
EGFR upon EGF stimulation is further confirmed. In addition to studies on FGFR2, the work 
was carried out with another member of the FGFR family, i.e. FGFR1. From these studies it 
emerges that active FGFR1, similarly to FGFR2, does not interact with Ack1.
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Figure 8.1. Proposed mechanism for the role of Ack1 in EGFR trafficking 
Ack1 predominantly associates within p62/SQSTM1-rich compartments in serum-starved cells. Upon EGF stimulation, a portion of Ack1 
translocates away from these compartments towards early-endosomes where it colocalizes with EGFR and diverts EGFR trafficking into a non-
canonical degradative pathway. In Ack1 knockdown (KD) cells, EGFR is free to traffic via a canonical endo-lysosomal pathway.  
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Thus, Ack1 may have a specific function in EGF signalling pathway and not in FGF 
signalling. The interaction between Ack1 and EGFR is likely dependent on the motifs that are 
absent in FGFRs. Additionally, this work emphasizes the divergence in the endocytic 
pathways of EGFR and FGFR2. Since Ack1 colocalizes with active EGFR, and not FGFR2, 
this suggests that these RTKs traffic through different endocytic compartments. Interestingly, 
NBR1 has been found to inhibit degradation of EGFR and FGFR upon ligand stimulation; 
however, through its interaction with Sprouty related with EVH1 domain 2 (Spred2), NBR1 
has also been shown to promote FGFR degradation (Mardakheh et al., 2009; Mardakheh et 
al., 2010). Additionally, Spred2 has been found in complex with NBR1 and p62/SQSTM1, 
the autophagic receptors. Therefore, it is possible that NBR1 interacts with Spred2 to target 
FGFR to p62/SQSTM1 compartments, whereas in the case of EGFR, Ack1 plays a role 
similar to NBR1 and Spred2. 
 
In Chapter 5, Ack1 subcellular localization is explored. The previous reports show that Ack1 
partially colocalizes with EGF on early endosomes following EGF stimulation (Shen et al., 
2007; Grovdal et al., 2008); however, the localization starved cells has not been reported. 
Additionally, nuclear localization for Ack1 has been proposed (Ahmed et al., 2004; Mahajan 
et al., 2007). In the work presented in Chapter 5, Ack1 exhibits cytoplasmic localization and 
is not detected within the nucleus following EGF stimulation. In contrast, truncated Ack1 
which lacks the C-terminal portion can be found within the nucleus and independently of EGF 
treatment. Therefore, this indicates that the domains located within Ack1 C-terminal portion 
prevent nuclear localization of Ack1. This could be the result of differences in conformation 
between full-length and truncated Ack1, or in the interactions with other proteins which 
would prevent Ack1 translocation to the nucleus.  
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Further colocalization studies described in Chapter 5 confirm previously published data on 
Ack1 partial localization to EEA1-positive early endosomes following EGF stimulation, in 
particular at 15 and 30 minutes post-EGF (Chapter 5.4)  (Shen et al., 2007; Grovdal et al., 
2008). Interestingly, similar EGF-dependent colocalization can be seen between Ack1 and 
ectopically expressed Rab5 (Chapter 5.5). Rab5 has been shown to localize to early 
endosomes and other structures, including autophagosomes (Stenmark, 2009). Similar to 
Rab5, partial increase in colocalization between Ack1 and ectopically expressed Rab4, Rab11 
and Rab7 can be found following EGF treatment. In particular, in the case of Rab4 an 
increase is noted at 15 minutes of EGF treatment, in the case of Rab11 at 30 minutes of EGF 
stimulation, whereas in the case of Rab7 at 15 and even more at 30 minutes of EGF 
stimulation. As explained in Chapter 1.3.4, Rab4 has been shown to promote fast recycling 
from early endosomes, whereas Rab11 controls slow recycling from the PNRC. Additionally, 
Rab11 has been proposed to regulate fusion of early endosomes with autophagosomes (Fader 
et al., 2008). Therefore, it is possible that Ack1 may play a role in endocytic recycling 
pathways via its association with Rab4 and Rab11, or in fusion of endosomes with 
autophagosomes via its association with Rab11. Rab7, as explained in Chapter 1.3.4, has 
been found to localize to late endosomes and autophagosomes, and has been proposed to 
regulate trafficking to lysosomes and to promote fusion between autophagosomes and 
lysosomes (Gutierrez et al., 2004; Stenmark, 2009). An increase in colocalization between 
Ack1 and Rab7 following EGF stimulation may suggest a potential role for Ack1 in 
trafficking through the late endosomal or autophagosomal compartments. However, the 
colocalization studies between Ack1 and the endogenous Rab11 and LBPA, a lipid enriched 
in late endosomal membranes (Kobayashi et al., 1998; Kobayashi et al., 1999; Galve-de 
Rochemonteix et al., 2000), reveal that Ack1 does not localize to recycling or late endosomes 
following EGF treatment (Chapter 5.6). This discrepancy may be due to the differences in 
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the experimental design (e.g. endogenous verus ectopically expressed Rab11), or in 
subcellular distribution (i.e. Rab7 verus LBPA). Since ectopically expressed proteins may 
perturb some cellular functions, or mislocalize within the cell, the studies employing 
endogenous proteins or molecules can be more reliable.  
 
In Chapter 6 Ack1 subcellular localization is further characterized. Since Ack1 does not 
strikingly localize to early, late or recycling endosomes particularly in serum-starved 
conditions (Chapter 5), Ack1 localization to other compartments has been examined. 
Previous reports indicate that Ack1 is ubiquitylated and interacts with mono- and 
polyubiquitin, and that the UBA domain of Ack1 binds ubiquitylated proteins (Shen et al., 
2007; Chan et al., 2009; Lin et al., 2010). I show that Ack1 localizes to ubiquitin-rich 
compartments and that the UBA domain contributes to this localization, which may reflect 
binding of ubiquitylated proteins by Ack1, as well as Ack1 ubiquitylation (Chapter 6.2). 
Protein ubiquitylation is an important signal for degradation via several degradative pathways, 
e.g. selective autophagy (Kraft et al., 2010). In this process, ubiquitylated cargo is 
concentrated within the double membrane autophagosomes. I find that Ack1 colocalizes and 
interacts with p62/SQSTM1, an autophagic receptor (Chapter 6.4). This is particularly 
enhanced in serum-starved conditions and decreases following EGF treatment. Thus, Ack1 
partially moves away from p62/SQSTM1 upon activation with EGF. The UBA domain is 
critical for the colocalization with p62/SQSTM1, indicating that binding of ubiquitylated 
proteins by the UBA domain is required for this to occur. Since Ack1 does not dramatically 
colocalize with NBR1, another autophagic receptor (Chapter 6.4), this suggests that the 
interaction with p62/SQSTM1 is highly specific. Interestingly, the presence of ectopically 
expressed p62/SQSTM1 promotes the colocalization between Ack1 and NBR1 (Chapter 
6.5). Since p62/SQSTM1 and NBR1 interact via their PB1 domains (Lamark et al., 2003; 
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Lamark et al., 2009), it is likely that ectopically expressed p62/SQSTM1 interacts with NBR1 
and thus indirectly enhances the colocalization between Ack1 and NBR1. 
 
In Chapter 6 I also identify an interaction between Ack1 and Atg16, which is an important 
regulator of autophagosome biogenesis (Mizushima et al., 1999; Mizushima et al., 2003). 
This interaction is enhanced following EGF treatment (Chapter 6.8). Growth factor 
stimulation has been shown to inhibit autophagy via mTOR activation, i.e. activation of 
mTOR downstream of RTKs has been proposed to phosphorylate Atg13 and thus disrupt its 
interaction with Atg1 during autophagosome formation (Kamada et al., 2000; Stephan et al., 
2009; Jung et al., 2010). Nevertheless, studies exist showing that clathrin-mediated 
endocytosis may provide membranes for autophagosome formation and inhibition of CME 
reduces autophagy (Ravikumar et al., 2010). Additionally, Atg16 has been shown to interact 
with clathrin and inhibition of CME resulted in decreased formation of Atg16-positive 
structures. Thus, since EGF stimulation promotes CME (Sigismund et al., 2005; Sigismund et 
al., 2008) it may also promote autophagosome formation. In addition, Ack1 partially 
colocalizes with LC3, a protein required at later stages of autophagosome formation and 
maturation (Chapter 6.9) (Ichimura et al., 2000; Mizushima et al., 2011). This, however, 
does not seem to be dependent on EGF treatment. Taken together, the results presented in 
Chapter 6 identify a novel implication of Ack1 in the autophagic pathway marked by its 
association with p62/SQSTM1, Atg16 and LC3. 
 
Chapter 7 describes the identification of novel phosphorylation and ubiquitylation sites 
within Ack1. The mass spectrometry technique used in the study allowed for identification of 
three novel phospho-serine residues and the SSS motif with one phosphorylated serine residue 
(Chapter 7.2). Through an online resource (NetworKIN) I identify potential kinases that 
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phosphorylate these three novel sites. In particular, Ser102 is suggested to be a target of 
CDK2, CDK3 or MAPK11-14, Ser761 to be phosphorylated by CSNK2A2 or CK2A1 and 
Ser936 by PIM2. These data may be further verified and potentially identify signalling 
cascades that comprise Ack1 and these kinases. Additionally, a potential novel ubiquitylation 
site within Ack1 has been identified (Chapter 7.3). This site may be mutated and the 
phenotype of the mutant may help in understanding the functions of Ack1 ubiquitylation in 
cell signalling and trafficking. 
 
I also combine SILAC technique with mass spectrometry to identify the proteins that interact 
with Ack1 in serum-starved cells and upon EGF stimulation (Chapter 7.4). This approached 
led to the characterization of known Ack1 interactors, such as Cdc42 and Nck1, as well as 
several novel binding partners. The identified interactors include the proteins that bind Ack1 
independently on EGF stimulation (e.g. Nck1, Nck2, HSP90α), proteins that preferentially 
interact with Ack1 upon serum-starvation (e.g. KAT7MYST2/HBO1, MCM7) and others 
whose binding is enhanced following EGF treatment (e.g. Cdc37, ARHGEF12/LARG). 
Interestingly, two of these proteins are implicated in DNA replication (MCM7 and KAT7) 
which potentially indicates that Ack1 may be involved in this process. Another two 
interactors (CPSF3 and TCEB2) are required for transcription, which may also suggests that 
Ack1 is implicated in some stages of the RNA synthesis and/or maturation process. Although 
the work presented in this thesis fails to identify nuclear localization of full-length Ack1 in 
HeLa cells (Chapter 5.2), other studies suggest Ack1 nuclear translocation and function in 
AR-mediated gene expression (Ahmed et al., 2004; Mahajan et al., 2007). Therefore, 
characterisation of Ack1 interaction with nuclear proteins is not surprising and further 
supports Ack1 functions in this context. 
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Finally, future plans would include investigations of the precise Ack1 functions in selective 
autophagy and how this affects EGFR signalling and trafficking. In particular, an 
understanding of the association between Ack1, p62/SQSTM1, Atg16L and LC3 would be of 
a highest priority. Does the UBA domain of Ack1 bind p62/SQSTM1 directly? Is Ack1 
ubiquitylation required for this interaction? Would the p62/SQSTM1 mutant that lacks the 
UBA domain still interact with Ack1? All these questions could be addressed using available 
approaches. For assessing the potential direct interaction between Ack1 and p62/SQSTM1, 
the yeast two-hybrid technique could be used. In this technique, the direct binding of the two 
proteins results in the activation of the transcription of the reporter gene (Bruckner et al., 
2009). Similar techniques could be used for assessing the interactions between Ack1 and 
Atg16, and possibly Ack1 and LC3. Additionally, since Ack1 colocalizes with both Atg16 
(Chapter 6.8) and EEA1 (Chapter 5.4), it is interesting to analyse whether a colocalization 
may be detected between Atg16 and EEA1. It has been shown previously that Atg16 does not 
colocalize with EEA1 (Ravikumar et al., 2010), and therefore it is expected that following 
EGF treatment, a portion of Ack1 colocalizes with EEA1, and another portion colocalizes 
with Atg16. Another interesting question is whether the Ack1 puncta that colocalize with LC3 
(Chapter 6.9) also colocalize with EEA1. Early endosomes have been shown to be required 
for autophagosome maturation (Razi et al., 2009) and therefore it is expected that a portion of 
the EEA1-positive Ack1 puncta would also colocalize with LC3. In addition, more precise 
characterization of the Ack1 functions in EGFR trafficking is required. Since approximately 
20 % of the EGFR puncta colocalize with Ack1 and p62/SQSTM1 following EGF treatment 
(Chapter 6.7), it is tempting to speculate that approximately one in five EGFR molecules is 
targeted by Ack1 into autophagosomes. Therefore, triple colocalization studies could also be 
applied in this instance, tracing the colocalization between Ack1, EGFR and LC3 following 
EGF treatment. Another interesting issue is how EGF stimulation affects interaction between 
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p62/SQSTM1 and LC3. All of these studies could be performed in order to understand the 
mechanisms underlying precise Ack1 involvement in the non-canonical trafficking of EGFR. 
Another set of future experiments would be aimed at investigation of the potential novel 
interactions between Ack1 and the proteins identified through SILAC and mass spectrometry 
techniques. These interactions would be confirmed at the endogenous level, i.e. through 
immunoprecipitation and microscopy. Confirmation of these associations would open a new 
area of research on an implication of Ack1 in the identified processes and pathways. 
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